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Overview of current treatments and the potential role of combi-
nation therapies in osteoporosis
Bente Lomholt Langdahl
Aarhus University Hospital, Department of Endocrinology and Internal
Medicine, Aarhus C, Denmark
The current therapies of osteoporosis can be divided into antiresorptive
and bone forming therapies. The antiresorptive therapies comprise bi-
sphosphonates, denosumab, SERMs, and HRT. The most eﬃcient anti-
resorptive therapies reduce the risk of vertebral, non-vertebral and hip
fractures by approximately 70%, 20% and 40%, respectively. The bone
forming therapies are teriparatide and abaloparatide (currently only
available in the US). Both stimulate the osteoblast through the PTH
receptor and reduce the risk of vertebral and non-vertebral fractures by
approximately 80% and 50%, respectively. Thus, eﬃcient therapies are
available for the treatment of osteoporosis, however, there are still
unmet needs. Antiresorptive therapies only increase bone mineral
density to a certain extent and reduce the risk of non-vertebral fractures
by 20%, and the eﬀect of bone forming therapy seems to level oﬀ over
time. At least in theory, combination therapy targeting both resorption
and formation could be a solution. Studies have investigated combi-
nations of teriparatide with orally and intravenously administrated
bisphosphonates and denosumab. In the PaTH trial the combination of
teriparatide and alendronate did not improve BMD more than with
either drug alone. In fact alendronate even appeared to impair the bone
forming eﬀect of teriparatide. A combination of teriparatide and zo-
ledronic acid results in the best of both therapies: the increase in hip
BMD seen with zoledronic acid combined with the increase in spine
BMD seen with teriparatide. In contrast, the combination of denosumab
and teriparatide appears to have an additive eﬀect. None of the studies
investigating combination therapy were powered to allow for conclu-
sions regarding anti-fracture eﬃcacy.
Conclusion: Eﬃcient antiresorptive and bone forming therapies for
osteoporosis are available and while studies investigating combination
therapies have shown interesting results pertaining to BMD, the lack of
evidence for anti-fracture eﬃcacy of combination therapies makes se-
quential treatment the currently preferred option for the management
of osteoporosis.
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IS3
Lessons from the SCOOP Study
Eugene McCloskey
Metabolic Bone Centre, Northern General Hospital, Herries Road, Sheﬃeld,
UK; Centre for Integrated research in Musculoskeletal Ageing (CIMA),
Mellanby Centre for Bone research, University of Sheﬃeld, Sheﬃeld UK.
The SCreening for Osteoporosis in Older women for the Prevention of
fracture [SCOOP] study was a community-based screening interven-
tion, in women aged 70 to 85 years in the UK, in which osteoporosis
treatment was recommended those at high risk of hip fracture using the
FRAX risk assessment tool. The study delivered an average 28% re-
duction in the incidence of hip fracture in the screening arm, an eﬀect
that was signiﬁcantly greater in those at higher risk targeted for ap-
propriate treatment
The SCOOP results have signiﬁcant impact on future healthcare policy.
A potential screening approach was recommended by NICE in 2012,
when it proposed that all women aged 65 years or older and men aged
75 years or older should have a fracture risk assessment using the FRAX
or QFracture tools. The SCOOP study readily demonstrates the rever-
sibility of high risk identiﬁed by FRAX. Health economic analysis of the
study indicates that the cost per prevented hip fracture is less than £8
000 and that the cost per QALY gained is less than £20 000. If the
SCOOP strategy was applied across the whole population of women in
this age group in the UK, then almost 8000 hip fractures could be
prevented each year; this could be further enhanced by mechanisms
that extended the strategy to the two-thirds of eligible women who did
not participate in the screening study, as well as combining osteo-
porosis treatment with falls prevention in eligible individuals.
Future studies should examine how this FRAX-based approach can be
made available to, or accessible by, the wider community to achieve
greater reductions in the number of hip fractures in the UK and else-
where.
IS4
Zoledronate every 18 months for 6 years in osteopenic post-
menopausal women: eﬀects on fractures and non-skeletal end-
points
Ian Reid, Anne Horne, Borislav Mihov, Mark Bolland, Sonja Bastin,
Gregory Gamble
University of Auckland, Auckland, New Zealand
Bisphosphonates prevent fractures in patients with osteoporosis, but
their eﬃcacy in women with osteopenia is unknown. Most fractures in
postmenopausal women occur in osteopenic individuals, so if phar-
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maceutical intervention is to impact signiﬁcantly on total fracture
numbers, therapies with eﬃcacy in osteopenic postmenopausal women
are needed.
We report a double-blind trial of 2000 osteopenic, postmenopausal
women, randomly assigned to receive 4 infusions of either zoledronate
5mg, or normal saline at 18-month intervals. Each was followed for 6
years. Monthly vitamin D supplements were provided but not calcium
supplementation. Women were recruited using electoral rolls. Inclusion
criteria were age >65 years, hip T-score between -1.0 and -2.5.
Exclusion criteria were: lumbar spine T-score <-3.0, eGFR <30 mL/
minute, major systemic disease, metabolic bone disease, or regular use
of bone-active drugs in the previous year. The study has 80% power to
detect a decrease in osteoporotic fractures of 30%.
At baseline, age was 71 (SD 5) y, BMI 27 (5), femoral neck T-score -1.5
(0.5), and 95% were white. Non-vertebral fractures (excluding skull,
face, hands and feet) occurred in 148 women in the placebo group and
in 101 in the zoledronate group (ITT analysis, hazard ratio 0.66 [95%CI
0.51, 0.85], P=0.0014, NNT = 22). Height loss, a surrogate for ver-
tebral fracture, was 9.3 (8.7, 9.9) mm in the placebo group and 7.4 (6.9,
8.0) mm in the zoledronate group (P<0.0001). Odds ratio for pre-
speciﬁed adverse events were as follows: death, 0.65 (0.40, 1.046);
myocardial infarction, 0.61 (0.36, 1.02); cancer 0.67 (0.50, 0.90). Odds
ratio for breast cancer was 0.58 (0.34, 0.98).
These results suggest this less intensive zoledronate regimen is eﬀective
for fracture prevention in osteopenia, and that it has beneﬁcial eﬀects on
cancer risk and, possibly, mortality. These ﬁndings have the potential to
substantially broaden the target population for pharmaceutical inter-
vention to prevent fractures, and suggest that zoledronate should be
further explored for the prevention of cancer and vascular disease.
DISCLOSURE:
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Update on teriparatide and the VERO clinical trial
Fernando Marín
Department Medical Research. Lilly, Madrid, Spain. Lilly Research Center,
Windlesham, United Kingdom
Clinical trials comparing the anti-fracture eﬃcacy of osteoporosis drugs as
the primary outcome are lacking. We compared the anti-fracture eﬃcacy
of teriparatide with risedronate in patients with severe osteoporosis.
In this double-blind, double-dummy trial, we enrolled postmenopausal
women with at least two moderate or one severe vertebral fracture
(VFx) and a bone mineral density (BMD) T-score of less than -1.50.
680 women were randomly assigned to receive 20 µg of teriparatide
once daily plus oral weekly placebo, and 680 to receive 35 mg of oral
risedronate once weekly plus daily injections of placebo for 24 months.
The primary outcome was the incidence of new radiographic VFx.
Secondary, gated outcomes included new and worsened radiographic
VFx, clinical fractures, and nonvertebral fractures. A prospectively
planned subgroup analyses of fracture data across subgroups predeﬁned
by the following baseline characteristics: age, number and severity of
prevalent VFx, prevalent nonvertebral fractures, glucocorticoid use,
prior osteoporosis drugs, recent bisphosphonate use, clinical VFx in the
year before study entry, and baseline BMD was carried out.
At 24 months, new VFx occurred in 5.4% of patients in the teriparatide
group, as compared with 12.0% in the risedronate group (risk ratio:
0.44; 95% conﬁdence interval [CI]: 0.29 to 0.68; p<0.001). Clinical
fractures occurred in 4.8% of patients in the teriparatide group, com-
pared with 9.8% in the risedronate group (hazard ratio: 0.48; 95% CI:
0.32 to 0.74; p<0.001). Nonvertebral fragility fractures occurred in
4.0% of patients in the teriparatide group and 6.1% in the risedronate
group (p=0.10). The rate ratio of all nonvertebral fragility fractures
estimated with a Poisson regression model was signiﬁcant in favour of
teriparatide (rate ratio 0.56; 95% CI 0.35 to 0.90; p=0.017). More
patients treated with teriparatide had at least one high value of serum
calcium or uric acid. 25-OH-vitamin D serum levels were lower in the
teriparatide group.
Amongst postmenopausal women with severe osteoporosis, the risk of
new VFx and clinical fractures was signiﬁcantly reduced in patients
receiving teriparatide compared with those receiving risedronate by
56% and 52%, respectively. The anti-fracture eﬃcacy of teriparatide
compared with risedronate was consistent within the various pre-
deﬁned subgroups.
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Non-invasive imaging of therapeutic responses in bone
Ken Poole
University of Cambridge, UK
Human imaging techniques now permit the evaluation of bone treat-
ment responses in great detail. Advances in 3D histology might have a
role in elucidating the response of bone to treatment, especially in the
rarer causes of bone pathology such as osteomalacia. With potentially
curative treatments such as anti-FGF23 on the horizon for XLH and TIO,
there are good reasons to consider what 3D histological imaging tech-
niques can provide by way of unmineralised and mineralised tissue
quantiﬁcation. Considering emerging osteoporosis therapies, novel
non-invasive imaging techniques have shown that key skeletal regions
such as the hips and spine become denser, thicker and importantly,
stronger within as little as 12 months. Monthly anti-sclerostin antibody
therapy and daily teriparatide injections have both been demonstrated
to have rapid eﬀects both on bone turnover, with particularly beneﬁcial
eﬀects in osteoporotic vertebrae. In this session the advances in ima-
ging that permit non-invasive estimation of vertebral strength, thick-
ness and compartment-speciﬁc density will be discussed.
IS7
Understanding ﬁbrodysplasia ossiﬁcans progressiva (FOP): ge-
netics and biological consequences
Eileen Shore
University of Pennsylvania School of Medicine, Philadelphia, USA. Center
for Research in FOP and Related Disorders, Philadelphia, USA
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During embryonic development, the induction of bone formation is
spatially and temporally regulated to specify the skeletal elements.
After birth, new bone formation is normally limited to regeneration
during fracture repair, a process that is also precisely regulated.
Fibrodysplasia ossiﬁcans progressiva (FOP) is a rare human genetic
disease in which extensive and progressive heterotopic ossiﬁcation –
the formation of bone outside of the normal skeleton – occurs in soft
connective tissues such as skeletal muscle. At birth, there is usually
little indication of the disease, except for a characteristic malformation
of the great toes. However during early childhood, episodes of bone
formation that are frequently associated with swelling and inﬂamma-
tion begin within soft tissues. In most patients examined to date, FOP is
caused by a single nucleotide change in the BMP type I receptor ACVR1
(Activin A receptor, type 1; alias, ALK2) that causes enhanced pathway
activation. All patients with a classic clinical presentation of the disease
possess a recurrent heterozygous c.617G>A (R206H) mutation.
Heterotopic ossiﬁcation in FOP frequently forms in response to tissue
injury, although also develops in the absence of overt tissue trauma.
Within the tissue, heterotopic bone formation in FOP patients pro-
gresses through well-described changes in aﬀected tissue: initial cata-
bolic events are followed by an anabolic stage and formation of en-
dochondral bone. In vivo mouse models have been instrumental in
providing a more detailed understanding of the tissue, cellular, and
molecular impact of the ACVR1 R206H mutation and the structural
changes in the soft connective tissues that are transitioning to cartilage
and bone. In response to injury, initial steps of wound healing in mutant
tissue appear to be normal, including an early immune response that
leads to tissue degradation and removal of damaged tissue. However,
this tissue repair trajectory rapidly diverges and, instead of repairing
and regenerating the injured muscle tissue, ectopic cartilage and bone
are formed. Understanding these events are providing more detailed
insight into the tissue, cellular, and molecular impact of the ACVR1
R206H mutation and the mechanisms that regulate tissue maintenance,
repair, regeneration, and heterotopic bone formation.
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Activin A and ACVR1 variants as tools to explore Activin A’s ability
to inhibit BMP-mediated signaling via ACVR1
Aris Economides, Richard Corpina, Alexandra Dimitriou, Sarah
Hatsell, Vincent Idone
Regeneron Pharmaceuticals, Inc., Tarrytown, USA
The genetic disorder Fibrodysplasia Ossiﬁcans Progressiva (FOP) is
caused by mutations in the intracellular domain of the type I Bone
Morphogenetic Protein (BMP) receptor ACVR1. ~97% of FOP patients
carry the variant ACVR1R206H. A signiﬁcant breakthrough in under-
standing FOP was the discovery that Activin A, a BMP/TGFbeta family
member, is a required factor for the development of HO in FOP by
acting as an agonistic ligand on ACVR1R206H (Hatsell, Idone et al,
2015). In contrast, Activin A normally antagonizes BMP signaling
mediated via wild type ACVR1. Outside of FOP, Activin A has been
studied as an agonist of type I receptors ALK4 and ALK7; hence, its
antagonistic properties remain largely unexplored. We are now ad-
dressing this knowledge gap by generating Activin A ‘muteins’ that
cannot antagonize ACVR1, as well as ACVR1 muteins that cannot re-
cognize Activin A. The learnings obtained thus far with these muteins
will be presented in the context of FOP, to inform the question of
whether BMPs can bypass the apparent requirement of Activin A as an
HO-causing ligand in FOP, and beyond FOP, to address the question of
whether the ability of Activin A to act as an inhibitor of BMP signaling
mediated by Acvr1 has physiological signiﬁcance.
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FOP and HME: Rare pediatric disorders with distinct causes, but
amenable to a similar treatment?
Maurizio Paciﬁci
The Children's Hospital of Philadelphia, Philadelphia, USA
Abstract
Fibrodysplasia Ossiﬁcans Progressiva (FOP) is a rare pediatric disorder
caused by gain-of-function mutations in ACVR1 that encodes the bone
morphogenetic protein (BMP) receptor ALK2. FOP is characterized by
formation and accumulation of extraskeletal endochondral bone at the
expense of muscles and other connective tissues, resulting in pro-
gressive impairment of body function and even premature death.
Hereditary Multiple Exostoses (HME) is a rare pediatric disorder linked
to loss-of-function mutations in EXT1 or EXT2 that encode Golgi en-
zymes responsible for heparan sulfate (HS) synthesis, resulting in HS
deﬁciency. HME involves the formation of benign cartilaginous-bony
tumors developing next to the growth plate in long bones, ribs and
vertebrae that cause multiple skeletal abnormalities and problems and
can transition to malignancy in some cases. Despite their obvious ge-
netic and clinical diﬀerences, FOP and HME share certain basic pa-
thogenic mechanisms. Chief among them is the fact that both require
the reprogramming and developmental redirection of progenitor cells
to form ectopic cartilage and bone at extraskeletal sites and within
neighboring tissues. Important also is the fact that both disorders rely
on abnormal and exuberant action by protein signaling pathways, in-
cluding the BMP pathway. These and other signiﬁcant ﬁndings have
resulted in a far better understanding of the cellular and molecular
pathogenesis of FOP and HME, with contributions by many research
groups. I will summarize salient data from such studies as well as new
data from ongoing studies, pointing to druggable therapeutic targets for
these diseases one of which is currently been investigated for clinical
relevance and eﬀectiveness.
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Clinical trials in rare bone diseases: challenges and revelations
Richard Keen
Royal National Orthopaedic Hospital, Stanmore, United Kingdom
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Fibrodysplasia ossiﬁcans progressive (FOP) is rare disorder, aﬀecting
approximately 1 in 2 million people (1). Since the discovery of the
ACVR1 gene, advances in our understanding about disease pathology
have led to the identiﬁcation of possible drug targets which are cur-
rently be studies in clinical trials. There are, however, considerable
challenges in undertaking trials in such a rare disease (2). Disease re-
gistries are important and how they can help identify subjects who may
be suitable participants in a trial, but also give useful information about
the natural history of the disease (3). It can be useful to have the
backing of patient support groups and charities to help publicise these
registries and aid recruitment. When designing a trial, the end points of
both clinical and regulatory signiﬁcance need to determined (4,5), and
there will need to be discussion with the appropriate authorities.
Designation of the drug in an orphan disease indication will help these
discussions and fast-track the process. With small samples sizes, the
classical randomised, placebo-controlled trial may not be possible, and
there are challenges in study design and in whether a historical control
group or a natural history study can be used as the comparator. With
limited patient numbers, participants often have to be recruited across a
number of countries and sites, and there is a large administrative
burden in managing these studies. Despite these challenges, progress is
being made and some of the preliminary data from these studies will be
shared.
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Novel approaches to the treatment of inherited disorders of
phosphate metabolism: FGF23 and other targets
Thomas Carpenter
Yale University School of Medicine, New Haven, USA
Hypophosphatemic rickets due to excess urinary excretion of phosphate
occurs in several related disorders. X-linked hypophosphatemia (XLH),
caused by loss-of-function mutations in PHEX, is the most common of
these, and is the prototype disorder of excess FGF23 activity. Impaired
renal tubular phosphate reabsorption and altered vitamin D metabolism
are the cardinal physiologic sequelae of excess FGF23 activity in XLH,
thus conventional therapy has consisted of frequent administration of
oral phosphate together with 1,25 dihydroxyvitamin D (1,25D) as a
replacement strategy. This approach has been the mainstay of therapy
for four decades, but the therapy is cumbersome, fraught with com-
plications, and often leaves patients with incomplete correction of de-
formity.
A humanized monoclonal antibody (burosumab) designed to inhibit
FGF23 activity has been developed as a novel approach to treat XLH.
We present here a summary of our extended clinical trial experience
with burosumab in children and adults: In the ﬁrst pediatric trial, 5-12
year old children with XLH received burosumab every 2 or every 4
weeks; with both groups showing improvements in biochemical,
radiographic, and patient-reported outcomes despite prior conventional
therapy. Next, a trial in 1-5 yr old children with XLH given burosumab
every 2 weeks improved biochemical and radiographic outcomes by
week 24 of therapy. A study of burosumab in adults with XLH has
shown improved biochemical and patient-related outcomes compared
to a placebo-treated group, with increased healing of fractures and
pseudofractures identiﬁed at baseline.
Children and adults aﬀected with XLH would beneﬁt from a more ef-
fective and better-tolerated therapy than currently available ap-
proaches. Administration of burosumab every 2-4 weeks improved
clinically important outcomes in growing children, and burosumab
treatment of aﬀected adults improved biochemical, radiographic, and
patient-reported outcomes. Inhibition of FGF23 activity using an anti-
FGF23 inhibitory antibody appears to be a safe and eﬀective strategy.
DISCLOSURE:
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Treating skeletal dysplasia and achondroplasia
Melita Irving
Guy's and St Thomas NHS Trust, London, United Kingdom
Abstract
Skeletal dysplasia refers to abnormal development of the skeleton,
usually owing to pathogenic variants in genes encoding proteins es-
sential to growth plate function, eﬀective ossiﬁcation, bone modelling
and turnover, and skeletal patterning. There are known to be over 450
distinct types of skeletal dysplasia condition, with a range of clinical
expression and severity. The FGFR3-associated condition achon-
droplasia is the most common type of skeletal dysplasia that causes
disproportionate short stature (dwarﬁsm) As our knowledge of the
causative molecular mechanisms continues to improve and better ap-
preciation of the underlying disruption of key pathways in skeletal
development is determined, opportunities to manipulate these net-
works and develop new therapeutic strategies emerge. Success of these
potential new treatments though is contingent upon our full under-
standing of the natural history of skeletal dysplasia conditions. Indeed
this knowledge constitutes the mainstay of current medical manage-
ment in the multidisciplinary setting.
In this talk, current practices in clinical care in skeletal dysplasia, with
focus upon achondroplasia as an exemplar, will be outlined. A overview
of current clinical trials will be provided and a look towards the future
will provide glimpse of what lies on the horizon in treating skeletal
dysplasia.
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New approaches to treating disorders of the calcium-sensing re-
ceptor
Fadil Hannan
University of Liverpool, Liverpool, United Kingdom. University of Oxford,
Oxford, United Kingdom
The calcium (Ca2+)-sensing receptor (CaSR) is a family C G-protein
coupled receptor (GPCR) that senses extracellular concentrations of
Ca2+and amino acids. The CaSR is most highly expressed in the para-
thyroid glands and kidneys, where it regulates parathyroid hormone
(PTH) secretion and urinary Ca2+ excretion, respectively. Germline
loss- and gain-of-function CaSR mutations cause familial hypocalciuric
Journal of Bone Oncology 13 (2018) 11–54
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hypercalcaemia (FHH) and autosomal dominant hypocalcaemia (ADH),
respectively. CaSR signal transduction is regulated by G-protein subunit
α11 (Gα11) and adaptor-related protein complex-2 sigma subunit
(AP2σ), and recent studies have identiﬁed germline mutations of these
proteins as a cause of FHH and/or ADH. Calcimimetics and calcilytics
are positive and negative allosteric modulators of the CaSR that have
potential eﬃcacy for symptomatic forms of FHH and ADH. Cellular
studies have demonstrated that these compounds correct signalling
defects caused by mutant CaSR, Gα11 or AP2σ proteins. Moreover,
mouse model studies indicate that calcilytics can rectify the hypo-
calcaemia and hypercalciuria associated with ADH, and patient-based
studies reveal calcimimetics to ameliorate symptomatic hypercalcaemia
caused by FHH. Thus, calcimimetics and calcilytics represent targeted
therapies for inherited disorders of the CaSR and its partner proteins.
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Which therapeutic interventions are, or will be, beneﬁcial to pa-
tients with Osteogenesis Imperfecta, and how do we determine
this?
Matthew Warman
Boston Children's Hospital and Harvard Medical School, Boston, USA
Osteogenesis Imperfecta (OI) comprises a heterogeneous group of
Mendelian genetic disorders that cause skeletal fragility. Most patients
with OI have dominant forms of the disease caused by type I collagen
mutations. Mutations in collagen chaperones or in signaling pathway
proteins cause recessive forms of OI seen more commonly in popula-
tions with higher coeﬃcients of inbreeding. A major focus of therapy
for all forms of OI is to prevent fracture and skeletal deformity.
However, these clinical problems are not the only ones that aﬀect an OI
patient’s quality of life. In order to improve bone strength in patients
with OI, drugs approved for osteoporosis are being used oﬀ-label; the OI
community is also anxious to participate in clinical trials for newer
bone anabolic agents. However, companies have been slow to embrace
OI as a target for clinical trials even though OI is among the more
common of the rare genetic diseases aﬀecting bone. This presentation
will address the challenge of performing clinical trials in patients with
OI, the missed opportunities that may result from conﬂating patients
with OI and those with osteoporosis, and the ethical conﬂict of waiting
for a drug’s safety and eﬃcacy to ﬁrst be conﬁrmed in a common
condition before clinical trials are initiated in a rare condition for which
the therapeutic eﬀect might be larger.
KEY REFERENCE
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Hunting for a therapeutic for sclerosteosis: a personal story
Timothy Dreyer1, 2, Mittal Shah2, Carl Doyle2, David McMillan2,
Alistair Henry2, David Ke2, Gill Holdsworth2, Vinny Naidoo1
1University of Pretoria, Pretoria, South Africa, 2UCB, Slough, UK
Sclerosteosis is a severe autosomal recessive sclerosing skeletal dys-
plasia that is characterised by excessive bone overgrowth. It is caused
by mutations in the SOST gene which lead to loss of expression of the
protein sclerostin (Scl). The condition has provided great insights into
the importance of sclerostin as a negative regulator of bone formation
through its actions as an inhibitor of the canonical Wnt signalling
pathway. Antibodies to inhibit sclerostin are currently in development
for the treatment of low bone mass conditions such as osteoporosis. In
contrast, the clinical management of sclerosteosis is limited to surgical
intervention. I am a sclerosteosis patient, and the aim of this study is to
explore exogenous recombinant Scl as a potential therapeutic approach
in sclerosteosis.
Recombinant wild type Scl and various fusions thereof were produced
by mammalian expression and were puriﬁed using standard chroma-
tography approaches. High aﬃnity (nM) binding of recombinant Scl
proteins to the Wnt co-receptor, LRP6, was demonstrated in vitro, and
addition of puriﬁed recombinant Scl proteins inhibited mineralisation
of MC-3T3 cells cultured in osteogenic conditions.
The pharmacokinetic properties of these proteins will now be explored
in vivo and the skeletal consequence of administration of these proteins
in a mouse model of sclerosteosis (SOST knock out mice) will be ex-
amined. This approach will provide insights into the potential of exo-
genous recombinant Scl as a treatment strategy for sclerosteosis.
This work is part-funded by UCB Pharma and the National Research
Foundation of South Africa
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The genetics and pathophysiology of Paget’s disease
Luigi Gennari
Dept. of Medicine, Surgery and Neurosciences, University of Siena, Siena,
Italy
Paget's disease of bone (PDB) is a chronic bone disorder which typically
results in enlarged and deformed bones in one or more regions of the
skeleton. The characteristic feature of the disease is an increased re-
sorption followed by an increase in bone formation. At aﬀected sites,
excessive bone breakdown and formation produces a disorganized and
structurally abnormal bone. As a result, bone pain, arthritis, noticeable
deformities and fractures can occur. In a small proportion of cases (<
1%) neoplastic degeneration in osteosarcoma, or, less frequently, giant
cell tumor has been described. Over the last two decades, thanks to the
development in technology, remarkable advances have made on the
genetic causes of PDB. Together with the discovery of the genes asso-
ciated with the pathogenesis of PDB-related syndromes (e.g.
TNFRSF11A, TNFRSF11B, and VCP) mutations in SQSTM1 gene were
described in up to 50% of familial and 15% of sporadic cases by a wide
variety of investigators in several populations. This gene encodes for
p62 protein, that acts as a scaﬀold in a range of signaling and ubiquitin
binding pathways. Relevant to bone biology, p62, through its interac-
tion with TRAF6, acts as a scaﬀold in signaling pathways involved in
Journal of Bone Oncology 13 (2018) 11–54
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the activation of NFkB transcription factor, including the pathway
which mediates RANKL activated osteoclastogenesis. More recently,
other candidate genetic variants were associated with PDB by a large
genome-wide approach, explaining about 13% of the familial risk of
PDB in SQSTM1 negative patients, and mutations in at least two addi-
tional genes (ZNF687, FKBP5) were identiﬁed in a limited number of
cases. In particular, a recurrent mutation of ZNF687 has been described
in severe, early onset, cases with neoplastic degeneration in giant cell
tumor. As a counterpart to the genetic hypothesis, the focal nature of
skeletal lesions together with the decline in prevalence rates and the
incomplete penetrance of the disease among family members all suggest
that one or more environmental triggers may play a role in the pa-
thophysiology of PDB. However, the exact nature of these triggers and
how they might interact with the genetic factors in the pathogenesis of
PDB is less understood.
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Secular changes in Paget’s disease: lessons from Medieval times
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Although both the incidence and severity of newly diagnosed cases
have declined over the past few decades, and reasons for these pro-
found secular changes are unclear, Paget’s disease of bone (PDB) re-
mains a relatively common condition. PDB-like changes have pre-
viously been noted in archaeological remains dating to Roman times,
however accurate diagnoses of ancient forms of the disorder are
lacking. Here we report highly unusual features within a collection of
130 articulated skeletons from the North-West of England dating to
the late Medieval period, with pathological changes resembling PDB.
In contrast to contemporary forms of PDB, this ancient bone disease
was very extensive throughout individual skeletons, with a high pre-
valence, often with low age-at-death estimations, but with very few
skeletal complications. Despite these clear phenotypic diﬀerences,
direct sequencing of ancient proteins extracted from the remains in-
dicates that the subjects were likely aﬀected with a precursor of
contemporary PDB, with detection of a modiﬁed form of a critical
PDB-associated protein. Thus, even greater secular changes may have
occurred in PDB since the late Medieval period. Our work provides
new insights into the natural history of PDB and supports the notion
that ancient forms of the disorder may have been potentiated by as yet
unidentiﬁed genetic factors or environmental triggers. Further
knowledge of these triggers may be relevant in understanding disease
aetiology and the more recent secular changes observed in con-
temporary PDB.
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Sarcopenia, ageing and frailty: deﬁning the scope and opportu-
nities
Cyrus Cooper
MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton, United Kingdom. Institute of Musculoskeletal Science,
University of Oxford, Oxford, United Kingdom
Musculoskeletal disease constitutes a major health burden worldwide.
The principal chronic musculoskeletal disorders are osteoporosis, sar-
copenia and osteoarthritis; these conditions increase in frequency with
advancing age, and understanding their epidemiology throughout the
life course is critical to the development of eﬀective preventive strate-
gies. Osteoporosis contributes to disability and death through its as-
sociation with age related fractures. These fractures typically occur at
the hip, spine and distal forearm. It has been estimated from incidence
rates derived in North America that the lifetime risk of a hip fracture in
Caucasian women is 17.5% with a comparable risk in men of 6%.
Sarcopenia refers to an age related loss of skeletal muscle mass and
function. Between the ages of 20 and 80 years, a decline in muscle ﬁbre
size and number causes a loss of muscle mass (30%), with a greater
accompanying loss of muscle strength (60%). The origins of sarcopenia
are multifactorial and include biological senescence, muscle disuse,
endocrine dysfunction, comorbidity, inﬂammation and nutritional de-
ﬁciency. While the clinical relevance of sarcopenia is widely re-
cognised, there remains no universally accepted deﬁnition of the term.
Recent approaches to deﬁnition incorporate combinations of decline in
fat free mass by DXA; strength assessments using isometric dynamo-
metry; and poor physical performance using observational tests (gait
speed, sit to stand time and standing balance). The establishment of
these recent methods for the assessment of sarcopenia has led to a
characterisation of the prevalence of this disorder with advancing age
in men and women. Modiﬁcations of the deﬁnition will inform out-
come studies and future randomised controlled trials. Finally, shared
aetiological mechanisms underpinning the senescence of bone, muscle
and joint, will open an arena in which novel therapeutic strategies for
musculoskeletal disease will become available.
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The Role of Senescence in Bone Biology
Sundeep Khosla
Mayo Clinic, Rochester, MN, USA
With the aging of the population and projected increase in osteoporotic
fractures, coupled with the declining use of osteoporosis medications,
there is a compelling need for new approaches to treat osteoporosis.
Given that age-related osteoporosis generally co-exists with multiple
other co-morbidities (e.g., atherosclerosis, diabetes, frailty), all sharing
aging itself as the leading risk factor, there is growing interest in the
“Geroscience Hypothesis”, which posits that manipulation of funda-
mental aging mechanisms will delay the appearance or severity of
multiple chronic diseases because these diseases share the same un-
derlying risk factor – age. In this context, one fundamental aging me-
chanism that has received considerable attention recently as con-
tributing to multiple age-related morbidities is cellular senescence.
There is now convincing evidence that senescent cells accumulate with
age and drive age-related tissue dysfunction. Consistent with this, se-
nescent cells have been shown to increase with aging in the bone mi-
croenvironment in mice and in humans. These cells produce a pro-
inﬂammatory secretome that leads to increased bone resorption and
decreased bone formation, and approaches that either eliminate se-
nescent cells or impair the production of their pro-inﬂammatory se-
cretome have been shown to prevent age-related bone loss in mice.
Moreover, targeting senescent cells leads to a reduction in bone re-
sorption and either a maintenance (trabecular bone) or increase (cor-
tical bone) in bone formation, thus making this approach
Journal of Bone Oncology 13 (2018) 11–54
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fundamentally diﬀerent from conventional anti-resorptive therapy,
which leads to a reduction in bone resorption and a coupled decrease in
bone formation. Thus, targeting cellular senescence represents a novel
therapeutic strategy to prevent not only bone loss but potentially
multiple age-related diseases simultaneously.
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Addressing fracture risk in the elderly with novel therapeutics
Gary Krishnan
Eli Lilly, Indianapolis, USA
Therapeutic approaches for osteoporosis (OP) have followed a dis-
covery and development paradigm that highlighted the imbalance of
exuberant bone resorption at the onset of this disease. This led to the
successful launch and treatment of numerous anti-resorptives, spear-
headed by bisphosphonates as ﬁrst line therapies. However, as we ap-
proach the new millennium, OP patients have exhausted their potential
interventions to rescue their bone strength to prevent future incident
fracture. These are driven by limitations on use of anabolic therapies
such as teriparatide (≤ 2 yrs.), and the emerging rare but relevant risks
associated with anti-resorptives because of suppression of bone turn-
over. In addition, the elderly patients who suﬀer from lower limb
skeletal muscle strength tend to be pre-disposed to fall-related fragility
fractures. We will highlight the development of therapies that target
this most exigent patient population who are at a high risk of fall re-
lated injuries including fractures. The therapy will discuss the con-
comitant improvement in skeletal muscle power and bone strength that
could oﬀer a unique protection from fall-related fractures for a sub-set
elderly patients.
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Eﬀects of bone active drugs on health and life span
John A Eisman
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Osteoporosis is an interesting stage in its management worldwide. We
now have available a variety of eﬀective the well-tolerated treatments
that have good safety proﬁles albeit with some potential adverse eﬀects
of low frequency. Hence it is surprising that a small proportion of
women, perhaps 20 to 30%, and an even smaller proportion of men,
perhaps 5 to 10%, receive eﬀective anti-osteoporosis therapy even after
well-recognised fragility fractures.
Many possibilities have been proposed for this low level of treatment.
They include lack of understanding of the signiﬁcance of the osteo-
porotic fractures with respect to future fragility fractures and early
mortality and concerns about side eﬀects despite their very low fre-
quency. In this context, evidence of the excess mortality after all types
of fragility fracture and the potential reduction of that excess mortality
with eﬀective anti-osteoporosis therapy has major clinical signiﬁcance.
In one large randomised controlled trial of intravenous zoledronic acid
after hip fracture in both men and women, there was a 28% reduction
in mortality in the treated individuals. A subsequent meta-analysis of all
of the pivotal studies of all the anti-osteoporosis drug indicated a 10%
lower mortality in the treated individuals. There are now a number of
observational studies that show a similar outcome, often with even
larger reductions in mortality.
Despite these ﬁndings, this is not considered part of the therapeutic
paradigms post fragility fracture. The challenge is the lack of a vali-
dated pharmacological mechanism for these apparent beneﬁts. Possible
mechanisms include prevention of release of bone sequestered toxic
factors, including lead, and or inﬂammatory factors as well as possible
actions in other tissues outside the skeleton.
This presentation will review both the randomised controlled trial and
cohort data and discuss potential biological mechanisms for this eﬀect.
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Clinical trials for patients with co-morbid conditions
Steven Cummings
San Francisco Coordinating Center, San Francisco, USA
Conventional randomized trials have proved the eﬃcacy of several drugs
for the “treatment of osteoporosis.” These drugs are underused parti-
cularly by patients with comorbid conditions who have the highest risk
of fracture. This is partly a consequence of the design of those conven-
tional trials. They enrolled people “with osteoporosis” by screening
general populations and practices of osteoporosis specialists with BMD,
risk assessment, and spine imaging, intended to maximize the eﬃcacy
and minimize the sample size to demonstrate reduction in new vertebral
deformities from radiographs. Consequently, patients deserving treat-
ment are also sought (or not) by generalists or osteoporosis specialists by
screening with BMD, risk assessment, and occasionally spine imaging.
The yield of this strategy has been shrinking and at least half of those
discovered to “need treatment” stop taking it within a year.
In the U.S. there are more patients who have a substantially increased
risk of hip fracture because they have a disease, such as Parkinson’s
disease, than there are patients with a T-score < -2.5. Evidence that
drugs are eﬃcacious for these older sicker patients is typically missing
because they have been excluded from conventional trials. These pa-
tients would warrant treatment at lower thresholds of fracture risk
because the preventable consequences of fractures are more severe.
However, very few receive and even fewer continue oral drug treat-
ments.
Older patients with Parkinson’s disease (PD) have a very high risk of
fracture but rarely receive treatments for osteoporosis. We have de-
signed a US-wide trial to be conducted without clinical sites to test the
approach of simply treating older Parkinson’s patients with zoledronate
at home by a visiting nurse without BMD testing or individual risk as-
sessment. If successful, it could lead to nearly universal long-lasting
treatment of older patients with Parkinson’s disease. The trial could
provide a model for reaching many more patients who could have the
greatest beneﬁts of drug treatment that reduces fracture risk.
Journal of Bone Oncology 13 (2018) 11–54
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Ageing and musculoskeletal function: an update on the work of
the Centre for Musculoskeletal Ageing Research
Janet Lord
University of Birmingham, Birmingham, United Kingdom
The MRC-ARUK Centre for Musculoskeletal Ageing Research was
awarded in 2012 and renewed in 2017 for a further 5 years. It is a
partnership between the Universities of Birmingham and Nottingham
and aims to understand the mechanisms underlying age-related mus-
culoskeletal decline with a focus on sarcopaenia. Furthermore in its
second phase the centre will investigate the links between age and
musculoskeletal diseases, notably rheumatoid arthritis. The ultimate
goal is to develop interventions to prevent or reverse musculoskeletal
decline with age and the centre includes a theme on interventions
which includes lifestyle, nutrition and pharmacological approaches. To
date the Centre has revealed some of the mechanisms that drive ana-
bolic resistance in muscle, shown that obesity may not in fact accelerate
sarcopaenia but instead modify the metabolic quality of muscle, de-
veloped a technology platform to use isotope labelling methods to asses
tissue turnover in community dwelling adults, co-developed novel MRI
methods to assess brain oxygen uptake in adults during exercise, in-
vestigated the role of the age-related decline in immune function with
the increased systemic inﬂammation found in ageing, carried out trials
with nutriceuticals to improve muscle metabolism in older adults, de-
termined just how much of age-related musculoskeletal decline is
driven by reduced physical activity with age.
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Big Data: integrating omics and cohorts
André Uitterlinden
Erasmus MC, Rotterdam, Netherlands
Many if not all human diseases and phenotypes have a genetic com-
ponent. Twin studies show that in particular the so-called complex
diseases and traits are heritable and that a certain fraction of the var-
iance among individuals is genetically determined varying typically
between 20-80%. The Human Genome Project and its sequela have
shown that the sequence of the human genome is in fact characterized
by numerous genetic variations (ranging from small Single Nucleotide
Polymorphisms to very large Copy Number Variations).Wwe currently
estimate that ~5% of all 3.3 billion nucleotides in the human genome
varies between subjects. In parallel, DNA analysis technology has un-
dergone several revolutions whereby it is now possible to sequence a
complete human genome in <24hours, and to analyze millions of SNPs
in millions of DNA samples. Together with the existence and creation of
large and well-characterized longitudinal cohorts studies and biobanks,
this DNA analysis technology has resulted in the identiﬁcation of
thousands of genetic factors by Genome Wide Association Studies
(GWAS). Such genetic factors are now beginning to ﬁnd their way into
clinical, forensic, and societal practice (such as with Direct To
Consumer (DTC) Companies as 23andme). GWAS and studies using
other genomic technologies based on analysis of DNA methylation, RNA
expression, and/or microbiomes, have led to global collaborative con-
sortia. In these consortia the best possible way to execute scientiﬁc
experiments is taking place including replication of discoveries in one
and the same collaborative study (and resulting manuscript). This new
culture of doing scientiﬁc research is not common in all scientiﬁc dis-
ciplines and so several learning curves are being followed currently. I
will describe some aspects of these developments, highlight a few il-
lustrative examples and provide an outlook on future developments and
opportunities.
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Bone biomarkers
Richard Eastell
University of Sheﬃeld, Sheﬃeld, United Kingdom
Bone turnover markers reﬂect the work of the osteoblast and the os-
teoclast. They can be measured in blood or urine and allow for an in-
expensive and non-invasive way to study bone metabolism. They have
been evaluated for their use in predicting risk of fracture, accelerated
bone loss or the presence of secondary osteoporosis, but for all these
uses they are not yet established. They are useful in monitoring the
response to treatment of osteoporosis, especially with drugs such as oral
bisphosphonates. One study focused on the clinical utility of modern
spectrum of bone turnover markers for monitoring oral bisphosphonate
therapy (alendronate, ibandronate, risedronate) in women with post-
menopausal osteoporosis. The study concluded that two approaches
could be used to identify response, namely a change beyond the least
signiﬁcant change or a change to below the mean value of bone turn-
over in healthy young women (1). This approach identiﬁed about 90%
of women from the study as responding by 12 weeks on treatment. The
International Osteoporosis Foundation and European Calciﬁed Tissue
Society proposed that a bone marker measurement made after 12 weeks
was a good way to identify patients who are not adhering to therapy, as
non-adherence is the commonest reason for non-response (2). Bone
turnover markers have proven useful in drug development. They pro-
vide information about the mechanism of action of a drug, for example
anabolic or anti-resorptive, and for the optimal dose and schedule of
treatment.
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Clinical utility of circulating microRNAs for diagnosis of bone
diseases
Matthias Hackl
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MicroRNAs are small RNA molecules that control changes in cell
function by selectively regulating the synthesis of proteins. Circulating
microRNAs, which are secreted into the blood by many cell types, are
associated with physiologic and pathologic processes at the cellular
level, and thus may allow conclusions on the development and pro-
gression of diseases before clinical symptoms are evident. MicroRNAs
fulﬁl key requirements of diagnostic tools such as i) non or minimally
invasive accessibility, ii) robust, standardized and non-expensive
quantitative analysis, iii) rapid turnaround of the test result and iv)
most importantly, because they provide a comprehensive snapshot of
current physiologic process in cells and tissues that package and release
microRNAs into cell-free space. These characteristics have established
circulating microRNAs as extremely promising biomarker candidates.
We have investigated the role of microRNAs in the context of bone
function and dysfunction and have found that serum concentrations of
certain microRNAs diﬀer between fractured and non-fractured patients
of osteoporosis [1,2], are responsive to anti-resorptive as well as ana-
bolic treatment, and are associated with parameters of bone quality as
detected by imaging techniques [3].
Recently, using OVX rats we were able to investigate time-dependent
eﬀects of anti-resorptive treatment as well as anabolic treatment on
microRNA levels in serum and femoral bone. Furthermore we could
show that patients with monogenetic (WNT1) diseases show an aber-
rant serum microRNA pattern that overlaps partially with that of
postmenopausal osteoporosis [4].
Based on our research ﬁndings, we have developed a prototype fracture
risk assessment tool (the osteomiR™ test) based on a panel of
microRNAs measured in blood. In order to generate evidence of the
test’s usefulness in terms of beneﬁt to the patient and resource con-
sumption, we have conducted a health economic study. Our simulations
provide evidence for the utility of the osteomiR™ test for fracture risk
assessment, and, furthermore, highlight the potential of circulating
microRNAs to be exploited as minimal-invasive diagnostic tools [5].
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Regenerative medicine and bone tissue engineering: clinical
translation
Frank Luyten
KU Leuven, Leuven, Belgium
Cell based therapies, classiﬁed in Europe as Advanced Therapy
Medicinal Products, have been explored for more than 2 decades now
as potential therapeutics in a large variety of clinical indications, in
particular also skeletal tissue repair. Their clinical impact has so far
been limited and this is due to many factors such as our lack of un-
derstanding of the mechanisms of action, the poor correlation between
in vitro cell characteristics and in vivo outcome in patients, and the lack
of robust manufacturing (1).
Recent scientiﬁc insights indicate that expanded mesenchymal stromal
cells (MSC) are aﬀecting tissue repair by paracrine mechanisms thereby
boosting the endogenous repair potential. However in large (bone)
tissue defects and in compromised conditions, the data indicate that the
generation of cell based tissue engineered implants is required, where
the stem/progenitor cells serve as “raw materials” to make the con-
struct. Indeed, the cells are contributing to the in vitro production of
living tissue intermediates or provisional tissues that upon implantation
direct a repair process in vivo with restoration of tissue function.
We have been focusing on the in vitro manufacturing of cartilage tissue
intermediates, following our developmental engineering paradigm
(2,3), to try to repair large long bone defects in vivo. We have chosen
the human periost as tissue source, and using periosteal derived cell
populations (hPDC), we have generated distinct cartilage tissue inter-
mediates in vitro, leading to successful ectopic bone formation and
orthotopic bone bridging in vivo in nude mice. Examples will be dis-
cussed including combination products using hPDCs, low dose Bone
Morphogenetic Proteins (BMP) on optimized scaﬀolds; implants pro-
duced using pre-conditioning media and BMP priming of periosteal
cells on a scaﬀold (4); and spheroid based micro-tissues assembled into
cartilaginous macro-tissues. Similar approaches have been explored
successfully using induced pluripotent stem cells (iPS). The successful
implants in the small animal models have been transferred into a pre-
clinical track into large animal models, being a critical size long bone
defect model and a non union long bone defect model in sheep (5),
with the intention to initiate a clinical explorative trial in patients.
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BMPs and bone repair
Slobodan Vukicevic
University of Zagreb, School of Medicine, Zagreb, Croatia
A novel BMP6 based autologous bone graft has been developed with
superior healing results and reduced side eﬀects in preclinical studies. It
was tested in Phase I/II clinical studies in patients with a distal radius
fracture (DRF) and high tibial osteotomy (HTO). It comprises of an
autologous carrier made from the peripheral blood (ABC – autologous
blood coagulum) and of rhBMP6. Such formulation circumvents the use
of animal-derived materials, signiﬁcantly limits inﬂammatory processes
and renders the carrier ﬂexible and injectable ensuring the ease of use.
The primary objectives of the DRF ﬁrst-in-human study were safety,
tolerability and systemic pharmacokinetics. There were three groups of
patients enrolled: standard of care, ABC alone and ABC+rhBMP6. In
Phase I 36 patients have been enrolled, while additional 39 patients will
be enrolled in Phase II. The Osteogrow device was formulated from 1
mL of autologous blood and 250 μg of rhBMP6, while placebo was
formed from 1 mL of autologous blood. No measurable plasma amounts
of rhBMP6 were detected after 5 min to 7 days, or BMP6 antibody after
13 weeks. In addition, no serious adverse eﬀects (SAE) have been re-
ported, including swelling, redness of the skin, edema, distant soft
tissue ossiﬁcation, pain or systemic side eﬀects. The use of a small dose
of rhBMP6 minimized the risk of side eﬀects and antibody production
as opposed to available therapy of DRF patients with a large dose of
BMP2 or BMP7 in a similar application.
In patients with HTO the weight bearing part of the knee was shifted
from overloaded knee compartment to realign the knee pressure. A
randomized, double blind, placebo controlled trial was conducted in
two stages in 20 patients treated with 10 ml ABC containing placebo or
1 mg rhBMP6. Phase I included 6 patients and in Phase II the remaining
16 patients were enrolled. No SAEs have been reported, and at 24
weeks of radiological follow up there were diﬀerent patterns of bone
healing within the osteotomy wedges observed. The results are cur-
rently evaluated and will be presented at the meeting.
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Clinical trials in degenerative disc disease
Lovorka Grgurevic
University of Zagreb, School of Medicine, Zagreb, Croatia
We will conduct a clinical program for the evaluation of a novel bone-
regeneration product OSTEOproSPINE as a treatment for intractable
chronic back pain. OSTEOproSPINE is a novel bone regeneration
therapy composed of OSTEOGROW (recombinant human bone mor-
phogenetic protein 6 [rhBMP6] delivered in autologous peripheral
blood coagulum) reinforced with allograft (a compression resistant
matrix). Preclinical results showed promising results of postero-lateral
spine fusion procedure in rabbits and sheep. OSTEOproSPINE in
humans is designed to guide the formation of new bone at extraskeletal
site and replace autograft harvested from patient’s iliac crest for the
fusion of lumbar vertebrae. By generating new bone, OSTEOproSPINE
will restore the spine’s weight bearing function, reduce the severity of
back pain and improve the success rate of posterolateral spinal fusion
surgery. The program consortium of 13 partners from 6 EU member
states has been assembled to conduct a Phase II, randomized, patient-
and evaluator-blinded clinical trial of OSTEOproSPINE. Three clinical
centers will enroll 192 patients suﬀering from degenerative disc disease
to assess OSTEOproSPINE eﬃcacy and safety in comparison with
Standard of care (autograft). A positive outcome of proposed trial will
conﬁrm OSTEOproSPINE potential to form a functioning new bone in
human and by this restore the spine’s function and improve the quality
of life in patients with degenerative disc disorders using the ground
principle of regenerative medicine: “provide the correct molecular
signals to a population of presumptive cells in a permissive micro-
environment”.
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Update on the pathogenesis of pain in OA
Tonia Vincent
University of Oxford, Oxford, United Kingdom
How pain arises in OA has divided the community for the past 30 years.
Epidemiology demonstrates independent correlations between pain and
synovitis, bone marrow oedema and cartilage loss. Causative evidence
for any of these tissues has been missing. We have studied spontaneous
painful behaviour in surgical models of murine OA. We have observed
that pain behaviour occurs late in disease, long after cartilage damage
and bone remodelling has started, and in the absence of signiﬁcant
synovitis. Careful molecular analysis reveals that key pain sensitising
molecules, including nerve growth factor (NGF) are regulated ex-
clusively in articular cartilage at the time of pain. Pain behaviour in
murine OA is abrogated by NGF neutralisation. These data will be re-
viewed and new data on novel methods for suppressing NGF will be
presented.
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Marrow lesions, pain and osteoarthritis
Nidhi Sofat
St George's, University of London, London, United Kingdom
Osteoarthritis (OA) is a condition aﬀecting the whole joint and is the
most prevalent arthritis worldwide. A number of pathological changes
are recognised in OA, including deterioration of cartilage integrity,
subchondral bone changes and synovitis. Although advances have been
made in our understanding of OA pathophysiology, there are no current
treatments that halt the progression of the disease. Treatments are
largely based upon physical therapies to improve function, anti-in-
ﬂammatory agents for pain and joint replacement surgery for late stage
disease in larger weight bearing joints. There is an urgent need to better
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understand OA pathophysiology, which could help in the development
of new treatments. Historically, evidence of OA structural damage was
established using plain radiography of aﬀected joints. In recent years,
more advanced imaging techniques including magnetic resonance
imaging (MRI) have led to an improved understanding of changes at the
bone-cartilage interface in OA, with recognition that loss of integrity at
the cartilage-bone junction and development of bone marrow lesions
(BMLs) in the subchondral bone is associated with OA pain from large
epidemiological studies. One of the next big challenges in OA BML
research has been to identify the structural characteristics, gene and
protein expression in OA BMLs. Gene analyses of BMLs have demon-
strated that they are highly metabolically-active structures, demon-
strating evidence of angiogenesis, new bone/cartilage formation and
expression of neurotrophic factors. Findings from gene and protein
studies of BMLs will be discussed in this talk. The gene signature of
BMLs may assist in identiﬁcation of new molecular targets in OA pa-
thophysiology and treatment.
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Zoledronic acid in arthritis
Erik Fink Eriksen1, Maziar Shabestari2
1Oslo University Hospital and Institute of Clinical Medicine University of
Oslo, Oslo, Norway. 2Institute of Odontology University of Oslo, Oslo,
Norway
Bisphosphonates have been shown to reduce erosions in rheumatoid
arthritis (RA) in combination with methotrexate, but are not generally
used for this indications because biologics and denosumab have been
shown to more eﬃcaceous. The focus of this overview will therefore be
osteoarthritis, where no current disease modfying treatment option
exists. In several diﬀerent animal OA models, bisphosphonates have
demonstrated eﬃcacy.
Active RA and OA are both characterized by the presence of bone
marrow lesions in subchondral bone (BMLs), and these lesions signal
progression and increased pain. Histologically BMLs are characterized
by pronounced increases in bone turnover and vascularity (1).
Bisphosphonates, probalby via their anti-angiogenic eﬀects, reduce the
size and pain associated with BMLs, which may the principal eﬀect in
OA. Eﬀects on synovitis and cartilage protection have also been in-
voked, however.
The ﬁrst human trial using oral risedronate was, however, negative
both in terms of symptomatic relief and joint space narrowing (2).
Another study using four iv. doses of Neridronate in OA patients with
demonstrable BMLs, however, showed reduction of bone marrow le-
sions, 80% reduction of pain and improved function (3). Another more
recent study using one dose of iv. zoledronic acid demonstrated
symptomatic relief at 6 months, but not at 12 months (4). Thus, iv.
bisphosphonate represnet promising candidates as disease modifying
drugs for the treatment of OA, but further studies are needed to es-
tablish optimal dosing fand duration of eﬀects.
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Epigenetics and osteoarthritis -the interplay between DNA me-
thylation, DNA polymorphism and gene activity
John Loughlin
Newcastle University, Newcastle upon Tyne, United Kingdom
Molecular genetic investigations of osteoarthritis (OA) have highlighted
cellular processes and pathways involved in disease development.
These studies include high-throughput genetic and genomic screens
that oﬀer genome-wide coverage and in recent years have involved
epigenetic analyses of regulatory RNAs, histones and DNA methylation.
My group has a particular interest in the interaction between epige-
netics and OA genetic susceptibility, including the interplay between
DNA methylation, DNA polymorphism and gene activity.
In this presentation, I will present our current work on PLEC as an
example of how epigenetic studies enable us to prioritise genes from
genetic scans for subsequent functional investigation. These involve an
analysis of cell lines and primary cells from patients undergoing or-
thopaedic procedures, the latter used, amongst other things, to map
methylation and expression quantitative trait loci (mQTLs and eQTLs).
PLEC codes for plectin, a multifunctional cytoskeletal linker that acts as
a scaﬀold for signalling proteins and as an organiser of cytoskeletal
ﬁlaments. Plectin is particularly abundant in tissues that are subjected
to mechanical stress and load, including cartilage.
PLEC resides within a gene rich region of high linkage disequilibrium,
with DNA polymorphisms ﬂanking the gene being associated with hip
OA at genome-wide signiﬁcance. An array analysis identiﬁed a com-
pelling mQTL operating on the locus, with the methylation of 15
intergenic CpGs correlating with genotype at the association signal.
Twelve of the CpGs are within an interval of 27kb located in the body
of PLEC and map to regions that have transcriptional regulatory
functions. A cartilage eQTL that correlates with the association signal
was also found to operate on the gene, with the OA risk-conferring
allele resulting in reduced PLEC expression. An analysis of OA versus
non-OA cartilage then revealed an increased expression of the gene in
diseased tissue. We posit that in a joint predisposed to
OA, PLEC expression increases to combat aberrant bio-mechanics and
that this is epigenetically regulated. However, carriage of the low
expressing allele hinders this response leading to an increased risk of
disease development.
Our studies demonstrate the utility of epigenetic investigation and its
power to prioritise genes and their encoded proteins.
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Cancer treatment induced bone loss (CTIBL): antiresorptive treat-
ment eﬀects and more….
Peyman Hadji
Krankenhaus Nordwest, Frankfurt, Germany
Osteoporosis is one of the most frequent diseases in postmenopausal
women leading to an increased fracture risk due to the physiologic loss
of the bone protective eﬀects of estrogen. Hereby, several risk factors
for fracture such as prevalent fracture, low BMD, age, low BMI, family
history, tendency to falls, smoking, use of SSRIs, glucocorticoid use etc.
have been identiﬁed. Additionally, the further reduction of endogenous
estrogens with chemotherapy (CHT), GnRH-analoga or aromatase in-
hibitors (AI) continuously increases fracture risk. Breast cancer (BC) on
the other hand is the most frequent cancer type in women. Recent re-
ports indicated a continuous increased incidence while mortality, due
to early diagnosis and treatment improvements is decreasing.
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Dependent on speciﬁc tumor characteristics, radiation, chemotherapy
(CHT), antibody treatment as well as endocrine treatment has been
introduced into the adjuvant clinical treatment setting.
Some but not all of this cancer speciﬁc treatments interfere with bone
turnover leading to an accelerate bone loss referred to as cancer
treatment induced bone loss (CTIBL). Whereas CHT leads to an un-
speciﬁc increased of bone resorption, Aromatase inhibitor (AI) reduces
residual serum endogenous estrogen level and is associated with a de-
crease of bone mineral density (BMD) and increased fracture risk.
Independent of the type of AI administered, bone loss is 2-3 fold in-
creased compared to healthy, age matched postmenopausal controls.
Therefore several guidelines have emerged to help managing CTIBL in
women with BC including strategies to identify and treat those at
highest risk for fractures.
Recently, several studies and a meta-analysis have investigated the
additional eﬀect of Bisphosphonates on breast cancer outcomes leading
to a 34% decreased rick of bone recurrence and a 17% decreased breast
cancer mortality risk. The workshop will summarizes the current
knowledge on CTIBL and fracturing risk and indicates current treatment
guidelines and intervention options as well as the additional eﬀects of
adj. antiresorptive treatments.
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Myeloma bone disease
Andrew Chantry
University of Sheﬃeld, Sheﬃeld, United Kingdom
Patients with Multiple Myeloma develop a devastating bone disease
driven by the uncoupling of bone remodelling, excess osteoclastic bone
resorption and diminished osteoblastic bone formation. The bone
phenotype is typiﬁed by focal osteolytic lesions leading to pathological
fractures, hypercalcaemia and other catastrophic bone events such as
spinal cord compression. This causes bone pain, impaired functional
status, decreased quality of life and increased mortality. Early in the
disease, malignant plasma cells occupy a niche environment that en-
compasses their interaction with other key cellular components of the
bone marrow microenvironment. Through these interactions, osteoclast
activating factors and osteoblast inhibitory factors are produced, which
together uncouple the dynamic process of bone remodelling, leading to
net bone loss and focal osteolytic lesions.
Current management includes anti-resorptive therapies i.e. bispho-
sphonates, palliative support and orthopaedic interventions.
Bisphosphonates are the mainstay of treatment for myeloma bone dis-
ease, but are only partially eﬀective and do have some signiﬁcant dis-
advantages, for example, they do not lead to the repair of existing bone
destruction. Thus, newer agents to prevent bone destruction and also
promote bone formation and repair existing lesions are warranted. This
presentation summarises conventional treatments and novel ways that
myeloma bone disease is being therapeutically targeted.
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Targeting integrin-mediated chemoresistance in breast cancer
bone metastases
Katherine Weilbaecher
Washington University School of Medicine, St. Louis, USA
Abstract
Bone metastases occur in approximately 70% of metastatic breast
cancer (BC) patients, often leading to skeletal injuries. Current treat-
ments are mainly palliative and underscore the unmet clinical need for
improved therapies. It is known that integrin β3 (β3) is expressed on
bone metastases and plays a role in metastatic tumor cell colonization.
Analysis of patient matched bone and primary breast tumors from 42
patients, demonstrated markedly increased β3 expression in bone me-
tastases compared to matched primary biopsies across all BC subtypes:
luminal A, luminal B, HER2-enriched, and triple-negative. Likewise, we
found increased expression of β3 on BC bone metastases as compared to
primary tumor or visceral metastases in 3 preclinical BC models: 4T1,
MDA-MB-231, and PyMT-BO1(luminal B ER+). Importantly, we found
that avb3 was expressed on microscopic bone marrow disseminated
tumor cells (DTC) from mice after primary tumor resection without
bone metastases. Mechanistic investigations revealed that TGFβ sig-
naling through SMAD2/SMAD3 was necessary for induction of β3
within the bone. Using a micelle-based nanoparticle therapy that re-
cognizes activated integrin αvβ3 (αvβ3-MPs of ∼12.5 nm), we de-
monstrated speciﬁc localization to BC bone metastases. Using this
system for targeted delivery of the chemotherapeutic docetaxel, we
showed that bone tumor burden was signiﬁcantly reduced with less
bone destruction and less hepatotoxicity compared with equimolar
doses of free docetaxel.
We found that bone metastases were more resistant to docetaxel com-
pared to lung metastases. Several groups have demonstrated that cancer
stem cells express αvβ3 and are resistant to chemotherapy. We examined
the role of αvβ3 in chemoresistance in bone metastases. We found that
bone metastases from BO1 cells with genetic deletion of β3 by CRISPR
(BO1-β3-/-) had increased sensitivity to DTX treatment in vivo, while re-
expression of β3 in β3-/- BO1 cells restored the relative DTX resistance,
but re-expression of signaling defective β3 did not. RNA sequencing
analyses point to anti-apoptosis mechanisms. Taken together, our results
oﬀer preclinical proof of concept for a method to enhance delivery of
chemotherapeutics to breast cancer cells within the bone by exploiting
their selective expression of integrin αvβ3 at that metastatic site.
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Lung cancer and bone metastases
Sarah Danson
University of Sheﬃeld, Sheﬃeld, United Kingdom
Bone metastases are common in lung cancer with an incidence of 40%.
Current national and international guidelines recommend the use of
denosumab or bisphosphonates in lung cancer patients with bone me-
tastases. However, these treatments are not always utilised as patients
with lung cancer have typically presented late with advanced disease,
poor performance status and limited life expectancies. This landscape is
changing with more lines of standard anticancer therapies now being
available.
The presence of bone metastases and the occurrence of skeletal related
events (SREs) are associated with reduced survival in non-small cell
lung cancer (NSCLC) [1]. Zoledronic acid reduces the risk of SREs in
solid tumours, including NSCLC [2]. In a large trial of patients with
solid tumours other than breast cancer and prostate cancer, a post-hoc
subset analysis of the NSCLC patients with bone metastases treated with
zoledronic acid or denosumab showed signiﬁcantly better overall sur-
vival in the group of patients treated with denosumab [3]. A subsequent
phase III study of denosumab in combination with ﬁrst line che-
motherapy compared with ﬁrst line chemotherapy alone in NSCLC,
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with a primary objective to assess the eﬀect of denosumab on overall
survival, has just closed to accrual and results are awaited. Other pos-
sible bone-targeting strategies for patients with lung cancer, such as
radium-223, will be discussed.
KEY REFERENCES
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Advances in detection and treatment of prostate cancer
Freddie Hamdy
University of Oxford, UK
The management of prostate cancer has seen unprecedented change
and evolution in recent years. Over three decades of prostate-speciﬁc
antigen (PSA) testing and opportunistic screening led to over-detection
and over-treatment of low-risk disease using radical treatments with
unnecessary side-eﬀects. At the same time lethal disease has been
under-treated, with androgen deprivation therapy prevailing in the
management of advanced, metastatic and cancer induced bone disease.
Findings in new, large randomized controlled trials - from testing the
eﬀectiveness of screening, to the treatment of PSA-detected, high-risk
and advanced prostate cancer as well as the development of cutting-
edge imaging and minimally invasive techniques for partial tissue ab-
lation - provide new transformational evidence which is changing
practice.1-5 In addition, recent investigations using high-throughput
platforms bring new insight into the complex biology and genomic di-
versity of prostate cancer, our Achilles heel in the management of this
common and ubiquitous malignancy. An overview of these changes and
transformation in the management of prostate cancer, and key new trial
ﬁndings will be presented and discussed.
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Recent advances in bone sarcomas: new therapeutic targets and
biomarkers
Dominique Heymann
University of Sheﬃed, Sheﬃeld, United Kingdom. Institut de Cancérologie
de l'Ouest (Regional Cancer Hospital), Saint-Herblain, France. Inserm,
U1232, University of Nantes, Nantes, France
Bone sarcomas and more speciﬁcally osteosarcomas are highly het-
erogeneous. This heterogeneity between the tumours (inter-tumour
heterogeneity) and within the tumours (intra-tumour heterogeneity)
can be related to genetic and non-genetic factors and introduces sig-
niﬁcant challenges for classifying patients that might beneﬁt from tar-
geted therapies. A new model for osteosarcoma development has been
recently proposed in which a TP53 and/or RB1 mutant cell initiated a
monoclonal disease. This cell population exhibited higher chromosomic
instability, leading to both the emergence of new cell clones and
polyclonal disease associated with these secondary genetic events and
the development or lung metastases and drug resistance. The combi-
nation of multiple genetic events and a favourable microenvironment
facilitate tumour growth. All of these events are regulated by epigenetic
events that may deﬁne new biomarkers and may be used as new ther-
apeutic targets. It has been also suggested that Circulating Tumour Cells
(CTCs) may reﬂect the biological evolution (e.g. new mutation events)
of primary tumours and associated metastases. Unfortunately, in con-
trast to carcinomas, in which CTCs have been isolated from epithelial
makers (e.g. Epcam), there are no speciﬁc makers expressed by sarcoma
cells. However, sarcoma cells like other cancer cells show frequently a
diﬀerential size compared to normal cells and a lower deformability.
Size and deformability criteria have been used in pre-clinical models for
isolating CTCs and could serve as proof-of-concept for pilot clinical
trials in bone sarcoma.
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Inﬂammatory macrophages, eﬀerocytosis, and skeletal metastasis
Hernan Roca, Laurie McCauley
University of Michigan, Ann Arbor, USA
Tumor associated macrophages are immune cells found in high num-
bers in a wide variety of tumors where their inﬁltration has been cor-
related with poor prognoses. They are involved in cancer-related in-
ﬂammation yet the precise mechanisms remain unclear and knowledge
of their impact in skeletal metastasis is lacking. When tumor cells dis-
seminate to the skeleton, they are bathed in a rich milieu of bone
marrow myeloid cells. Diﬀerentiation into bone marrow macrophages
suggests they are poised to engulf apoptotic tumor cells in a manner
similar to when they engulf normal apoptotic cells during development
and homeostasis, a process termed eﬀerocytosis. A unique transcrip-
tional proﬁle and cytokine production occurs in macrophages that en-
gulf apoptotic prostate cancer (PCa) cells versus non-cancer cells. Upon
eﬀerocytosis of apoptotic cancer cells macrophages activate NF-κB and
Stat 3 leading to pro-inﬂammatory cytokine production, especially
CXCL5, versus anti-inﬂammatory cytokines normally attributed to ef-
ferocytosis. A novel inducible gene-targeted apoptosis construct in PCa
cells resulted in pro-inﬂammatory cytokine production in eﬀer-
ocytosing macrophages in vitro, and triggering apoptosis in vivo led to
further cancer cell growth. Diminished tumor growth in CXCL5 deﬁ-
cient mice further implicated the tumor associated macrophage eﬀer-
ocytic pathway in supporting tumorigenesis. Peripheral blood mono-
nuclear cells from human patients with PCa skeletal metastases showed
increased numbers of non-classical CD14+CD16+ monocytes with
high eﬀerocytotic potential, and PCa patients had higher circulating
levels of CXCL5. Such a tumor associated macrophage destructive
cascade via apoptotic cell clearance provides clues for potential ther-
apeutic interventions that will maintain the critical clearance of apop-
totic tumor cells while diminishing the pro-inﬂammatory landscape.
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Mechanisms that drive skeletal pain
Patrick Mantyh
University of Arizona, TUCSON, USA
Skeletal pain is common and frequently diﬃcult to fully control. Recent
data suggests that the skeleton is innervated by a restricted set of no-
ciceptors and that many skeletal pains have both a nociceptive and a
neuropathic component. Signiﬁcant progress has been made in deﬁning
the mechanisms that drive skeletal pain. These mechanisms include;
peripheral sensitization, translational changes in sensory neurons, ec-
topic sprouting of sensory and sympathetic nerve ﬁbers and central
sensitization. These insights have the led to human clinical trials of
bisphosphonates, anti-RANKL and anti-NGF antibodies for the relief of
acute and chronic skeletal pain. Understanding which therapies are
most eﬃcacious in relieving diﬀerent types of skeletal pain may allow
more eﬀective control of pain while minimizing unwanted side eﬀects.
DISCLOSURE
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Pharmacology of bisphosphonates in pain
Thomas Tzschentke
Grünenthal GmbH, Aachen, Germany
The treatment of chronic pain remains a clinical challenge particularly
for pain associated with rare conditions e.g. vulvodynia or CRPS.
Recently, the search for new analgesics has turned towards bispho-
sphonates. There is a small literature on antinociceptive and anti-
hypersensitive eﬀects of bisphosphonates in animal pain models. There
is also evidence for clinical eﬃcacy of bisphosphonates in chronic pain
states. However, the pharmacological/mechanistic rationale for bi-
sphosphonate activity against pain is still elusive.
Several studies have shown positive eﬀects for bisphosphonates in an-
imal-models of inﬂammatory pain. Where measured, the eﬀect ap-
peared to coincide with a reduction of inﬂammatory markers. Very
limited data exist on the eﬀects of bisphosphonates in animal-models of
neuropathic pain, where bisphosphonates had no or only very moderate
eﬀects. On the other hand, zoledronate and alendronate had anti-
allodynic eﬀects in a rat model of CRPS, and neridronate showed
clinical eﬃcacy in CRPS patients. Furthermore, zoledronate, alen-
dronate and ibandronate were shown to reduce allodynia and hyper-
algesia in bone cancer pain models, which may at least partly be related
to a direct anti-tumor eﬀect. Bisphosphonates have also been char-
acterized in animal-models of osteoarthritis pain, and were usually
found to reduce pain-related behavior. Overall, this eﬀect appeared to
coincide with reduced cartilage degradation. A clinical study of zole-
dronate in osteoarthritis pain is ongoing.
Regarding the analgesic mechanism of action, a few studies have sug-
gested pain-relevant ´oﬀ-target´ eﬀects, e.g. via P2X2/3 receptors for
minodronate, or inhibition of vesicular ATP release for clodronate.
Although such activity may contribute to the eﬀects of individual bi-
sphosphonates, they cannot explain the analgesic eﬀects in their en-
tirety. It rather appears that pain reduction is often secondary to the
bisphosphonates´ primary eﬀects on osteoclasts and/or chondrocytes
(osteoarthritis pain), eﬀects on inﬂammatory mediators (inﬂammatory
pain) and eﬀects on tumor-growth (bone cancer pain). Taken together,
current evidence suggests that bisphosphonates can exert analgesic ef-
fects, and that these eﬀects may largely be secondary to their anti-os-
teolytic/anti-chondrolytic, anti-inﬂammatory and anti-tumor activity.
The degree to which a particular bisphosphonate aﬀects pain may de-
pend on the potency and eﬃcacy with which the bisphosphonate in-
ﬂuences the relevant underlying primary mechanisms.
DISCLOSURE:
The author is an employee of Grünenthal GmbH. Grünenthal develops ner-
idronate for the treatment of CRPS.
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Monoclonal antibody antagonists of GFRα3 signiﬁcantly attenuate
nociceptive responses in mouse models of joint pain
Michael LaCroix-Fralish, Luz Cortes-Burgos, Emily Thayer, Min
Gao, LiQin Xie, Ashique Raﬁque, Jeanette Fairhurst, Ashok
Badithe, Robert Babb, Frank Delﬁno, Charleen Hunt, William
Poueymirou, Andrew Murphy, Lynn Macdonald, Susan Croll
Regeneron Pharmaceuticals, Tarrytown, USA
Artemin is a member of the glial-derived neurotrophic factor (GDNF)
family of growth factor ligands (GFLs). It binds with high aﬃnity to the
GFL family receptor GFRα3. Upon binding to artemin, GFRα3 forms a
complex with the RET tyrosine kinase receptor, leading to activation of
intracellular signaling. GFRα3 is preferentially expressed in sensory and
sympathetic neurons of the peripheral nervous system, and has been
implicated in the initiation, sensitization, and maintenance of noci-
ceptive responses. We generated high aﬃnity mouse and human
monoclonal antibodies against GFRα3 that prevent artemin binding,
and have used these antibodies in two mouse models of joint pain. In
the DMM (Destabilization of the Medial Meniscus) model of osteoar-
thritic-like pain, knees of adult male C57Bl/6 mice were surgically
destabilized. Sixteen weeks after surgery, mice exhibited signiﬁcant
tactile allodynia, measured using Von Frey Hairs, and marked devel-
opment of knee joint osteophytes, evaluated by μCT scan. Both mouse
and human monoclonal antibodies against GFRα3 prevented and re-
versed tactile allodynia in this model. Administration of anti-GFRα3 did
not appear to be disease-modifying, because withdrawal of antibody
treatment restored the allodynic response. In addition, knee joint os-
teophyte burden was similar for animals treated with anti-GFRα3, PBS,
or an isotype control antibody. A second model of joint pain, the intra-
articular CFA (Complete Freunds’ Adjuvant) model, was also used to
evaluate the eﬃcacy of anti-GFRα3. In this model, CFA was injected
into the knee joint of adult male C57Bl/6 mice and nociceptive re-
sponses were evaluated for 5 weeks. Anti GFRα3 signiﬁcantly pre-
vented both tactile allodynia and thermal hyperalgesia (evaluated with
the Hargreaves’ Test) in this model. Knee joints were collected at the
end of the experiment and inﬂammation was scored by a blinded eva-
luator using a subjective rating scale. No diﬀerences were observed
among the treatment groups in inﬂammation scores, suggesting that the
antibody reduced nociceptive responses without reducing CFA-induced
inﬂammation. Our data suggest that inhibition of artemin binding to
GFRα3 may be eﬃcacious against chronic joint pain.
DISCLOSURE
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Skeletal pain, Radium-223 and bone metastases
Øyvind Bruland
University of Oslo and Norwegian Radium Hospital, Oslo, Norway
The presentation will brieﬂy address key pathophysiological aspects
related to skeletal pain in patients with bone-metastatic prostate cancer
and also some clinical experiences with beta-emitting bone-seeking
Journal of Bone Oncology 13 (2018) 11–54
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radiopharmaceuticals. Main focus will be on results from various clin-
ical trials during the development of radium-223 dicloride (Xoﬁgo).
Already in the phase 1 trial with single-dosage administration of in-
creasing amounts of Ra-223, pain relief was indicated in more than half
of the 25 patients. In a subsequent phase 2 dose-response study, pain
palliation was seen in up to 71% of 100 pts with castration-resistant
prostate cancer (CRPC) and painful bone metastases. The primary
endpoint was pain index (visual analogue scale and analgesic use) used
to classify patients as responders or non-responders. The pivotal ran-
domized phase 3 study, ALSYMPCA study, included 921 CRPC pts with
bone mets (Ra-223, n=614; placebo, n=307). Here six doses of Ra-223
given monthly signiﬁcantly improved overall survival vs placebo, de-
layed subsequent symptomatic skeletal related event and was well
tolerated. QoL was assessed with the Functional Assessment of Cancer
Therapy—Prostate (FACT-P) instrument. The pain analysis was based
on 4 pain-related questions from the FACT-P prostate cancer subscale
(PCS) using ANCOVA. Time to initial opioid use was analysed using the
log-rank test.
Baseline pain characteristics were similar between Ra-223 and placebo
groups. The FACT-P PCS pain scores revealed that Ra-223 pts had a
signiﬁcantly greater increase in pain-related QoL than did placebo pts
at both pre-scheduled treatment visits (week 16, P=0.010; week 24,
P=0.005). Fewer pts in the Ra-223 group (36%) than in the placebo
group (50%) required opioid use for pain relief. Furthermore, the dif-
ference in time to initial opioid use was statistically signiﬁcant between
the treatment groups (P = 0.0023).
Results from ALSYMPCA support the positive eﬀect of Ra-223 on pain
relief in CRPC pts with bone mets, with less opioid use and improved
pain-related QoL compared with placebo.
DISCLOSURE
Øyvind Bruland has served as a consultant (paid to Institution) for Bayer
AS, was one of the co-founders of Algeta ASA, and has had patents related
to radium-223
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Systemic eﬀects of the tumor-bone microenvironment: mechan-
isms and therapeutic approaches
David Waning1, Khalid Mohammad2, Trupti Trivedi2, Andrew
Marks3, Theresa Guise2
1Penn State University, State College, USA. 2Indiana University,
Indianapolis, USA. 3Columbia University, New York, USA
Breast and other cancers commonly metastasize to bone to cause bone
destruction, pain, fractures hypercalcemia and muscle weakness.
Recently, we described a speciﬁc molecular mechanism by which
bone-derived transforming growth factor (TGF)-beta, released as a
consequence of tumor-induced bone destruction causes muscle dys-
function, before the loss of muscle mass. Circulating TGF-beta induces
oxidation of the ryanodine receptor (RYR1) on the sarcoplasmic re-
ticulum of skeletal muscle to induce calcium leak and muscle weak-
ness. Blocking TGF-beta, or its release from bone (with bispho-
sphonates), preventing oxidation of or stabilizing RyR1 all prevented
muscle weakness in mouse models of breast cancer bone metastases.
In addition to these eﬀects on skeletal muscle, circulating TGF-beta
may act on beta cells of the pancreas to impair insulin secretion and
result in glucose intolerance. These and other potential systemic ef-
fects of TGF-beta released from the tumor-bone microenvironment or
from cancer treatment-induced bone destruction implicate bone as a
major source of systemic eﬀects of cancer and cancer treatment.
Therapy to block the systemic eﬀects of the bone microenvironment
will improve morbidity associated with bone metastases and cancer
treatment.
Funding sources: NIH/NCI: U01 CA143057, R01CA206025; Susan G.
Komen Foundation; DoD: BC150678
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Cancer: the evil companion corrupting good behaviour
Ilaria Malanchi
The Francis Crick Institute, London, United Kingdom
The tumour microenvironment or niche is the vital non-cancerous
compartment of the tumour structure. Tumour cells and their micro-
environment establish a synergistic cooperation that characterizes all
aspects of tumour growth, from onset to metastasis. Importantly, this
ever-changing interaction is a key source of cancer cells’ plasticity and
plays an important role in every aspect of tumour progression. Indeed,
cancer cells with higher ability to establish favourable crosstalk with
their surrounding are more tumorigenic (1). Thus, targeting non-tu-
mour-derived cellular components represents a promising avenue to
better therapeutic interventions. For instance, we identify neutrophils
as the main component and driver of metastatic establishment within
the pre-metastatic lung microenvironment in mouse breast cancer
models. Importantly, we ﬁnd that neutrophil-derived leukotrienes aid
the colonization of distant tissue by selectively expanding the sub-pool
of cancer cells that retain high tumorigenic potential. Pharmacologic
inhibition of the leukotriene-generating enzyme arachidonate 5-lipox-
ygenase (Alox5) reduces metastasis, revealing the eﬃcacy of using
targeted therapy against a speciﬁc tumour microenvironment compo-
nent (2).
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Inﬂuence of sympathetic nerves on the bone metastatic niches.
Lise Clément-Demange1, Troy Tabarestani2, Florent Elefteriou1
1Baylor College of Medicine, Houston, USA. 2Rice University, Houston, USA
Bone metastasis is a complication of many cancers such as lung, pros-
tate and breast. Once the tumor grows in bone, treatment options are
limited and clinical management can only be palliative. Identifying the
mechanisms driving the engraftment of metastatic cancer cells into the
skeleton is thus crucial to design eﬃcacious therapeutic options.
Progression and recurrence of breast cancer, as well as reduced survival
of patients with breast cancer, are associated with chronic stress, a
condition known to stimulate sympathetic nerve outﬂow. In this con-
text, our previous work has shown that β-adrenergic stimulation in
bone-forming cells leads to a VEGF-dependent increase in bone vascular
density and to a RANKL-mediated migration of metastatic breast cancer
cells toward the osteoblastic niche. The impact of sympathetic nerves
on the bone marrow environment in the context of the early stages of
bone metastasis will be summarized, including new data related to
aging and role of pro-inﬂammatory cytokines into the equation.
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Tumour-intrinsic interferons as key dictators of bone metastasis
Katie Owen, Belinda Parker
La Trobe Institute for Molecular Science, Melbourne, Australia
Prostate and breast cancer have 10-year patient survival rates as high as
90%. Despite this, they remain the 2ndleading cause of cancer-related
deaths in men and women due to metastatic spread to distant tissues,
particularly bone. Bone-metastatic disease can develop decades after
primary tumour diagnosis and treatment. This is largely due to the early
escape of cancer cells beyond the primary tumour site to the bone
marrow, where they can exist in a dormant state fora prolonged period
until they become activated in some patients to form deadly metastases.
Predicting and targeting this reactivation phase is critical for impacting
patient mortality rates. Using metastatic prostate cancer models, we
recently discovered that the switch from dormancy to tumour cell ac-
tivation in bone is accompanied by the loss of the type I Interferon (IFN)
pathway, a pathway well known for its role in activating an immune
response to protect against diseases, including cancer1. This supports
our previous investigations in breast cancer demonstrating that tumour-
inherent type I IFN signalling activates immune surveillance mechan-
isms to block metastatic spread in breast cancer,and that loss of the-
sesignals promotes bone metastasis2,3,4. Given very little is known
about what mechanisms control the dormancy switch, current studies
are focused on the role of IFN signalling in the earliest stages of me-
tastatic outgrowth in bone and the identiﬁcation of IFN signatures as
biomarkers to predict bone metastatic spread.
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New approaches in in vivo imaging. New whole body optical
imaging and multi-modality imaging tools and their use in cancer
research.
Clemens Lowik
Erasmus Medical Center, Rotterdam, Netherlands
In my presentation new bioluminescent and ﬂuorescent based gene
reporters will be discussed that can be used for imaging stem cell dif-
ferentiation, tumor progression and metastasis in mice. Also, the use of
a triple multi-modality gene reporter to image bone metastasis in
combination with CT and MRI. We have also generated a new mutated
codon optimized Click Beetle Red2 luciferase and substrate that allows
more sensitive and deeper imaging with higher resolution in living
mice. We also developed transgenic dual-color T-cell reporter mice that
can be used to study T-cell migration and activation. I will also discuss
the use of new luciferin based caged-substrates which now, together
with the new dual-color mutated luciferases, enables a wide variety of
multiplexing. Together with my colleagues we have developed software
for automated registration of whole-body follow up micro-CT data in
mice with bone metastases.
I will also brieﬂy discuss new clinical developments on Near Infra-Red
Fluorescent (NIRF) probes that can be used for image guided surgery of
tumor tissue and to detect sentinel lymph nodes.
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Single cell analysis of MPN stem cells
Adam Mead
University of Oxford, UK
Single-cell RNA-sequencing has emerged as a powerful tool to resolve
transcriptional heterogeneity. However, its application to study can-
cerous tissues is currently hampered by the lack of coverage across key
mutation hotspots in the vast majority of cells, which prevents corre-
lation of genetic and transcriptional readouts from the same single cell.
Therefore, it remains unclear to what degree transcriptional hetero-
geneity in myeloproliferative neoplasm stem/progenitor cells is driven
by somatic mutations versus other factors. To overcome this, we de-
veloped TARGET-seq, a method for the high-sensitivity detection of
multiple mutations within single-cells from both genomic and coding
DNA, in parallel with unbiased, high-depth whole transcriptome ana-
lysis. Using this technique, we achieve a 98% sensitivity in the detec-
tion of multiple mutations within single-cells, which allows accurate
reconstruction of tumour phylogenetic trees at single cell resolution.
We demonstrate how TARGET-seq uniquely resolves transcriptional
and genetic heterogeneity in myeloproliferative neoplasm stem/pro-
genitor cells, providing insights into deregulated pathways of both
mutant and non-mutant cells. Speciﬁc examples of how this approach
might be applied clinically for risk stratiﬁcation, minimal residual
disease monitoring and tracking of clonal evolution will be presented.
In summary, TARGET-seq provides a powerful tool to resolve molecular
signatures of genetically distinct subclones of tumour cells.
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Epigenetic suppression in myeloma bone disease
Juraj Adamik1, Rebecca Silbermann2, Deb Galson1, G David
Roodman3,4
1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Oregon
Health and Science University, Portland, OR, USA. 3Indiana University
School of Medicine, Indianapolis, IN, USA. 4Roudebush VA Hospital,
Indianapolis, IN, USA
Multiple myeloma bone disease (MMBD) results from markedly in-
creased bone resorption and severely suppressed bone formation,
causing lytic lesions that rarely heal. These lesions can persist even
when patients are in complete remission. We showed, using in vivo
models of MM and patient samples that Runx2 and Osterix expression
remained suppressed in bone marrow stromal cells (BMSCs) from MM-
bearing bones, and that MM-exposed BMSCs failed to diﬀerentiate into
osteoblasts (OBs) weeks after removal of MM cells. We hypothesized
that MM cells induce repressive epigenetic changes in the Runx2 and
Osterix promoters that inhibit OB diﬀerentiation of BMSCs which per-
sists in the absence of MM cells. Therefore, we characterized these
promoters in murine pre-osteoblast MC4 cells and patient BMSCs by
chromatin immunoprecipitation (ChIP). The Runx2 and Osterix tran-
scriptional start sites (TSSs) in untreated MC4 cells were co-occupied by
transcriptionally active histone-3 lysine-4 tri-methylation (H3K4me3)
and transcriptionally repressive histone-3 lysine-27 tri-methylation
(H3K27me3) modiﬁcations, termed “bivalent domains”. Co-culture of
MC4 cells with MM cells or treatment with TNF-α increased H3K27me3
levels in these bivalent domains making them transcriptionally silent.
This occurred because MM cells induced the Runx2-transcriptional re-
pressor Gﬁ-1 in BMSCs via p62/sequestosome 1 to suppress OB diﬀer-
entiation of BMSCs. Gﬁ-1 directly bound the Runx2 promoter and re-
cruited histone co-repressors (HDAC1, LSD1, and EZH2) to the
promoter, thereby decreasing H93K9ac and H3K4me3 and increasing
H3K27me3 modiﬁcations, to block Runx2 expression. These repressive
chromatin changes in Runx2 persisted after MM cell removal. Further,
Gﬁ-1 knockdown, selective pharmacological inhibition of HDAC1 or
EZH2, or treatment of BMSCs with a p62-ZZ domain small molecule
inhibitor (XRK3F2) both prevented and reversed MM-induced Runx2
repression and rescued OB diﬀerentiation. These results suggest that
HDAC1 or EZH2 inhibitor treatment or targeting the p62-ZZ domain in
BMSCs of MM patients with XRK3F2 may restore OB function in MMBD.
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Bisphosphonates for Delivering Drugs to Bone
Frank H. (Hal) Ebetino1,2,3,4, Shuting Sun2, R. Graham G.
Russell3,4, Lianping Xing1, Robert Boeckman1, Brendan Boyce1,
Charles E. McKenna5, Zibo Li6, Ichiro Nishimura7, Parish
Sedghizadeh5
1University of Rochester, Rochester, NY, USA. 2BioVinc, Pasadena, CA,
USA. 3University of Oxford, Oxford, United Kingdom. 4University of
Sheﬃeld, Sheﬃeld, United Kingdom. 5University of Southern California, Los
Angeles, CA, USA. 6University of North Carolina, Chapel Hill, NC, USA.
7University of California Los Angeles, Los Angeles, CA, USA
An ideal therapeutic drug or diagnostic for use in the management of
bone diseases should be bone tissue speciﬁc with no pharmacological
activity at other anatomical sites. A drug or diagnostic that targets the
most diseased sites of the skeleton is even more desirable, and is an
attribute that bisphosphonates (BPs) can provide with their propensity
to favor sites of high bone turnover. For imaging, we have been capi-
talizing on this property to develop new ﬂuorescently labeled BP ana-
logs as well as novel PET scanning probes, with non-releasable BP
linked conjugates, particularly for use in multiple myeloma. For drug
development we have been utilizing a “target and release” linker
strategy designed to have serum-stable BP linkers that metabolize and
release drugs at the bone surface. We have also been designing our
conjugates with antiresorptive inactive or less active bisphosphonates
to avoid confounding our study conclusions with BP pharmacology. Our
teams has recently described a proof of concept study to develop new
therapies for osteomyelitis, where inadequate eﬃcacy has been as-
cribed to the limited access of current systemically administered anti-
biotics to sites where causative bacteria (eg. S. aureus) can reside in
bioﬁlms on bone and even within the osteocytic canalicular network.
We recently reported impressive in vivo eﬃcacy with a novel bispho-
sphonate-ciproﬂoxacin conjugate, BV600022. (Sedghizadeh et al, J
Med Chem, 2017). An in vitro comparison of our new bone targeted
antibiotic conjugates further demonstrates their eﬃcacy advantages vs
commonly used antibiotics such as minocycline and vancomycin. In
addition, the rate of release of these conjugates can be adjusted to
maximize eﬃcacy and duration of action. Our work also continues to-
ward the utilization of these approaches in the management of other
bone diseases such as multiple myeloma, bone metastases, and arthritis.
In particular, new mechanistic understanding and an interesting drug
development approach for a potentially improved treatment for mul-
tiple myeloma has evolved from this work by targeting proteasome
inhibitors that should provide greater eﬃcacy as well as greater safety
at non skeletal sites.
SUPPORT:
NIH/NIDCR: R42-DE025789-02; NIH/NIAID: R43AI125060-01; NIH/
NIDCR: R44DE025524-02, 1R21AR070984-01, NIH/NIAMS
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10-year patterns of recurrence from early breast cancer: Analyses
of the AZURE (BIG 01/04) study of adjuvant zoledronic acid.
Stella D'Oronzo1, Janet Brown1, Keith Chong1, Simon Nicholson1,
Walter Gregory2, Robert Coleman1
1Department of Oncology and Metabolism, Academic Unit of Clinical
Oncology, Weston Park Hospital, University of Sheﬃeld, Sheﬃeld, United
Kingdom. 2Clinical Trials Research Unit, University of Leeds, Leeds, United
Kingdom
INTRODUCTION: The AZURE clinical trial recruited 3360 patients with
early breast cancer at moderate/high risk of recurrence, randomised 1:1
to receive standard adjuvant therapy +/-zoledronic acid (ZOL). The
study oﬀers an excellent opportunity to record patterns of relapse in the
modern treatment era and the impact of adjuvant bisphosphonate
treatment, not only in bone but also in local and other distant sites.
METHODS: Patients were regularly reviewed during the 5-year treat-
ment phase and then annually to 10 years (total median follow-up: 117
months) or until recurrence in bone or death. Local and distant re-
currences were recorded and classiﬁed according to recurrence sites
(with further breakdown of anatomical site for recurrence in bone),
expression of estrogen receptor (ER) in the primary tumour and pa-
tient’s menopausal status at diagnosis. Data were adjudicated with trial
site where necessary to remove errors or ambiguities.
RESULTS: At 10 years, 1191 patients had developed disease recurrence
(ZOL arm: 577 relapsed pts out of 1681; Control arm: 614 relapsed
patients out of 1678). A summary of the data according to ER and
menopausal status is listed below:
• In control group, patterns of relapse were similar in postmenopausal
(PM: at least 5 years since menopause) and non-postmenopausal
(NPM) patients, with distant recurrence prevailing over loco-re-
gional one;
• In the same arm, bone recurrence (± extra-skeletal relapse) was the
most frequent in ER positive ladies;
• As expected, visceral relapse was more common in the ER negative
group;
• In ZOL group, reduction in bone metastases (especially “bone only”,
as compared with bone and other sites at ﬁrst recurrence) was
greater in NPM patients (ER positive: 8.1% vs 11.1% of controls; ER
negative: 3.6% vs 6.5% of controls);
• ZOL increased extra-skeletal disease free survival (DFS) events in
PM patients;
• Little eﬀect of ZOL was found on bone metastases occurring after a
non-skeletal ﬁrst relapse.
Conclusions: These analyses yield valuable new data on the patterns of
local and distant recurrence occurring over 10 years of post-diagnosis
follow-up in patients with early breast cancer.
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ERRα in primary breast tumours promotes tumour cell dis-
semination to bone by regulating RANK
Geoﬀrey VARGAS1, Mathilde BOUCHET2, Lamia BOUAZZA1,
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Bone is the most common metastatic site for breast cancer. Because
Estrogen-Related-Receptor alpha (ERRα) has been implicated in cancer
cell invasiveness and bone metastasis progression, we determined
whether ERRα expression in primary breast tumours could modulate
the molecular mechanisms that drive breast cancer cell dissemination
to bone. In breast cancer patients, we showed that high ERRα expres-
sion level in primary tumours (n=295) was associated with relapse to
bone but not to lungs. ERRα expression was also detected in the cir-
culating tumour cells from metastatic breast cancer patients. Using a
murine 4T1 breast cancer cell line that spontaneously metastasizes to
lung and bone when inoculated orthotopically to animals, we found
that ERRα overexpression in 4T1 cells (4T1-ERRα) promoted sponta-
neous bone micro-metastasis formation whereas lung metastasis for-
mation remained unchanged. RANK was identiﬁed as an ERRα regu-
lated gene in 4T1-ERRα primary tumours both as transcriptomic and
protein levels. Concomitantly, we showed that RANKL stimulated 4T1-
ERRα cells migration as well as the phosphorylation of mTOR in vitro.
In line with these data, RANK was up-regulated in human MCF7 breast
cancer cells overexpressing ERRα. A positive correlation was also ob-
served between high ERRα/RANK expression levels in primary tumours
from patients with breast cancer (n=446) and occurrence of bone
metastases (n=248). Furthermore, in order to determine whether in-
hibition of ERRα abrogates primary tumour outgrowth and tumour cell
dissemination to bone, the pharmacological eﬀect of the ERRα inverse
agonist C29, which is known to block ERRα transcriptional activity,
was studied. We ﬁrst showed that C29 inhibited RANK mRNA expres-
sion in 4T1 and MCF7 breast cancer cells in vitro. Then, 4T1-ERRα cells
were inoculated orthotopically and mice were treated with the C29.
Reinforcing our data, we found that the pharmacological inhibition of
ERRα reduced primary tumour growth, bone micro-metastasis forma-
tion in vivo, and decreased RANK expression in situ. In conclusion, our
results reveal a novel ERRα/RANK axis through which ERRα in primary
breast cancer promotes dissemination of tumour cells to bone. We
propose that ERRα may be a useful biomarker to identify breast cancer
patients at high risk of relapse in bone.
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HDAC inhibitors stimulate LIFR and other pro-dormancy genes in
dormant and aggressive breast cancer cells
Miranda Sowder1, Lauren Holtslander1, Vera Mayhew1, Samuel
Dooyema1, Rachelle W Johnson2
1Vanderbilt University, Nashville, USA. 2Vanderbilt University Medical
Center, Nashville, USA
Breast cancer cells often metastasize to the bone, where they remain
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dormant for years. Our laboratory previously found that loss of leu-
kemia inhibitory factor receptor (LIFR) in breast cancer cells results in
poor patient survival and promotes tumor cell exit from dormancy in
the bone marrow. Treatment with the pan-histone deacetylase inhibitor
(HDACi), valproic acid, induces LIFR expression and other pro-dor-
mancy genes through an undeﬁned mechanism. We hypothesize that
additional HDACi (romidepsin, panobinostat, vorinostat, entinostat)
can be used to directly stimulate LIFR expression through histone
acetylation on the LIFR promoter and maintain tumor cells in a chronic
dormant state. HDACi dramatically induced LIFR mRNA levels (up to
9.5-fold, p<0.05-0.0001) and protein levels by 24 hours in breast
cancer cells with low (MCF7, SUM159, D2.0R) and high metastatic
potential (MDA-MB-231b, D2A1, 4T1BM2). MCF7 cells treated with
HDACi showed a signiﬁcant enrichment of acetylated-H3K9 along the
LIFR promoter (up to 10.9-fold, p<0.05-0.001), indicating that HDACi
directly stimulate LIFR transcription. HDACi also induced other pro-
dormancy genes including AMOT, TGFB2, and IGFBP5 (up to 5.5-fold,
p<0.05-0.0001), but did not enrich for acetylation of the promoters,
suggesting HDACi indirectly regulates these dormancy genes.
Furthermore, using MCF7shLIFR cells, we determined that induction of
AMOT, TGFB2, and IGFBP5 is not dependent on LIFR expression.
Together, these data indicate that HDACi enhance promoter acetylation
and expression of LIFR while also upregulating other pro-dormancy
genes in a LIFR-independent manner. To determine whether HDACi
treatment promotes tumor dormancy in vivo, mice were treated with
VPA (~2mg/kg; 3x/wk) following intracardiac inoculation of MDA-
MB-231b cells, but there was no signiﬁcant diﬀerence in tumor-induced
osteolysis or tumor burden with HDACi treatment. However, VPA
treatment in naïve mice revealed a signiﬁcant reduction in bone vo-
lume, suggesting that VPA negatively impacts bone remodeling and
should be combined with a bone protective agent in future in vivo ex-
periments. Importantly, these studies suggest that HDACi can stimulate
pro-dormancy gene expression and therefore may have clinical im-
plications for the use of HDACi as a means to maintain breast cancer
cells in a chronic dormant state.
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TGFβ inhibition in combination with chemotherapy repairs ex-
isting lytic bone lesions in a novelplateau phase model of multiple
myeloma
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Multiple myeloma (MM) causes a destructive bone disease in >85% of
patients and current therapies do little to repair existing bone damage.
We previously identiﬁed that combined bone anabolic and anti-re-
sorptive therapy repairs osteolytic lesions in mice with high tumour
load. In patients, if bone repair agents were given, they would be ad-
ministered in combination with chemotherapy. Thus, this study aimed
to determine if bone recovers after chemotherapy and if this is en-
hanced by bone anabolic therapy.
Human U266-GFP-luc MM cells were i.v. injected into NSG mice (n=5-
7/group). After tumour and lytic bone lesion development, mice were
administered ﬁrst-line chemotherapeutics (bortezomib ± lenalido-
mide) ± a bone anabolic (SD208; transforming growth factor β re-
ceptor 1 inhibitor) or vehicles for 2 weeks. Tumour and bone lesions
were monitored in vivo by bioluminescence imaging (BLI), serum
paraprotein ELISAs and μCT. Flow cytometry, histomorphometry, μCT,
TRAP and P1NP ELISAs and QPCR were performed for endpoint ana-
lyses.
Chemotherapy signiﬁcantly reduced total body tumour burden and
paraprotein, and increased survival. Combined chemotherapy was more
eﬀective than either given alone, reducing tumour to levels un-
detectable by BLI and paraprotein. However, ﬂow cytometry revealed
low tumour levels of 100MM cells/106 bone marrow cells. Lytic bone
lesions developed ~8 weeks after tumour inoculation. Vehicle treated
mice exhibited progressive bone lesion development and virtually no
trabecular bone at endpoint. Lesions in mice administered bortezomib
± lenalidomide were unchanged after 1 week but began to repair after
2 weeks, with signiﬁcantly reduced TRAP+ osteoclasts and increased
osteoblasts, indicating recovery of bone. Mice treated with che-
motherapy + anabolic SD-208 exhibited enhanced repair of bone le-
sions, with partial repair of perforating cortical lesions on all tibial
surfaces within 1 week and complete repair of lesions within 2 weeks.
SD-208 also signiﬁcantly increased trabecular bone volume after 2
weeks.
This study identiﬁed SD-208 enhances MM bone lesion repair when
combined with ﬁrst-line chemotherapeutics. Future studies combining
SD-208 and chemotherapy with anti-resorptive therapy will identify
optimum treatment regimens for translation of bone anabolic therapy
into MM clinical trials.
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Bone microenvironment induction of tumoral integrin β3 expres-
sion promotes resistance to chemotherapy in breast cancer bone
metastases.
Gregory C. Fox, Michael H. Ross, Xinming Su, Yalin Xu, Elizabeth
Cordell, Elisabeth Wilson, Barbara Muz, Abdel Kareem Azab,
Gregory M. Lanza, Katherine N. Weilbaecher
Washington University School of Medicine, Saint Louis, USA
Breast cancer (BC) cells that have disseminated to the bone micro-
environment exhibit relative resistance to treatment with che-
motherapy compared to primary breast tumors. Given that over two-
thirds of patients with metastatic BC will develop bone lesions at some
point in the clinical course, understanding of the mechanisms re-
sponsible for bone-induced therapeutic resistance in BC cells represents
an urgent and unmet clinical need. We have previously shown that
expression of the β3 integrin subunit is increased in bone-residing tu-
mors compared to matched primary breast cancers in both preclinical
models and patient samples. This upregulation of integrin β3 in BC
bone metastases was dependent on TGF-β signaling through SMAD2/3.
Finally, integrin αvβ3-targeted nanoparticles (~12.5nm) harboring the
microtubule-stabilizing chemotherapy docetaxel were signiﬁcantly
more eﬀective than free docetaxel in treating bone metastases. In the
present study, we next investigated whether signaling through integrin
β3 (β3) itself has a functional role in mediating chemotherapy re-
sistance in bone metastases. In vitro docetaxel treatment of either bone-
avid MMTV-PyMT-derived BC cells (BO1-FL-GFP) or 4T1 BC cells en-
riched for populations with higher β3 expression. Chemotherapy re-
duced BrdU incorporation in β3lo BC cells but not in β3hi cells, sug-
gesting a relative resistance to chemotherapy in the β3hi population.
To evaluate the necessity of β3 expression for chemoresistance in vivo,
β3 was genetically deleted in BO1 cells using CRISPR/Cas9 (β3-/- BO1).
Bone metastases established with β3-/- BO1 cells were more sensitive to
docetaxel treatment compared to the relative docetaxel resistance ob-
served in wild type bone metastases. Retroviral rescue of β3-/- BO1
cells with human integrin β3 (hβ3) restored docetaxel resistance in
bone metastases, while β3-/- BO1 cells expressing either a signaling-
deﬁcient mutant integrin β3 (Δβ3) or empty vector (pMx) remained
sensitive, indicating that integrin β3 signaling promotes a che-
motherapy resistance phenotype. In vitro, hβ3-expressing cells demon-
strated increased viability, higher BrdU incorporation, and reduced
caspase-3/7 activity compared to either Δβ3-expressing cells or pMx
cells in the presence of docetaxel or the microtubule-destabilizing agent
eribulin. RNAseq and qPCR analysis of hβ3-expressing cells demon-
strate upregulation of multiple genes associated with chemoresistance,
including anti-apoptotic factors. Collectively, this study demonstrates
Journal of Bone Oncology 13 (2018) 11–54
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that integrin β3 expression on BC bone metastases promotes resistance
to potent anti-breast cancer, microtubule-targeted chemotherapies.
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Development of ROS-responsive and Bone-Targeted Nanocarriers
of Gli-Inhibitors for Treatment of Tumor-Induced Bone Disease
Joseph Vanderburgh, Kristin Kwakwa, Mukesh Gupta, Sean Wang,
Alyssa Merkel, Craig Duvall, Julie Sterling, Scott Guelcher
Vanderbilt University, Nashville, USA
In multiple cancer types including breast and lung, increased expression
of Gli2, a Hedgehog family transcription factor, has been shown to
contribute to tumor-induced bone disease (TIBD). Small molecule drug
candidates have been identiﬁed to antagonize the aberrant activation of
the Hedgehog pathway; however, these molecules are hydrophobic and
exhibit poor pharmacokinetic properties. Here, we have developed re-
active oxygen species (ROS, prevalent in tumor and inﬂamed sites)
responsive and bone-targeted polymeric nanocarriers to encapsulate
the small molecule Gli2-inhibitor, GANT58, to create GANT58 nano-
particles (GANT58-NPs). A block-copolymer formulation of poly(pro-
pylene sulﬁde)-poly(oligoethylene glycol acrylate) (PPS-b-POEGA) was
synthesized using reversible addition fragmentation chain transfer
(RAFT) polymerization, and NPs encapsulating GANT58 were fabri-
cated by an oil-in-water solvent evaporation method. The GANT58-NPs
were tested in a mouse model of breast and lung cancer invasion into
the tibia. MDA-MB-231 human breast cancer cells and RWGT2 human
lung cancer cells were injected into the tibiae of athymic nude mice,
and GANT58-NPs were delivered by tail vein injections daily. GANT58-
NP treatment signiﬁcantly reduced bone destruction in both the MDA-
MB-231 and RWGT2 models, and the biodistribution of the GANT58-
NPs demonstrated preferential uptake in the tumor site. To further
improve the site speciﬁcity of the GANT58-NPs toward the bone mi-
croenvironment, a new polymer formulation incorporating the bone-
binding bisphosphonate alendronate has been developed. In vitro hy-
droxyapatite (HA) binding assays show the bone-targeted GANT58-NPs
(GANT58-BTNPs) have a tunable bone-binding aﬃnity dependent on
the alendronate content in the polymer formulation. In vivo biodis-
tribution conﬁrmed the in vitro ﬁndings, with the GANT58-BTNPs
showing over a two-fold increase in bone localization compared to the
non-targeted formulation. It is hypothesized that these GANT58-BTNPs
will not only improve the eﬀective dosage of GANT58 to the bone-
tumor site, but could also be used as a preventive treatment, as GANT58
has shown antitumor eﬀects in vitro and thus could prevent tumor es-
tablishment in bone. In summary, the polymeric nanocarriers devel-
oped here have successfully encapsulated the Gli2-inhibitor GANT58
and reduced bone destruction in mouse models of TIBD, and the bone-
targeting of these nanocarriers is hypothesized to provide a platform for
prevention of tumor establishment in bone.
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A novel osteolineage-derived cancer associated ﬁbroblast popu-
lation in primary tumors expresses Dkk1 and enhances tumor
growth
Biancamaria Ricci, Francesca Fontana, Roberto Civitelli, Roberta
Faccio
Washington University, St. Louis, USA
We recently described that mice bearing extra-skeletal tumors have in-
creased levels of the Wnt/β-catenin inhibitor Dkk1 in circulation and
bone marrow ﬂuid. Although Dkk1 is known to modulate bone re-
modeling, during tumor progression Dkk1 induces the expansion of
myeloid derived suppressor populations to inhibit anti-tumor T cell re-
sponses. The goal of this study was to determine the source of Dkk1 and
whether Dkk1 acts locally or systemically to exert immune suppressive
functions. Dkk1 was highly expressed by osteoblasts (OBs) and osteo-
cytes in mice with extra-skeletal tumors. Although we did not detect
expression of Dkk1 in our tumor lines, we found expression in the tumor
mass by the cancer-associated ﬁbroblasts (CAFs). Unexpectedly CAFs
also expressed two OB-speciﬁc markers Osterix (Osx) and Osteocalcin
(Ocn), leading to the hypothesis that Dkk1 at tumor site is produced by a
novel osteolineage-derived ﬁbroblast population. To test this possibility,
we turned to a mouse model carrying the R26R-tdTomato reporter pro-
tein (TdTomato) under the control of a TET-oﬀ doxycycline Osx-Cre
(TdTOsx) driven promoter. Doxycycline was administered to moms and
pups until weaning to prevent Osx-Cre activation in perinatal mesench-
ymal stem cells and, at 8 weeks of age, mice were orthotopically in-
oculated with B16 or PyMT cell lines. We found that 3-9% cells in the
tumor mass were TdTOsx+. This population expressed several ﬁbroblast
markers and Dkk1. Importantly, TdTOsx cells isolated from B16 tumors
and co-injected together with B16 cells into WT recipient mice sig-
niﬁcantly increased tumor growth compared to the tumor line alone.
Next, to determine whether Osx+ cells support tumor progression via
production of Dkk1, we generated Osx-Cre;Dkk1ﬂ/ﬂ mice and observed
a signiﬁcant reduction in tumor size compared to control mice. Since
Osx-Cre targets also the OBs, to speciﬁcally evaluate the contribution of
CAF-derived Dkk1, we generated Fsp1-Cre;Dkk1ﬂ/ﬂ mice. Strikingly,
tumor growth was also signiﬁcantly reduced in the Fsp-Cre;Dkk1ﬂ/ﬂ
mice indicating that ﬁbroblast-derived Dkk1 plays an important role
during tumor progression. In summary, we have identiﬁed a novel po-
pulation of CAFs that expresses the osteolineage marker Osx and con-
tribute to Dkk1 production and strongly support tumor growth.
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ROUNDABOUT 4 MEDIATES THE HOMING OF HUMAN BREAST
CANCER CELLS IN THE BONE MARROW
Margaux Bernard, François Le pape, Lise Clément-Demange, Lamia
Bouazza, Sandra Geraci, Soﬁa Sousa, Martine Croset, Chantal Diaz-
Latoud, Philippe Clézardin
LYOS, Lyon, France
Bone metastases contribute substantially to morbidity and mortality in
women with advanced breast cancer and current treatments are only
palliative. In order to prevent bone metastasis, it is vital to increase our
understanding of the molecular mechanisms that control cellular events
preceding the development of overt skeletal lesions. A comparative
transcriptional analysis was performed between human MDA-MB-231
breast cancer cells that metastasise to several organs in animals, and a
sub-population of the MDA-MB-231 cell line (B02) that metastasises to
bone only. Compared to MDA-MB-231, B02 cells overexpressed
Roundabout 4 (Robo4), a cell surface receptor belonging to the
Roundabout family of axonal guidance receptors. Robo4 is involved in
angiogenesis, blood vessel integrity and homing of hematopoietic stem
cells in the osteoblastic niche. To determine whether Robo4 could also
mediate the homing of tumour cells in the bone marrow, we invalidated
ROBO4 in B02 cells using a CRISPR/Cas9 strategy. In vitro, the inter-
action of ROBO4-depleted B02 cells (B02-ROBO4-) with pre-osteoblasts
(MC3T3-E1) was decreased, compared to that observed with parental
B02 cells (B02-C). After culture of B02-C or B02-ROBO4- cells in sus-
pension, tumour cells formed mammospheres. Their size was however
substantially reduced upon ROBO4 depletion. Similar ﬁndings were
observed when co-culturing B02-C or B02-ROBO4- cells with murine
MC3T3-E1 cells or human mesenchymal cells. Ex vivo, the number and
size of tumour cell colonies in the bone marrow from animals in-
oculated with B02-ROBO4- cells were signiﬁcantly decreased compared
to that observed with B02-C cells. In situ visualization by dual-photon
microscopy of DiD-labelled B02-ROBO4- and B02-C cells in the hind
limbs from tumour-bearing animals showed that ROBO4 depletion
impeded the homing of tumour cells in the bone marrow. Furthermore,
compared to B02-C cells, the homing of B02-ROBO4- cells in a huma-
nized osteoblastic niche implanted subcutaneously in NOD/SCID mice
was also markedly reduced. Overall, these results suggest that ROBO4
mediates the early seeding of human breast cancer cells in bone.
Journal of Bone Oncology 13 (2018) 11–54
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Potent therapeutic impact of TAK1 inhibition on myeloma pro-
gression and bone destruction
Jumpei Teramachi1, Hirofumi Tenshin1, Masahiro Hiasa1, Asuka
Oda1, Takeshi Harada1, Shingen Nakamura1, Hirokazu Miki2,
Itsuro Endo1, Toshio Matsumoto1, Masahiro Abe1
1Tokushima University, Tokushima, Japan. 2Tokushima University
Hospital, Tokushima, Japan
Multiple myeloma (MM) has a unique propensity to develop and ex-
pand in the bone marrow with devastating bone destruction. We have
reported that MM cells constitutively overexpress PIM2, and that bone
marrow stromal cells (BMSCs) as well as osteoclasts (OCs) further up-
regulate PIM2 as an anti-apoptotic mediator in MM cells. Besides, the
interaction with MM cells induce PIM2 in BMSCs and OCs to progress
bone destruction, indicating the critical role of PIM2 in MM tumor
growth and bone destruction. We recently identiﬁed TGF-β-activated
kinase-1 (TAK1) as an upstream mediator responsible for PIM2 up-
regulation in these cells. Therefore, we aimed to clarify the role of TAK1
in MM growth and bone destruction, and the therapeutic impact of
TAK1 inhibition on MM. TAK1 was constitutively overexpressed and
phosphorylated in MM cell lines tested. Immunoreactivity of phos-
phorylated TAK1 was apparently observed in MM cells in 36 out of 50
MM patients, but not in normal peripheral blood mononuclear cells.
The TAK1 inhibitor LLZ1640-2 reduced the PIM2 expression and in-
duced apoptosis in MM cells. Although TNF-α and IL-6 upregulated
PIM2 expression in MM cells, LLZ1640-2 abolished TNF-α-induced NF-
κB activation and IL-6-induced STAT3 activation in MM cells to reduce
PIM2. The TAK1 inhibition suppressed VEGF production and the ex-
pression of BCMA and TACI, receptors for BAFF and APRIL. TAK1
phosphorylation was induced in BMSCs when the cells were co-cultured
with MM cells; however, LLZ1640-2 suppressed PIM2 up-regulation and
induced apoptosis in MM cells in cocultures with BMSCs. TAK1 in-
hibition reduced VCAM-1 and RANKL expression and IL-6 production
by BMSCs, which impaired adhesive interactions between MM cells and
BMSCs, and blunted protective activity of BMSCs for MM cells against
anti-MM agents. LLZ1640-2 abolished the PIM2 induction in MC3T3-E1
cells by MM cells to restore osteoblastogenesis. Furthermore, LLZ1640-
2 suppressed osteoclastogenesis by RANKL as well as MM cells.
Treatment with LLZ1640-2 suppressed MM growth and prevented bone
destruction in mouse MM models. These results demonstrate that TAK1
plays a pivotal role in tumor progression and bone destruction in MM.
TAK1 inhibition may become a unique anti-MM therapeutic option with
bone-modifying activity.
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Dual BRD4/autophagy inhibitor as novel strategy for the treat-
ment of multiple myeloma
Marilena Tauro, Muhammad Ayaz, Harshani Lawrence, Nicholas
Lawrence, Ernst Schonbrunn, Conor Lynch
H Lee Moﬃtt Cancer Center, Tampa, USA
The bromodomain and extra-terminal (BET) family of proteins are
important epigenetic regulators of oncogenes, including c-Myc. JQ1 is a
potent BRD4 inhibitor and the focus of current clinical trials for the
treatment of hematologic malignancies. Unfortunately, resistance to
BET inhibitors is acquired, indicating that single agent therapies may
not provide durable therapeutic responses.
To overcome this limitation, we have developed a new class of dual
inhibitors, that simultaneously target BRD4 and a panel of tyrosine
kinases highly expressed in cancer including JAK2, FLT3, RET, FGFR1,
ULK1 and ULK3.
Preliminary in vitro screening identiﬁed SG3 as the lead compound with
BRD4 and c-Myc IC50’s similar to JQ1 (nM). SG3 however, was also
inhibiting JAK2, FLT3, ULK1 and ULK3 in the nM range. We initially
explored the eﬃcacy of SG3 on MM. In vitro assays on cell lines
revealed higher SG3 sensitivity (5TGM1, 0.85mM; U266, 0.99mM)
compared to JQ1 (5TGM1, 4.7mM; U266, 16mM). In vivo studies with
5TGM1-Luc cells demonstrated that SG3 treatment signiﬁcantly con-
tributes to overall survival compared to control (median survival
CTRL=40.5; SG3=50.5; JQ1=46 days).
Post-study analyses demonstrated a signiﬁcant reduction in myeloma-
induced bone disease in the SG3 treated mice, quantiﬁed by X-ray/
mCT/ histomorphometry. No toxicities or adverse eﬀects were noted.
As expected, SG3 inhibited c-Myc expression. To identify potentially
additional mechanisms of action we explored the prevalence of SG3
target kinases in publicly available datasets. We identiﬁed ULK3 as a
candidate kinase of SG3 targeting activity and correlated its expression
with MM disease stages. High basal levels of autophagy are present in
MM and ULK3 is a key regulator of the process. We therefore explored
whether the additional eﬃcacy of SG3 was being mediated by autop-
hagy inhibition. We noted, in vitro, that within 6 hours, SG3 completely
shut down autophagy with decrease levels of ULK1, beclin-1, ATG16L-
1, ATG12, ATG3, p62 and increased LC3I/II ratios (additionally con-
ﬁrmed by microscopy and ﬂow cytometry). These eﬀects were not
noted with JQ1.
In summary, we believe SG3 is an exciting new dual inhibitor that will
be eﬀective for the treatment of treatment-naïve and potentially re-
fractory multiple myeloma.
OC11
Two-way Signalling between Multiple Myeloma Cells and Bone
Marrow Adipocytes
Michaela Reagan, Heather Fairﬁeld, Carolyne Falank
Maine Medical Center Research Institute, Scarborough, USA
Multiple myeloma is a plasma cell cancer within the bone marrow
(BM). Myeloma cells have a dependency on the BM microenvironment
for survival and proliferation, and BM adipocytes (BMAs) demonstrate a
unique, endocrine signaling capacity and lipid composition that is likely
to cause unique cross-talk between myeloma cells and BM adipose
tissue (BMAT).
We generated BMAT from human BM-derived stromal cells (BMAT)
using adipogenic media. We performed proliferation, adhesion, gene
expression, lipid accumulation, adipokine array, and drug resistance
screens to study the relationship between BMAT and myeloma cells.
Myeloma cells were cultured on, or with conditioned media (CM) from,
BMAT+/-chemotherapies. We also developed a tissue-engineered 3D
BMAT-myeloma model using silk scaﬀolds.
Direct culture with BMAT rescued OPM2 myeloma cells from dex-
amethasone- and bortezomib-induced apoptosis and cell death. We
explored changes in cell-cell adhesion genes using qRT-PCR and found
that VCAM-1 was increased in OPM2 cells after co-culture with BMAT,
and this was further increased after addition of bortezomib, while other
genes (e.g., N-cadherin) were not changed. MM1S cells also showed
signiﬁcant dexamethasone resistance and decreased apoptosis when co-
cultured with BMAT CM. IL-6, resistin, and leptin showed promise as
molecules that contribute to this. Our 3D BMAT models also induced
OPM2 dexamethasone resistance.
We also observed the phenomenon “adipomimicry” in tumor cells.
OPM2 cells expressed FABP4, PPARγ and ADIPOQ when co-cultured
with BMAT, and these were further increased upon treatment with
bortezomib. Myeloma cells were also observed to contain lipid droplets
only when co-cultured with BMAT. Whether these changes are gov-
erned by direct lipid transfer, exosome (miRNA/mRNA) transfer, or
cell-cell soluble or adhesion-based activation of downstream signalling
pathways is under investigation in our lab. In both 2D and 3D co-cul-
tures, we also found a reduction in BMAT lipid content using Oil-Red-O
staining. Lastly, an adipokine array revealed signiﬁcant increases in
tumor supportive secreted factors (AgRP, IGF2, IL6, Lipocalin-2, RAGE,
RANTES, and RBP4) from 3T3L1 adipocytes after transwell co-culture
with myeloma cells.
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Overall, we propose a positive feedback loop between myeloma cells
and BMAs, which has great potential for targeting with novel ther-
apeutics in multiple myeloma.
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The small molecule adiponectin receptor agonist AdipoRON ex-
hibits anti-myeloma activity in vitro and in vivo.
Sam Olechnowicz, Emma Morris, Siobhan Webb, Aneka Sowman,
Claire Edwards
University of Oxford, Oxford, United Kingdom
Multiple Myeloma (MM) is a plasma cell malignancy which interacts
with the bone microenvironment, inducing bone lesions and pain.
Adiponectin is an adipocyte-secreted cytokine which is thought to have
beneﬁcial eﬀects against obesity, diabetes and cardiovascular health.
Serum levels of adiponectin are negatively correlated with MM pro-
gression in patients, while bone microenvironment-produced adipo-
nectin is protective against myeloma in mouse models. AdipoRON, a
recently developed orally-available adiponectin receptor agonist com-
pound, binds both adiponectin receptors AdipoR1 and AdipoR2 and
activates downstream signalling. We examined the eﬀect of AdipoRON
on MM growth in vitro, using both primary MM samples and MM cell
lines, and used the C57Bl/KaLwRij strain of mouse with 5TGM1-GFP+
MM cells to examine the eﬀect of AdipoRON as a therapeutic in vivo, in
comparison to the widely used therapeutic bortezomib.
Treatment with AdipoRON reduced viability and induced cleaved PARP
and apoptosis in a panel of MM cell lines in vitro, and death of patient-
derived MM cells as revealed by ﬂow cytometry. In vivo, IgG2b para-
protein (a marker of tumour burden) was signiﬁcantly reduced by ei-
ther oral AdipoRON treatment or bortezomib three times per week
(p<0.01) relative to vehicle control. Bone marrow and spleen GFP+
tumour cell percentages by ﬂow cytometry conﬁrmed MM invasion to
both sites. Spleen weights were signiﬁcantly increased in MM-bearing
mice after control or bortezomib treatments (p<0.01 and p<0.001
respectively), but not AdipoRON treatment. Preliminary micro-CT
analysis indicated a beneﬁcial eﬀect of both AdipoRON and bortezomib
on trabecular number and BV/TV in the tibia of MM-bearing mice.
Neither treatment had a signiﬁcant eﬀect on cortical bone strength in
vivo at this time point as measured by 3-point bend analysis, however in
vitro AdipoRON increased 2T3 mouse osteoblast mineralisation, sug-
gesting a potential secondary eﬀect of long-term AdipoRON treatment.
This work further underscores the potential of adiponectin-based
therapeutics in MM treatment.
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MSCs promote the evolution of apoptosis resistant bone metastatic
prostate cancer via interleukin-28
Jeremy McGuire1,2, Jeremy Frieling1, Leah Cook3, Conor Lynch1
1Moﬃtt Cancer Center, Tampa, USA. 2University of South Florida, Tampa,
USA. 3University of Nebraska, Lincoln, USA
Bone metastatic prostate cancer is incurable and often has osteoblastic
phenotype. Osteoblast precursors, mesenchymal stem cells (MSCs), re-
side in the bone marrow and are thought to promote cancer growth. We
therefore hypothesized that prostate cancer interactions with MSCs in
the bone microenvironment would lead to an osteoblastic phenotype
and accelerated tumor growth. Rag2 immunocompromised mice (n=8/
group) were intratibially inoculated with primary MSCs (2x104),
PaIIILucs (2x104), or a 1:1 ratio of MSCs:PaIII (4x104 total).
Surprisingly, we observed an initial suppression of prostate cancer
growth by MSCs until day11 (p<0.05) after which we noted rapid
expansion of the prostate cancer cells. Ex vivo analyses demonstrated
that co-injection of MSCs signiﬁcantly reduced tumor induced osteo-
lysis (X-ray) and promoted trabecular bone formation (μCT). In vitro,
co-culture of prostate cancer cells (PaIII, DU145, MycCAP) with MSCs
or MSC conditioned media (CM) induced prostate cancer cell apoptosis
as measured by cleaved caspase-3. However, not all cells succumbed
and two further rounds of selection in MSC CM yielded sub-populations
(F2) of prostate cancer cells resistant to MSC CM, etoposide and doc-
etaxel. Repeat of our in vivo study now demonstrated that MSC edu-
cated prostate cancer cells lines grew signiﬁcantly faster than in the
presence of MSCs compared to the parental (F0) cells lines. Cytokine
array analyses of MSC CM revealed interleukin 28 (IL-28) as a candi-
date factor promoting prostate cancer cell apoptosis. We found that
depletion of IL-28 from MSC CM prevented F0 prostate cancer cell
apoptosis with no eﬀect on F2 populations. This was further validated
using shRNA approaches. Analysis of downstream eﬀectors of the IL-28
receptor revealed rapid phosphorylation of STAT3 in the F2 cell lines.
Using a STAT3 inhibitor (S3I-201) we observed that F2 prostate cancer
cell lines were more sensitive than their parental counterparts in vitro.
In vivo, we observed MSC educated F2 PAIII cells were signiﬁcantly
inhibited by S3I-201 compared to vehicle control. Taken together, our
results indicate that bone MSCs promote the evolution of apoptosis
resistant prostate cancer cells via chronic exposure to IL-28 but the
evolved cells are sensitive to STAT3 inhibition.
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The Physical Bone Microenvironment Modulates Osteolytic Gene
Expression in Metastatic Breast Cancer
Kristin Kwakwa, Joseph Vanderburgh, Shanik Fernando, Jonathan
Page, Alyssa Merkel, Scott Guelcher, Julie Sterling
Vanderbilt University, Nashville, USA
Tumor-induced bone disease is a common comorbidity in patients with
metastatic breast cancer. Patients suﬀer from debilitating skeletal-re-
lated events primarily because the bone microenvironment, including
resident bone cells and soluble factors, provides a fertile niche for
breast cancer cells to promote osteoclast-mediated bone resorption.
Speciﬁcally, our group has established that bone-metastatic breast
cancer cells overexpress the Hedgehog (Hh) transcription factor Gli2 in
response to transforming growth factor beta (TGF-β), which induces
parathyroid-related protein (PTHrP) secretion and bone destruction.
However, Gli2 expression is not solely regulated by soluble factors like
Hh ligands or TGF-β. Our previous investigations show that matrix ri-
gidity can also regulate tumor cell expression of Gli2 and PTHrP. Breast
cancer cells cultured on 2D polyurethane ﬁlms with elastic moduli
ranging from the basement membrane to cortical bone had signiﬁcantly
increasing mRNA levels of Gli2 and PTHrP as well as the mechan-
osensitive gene integrin beta 3 (ITGB3), which has been implicated in
breast cancer metastasis to bone. Other parameters of the physical and
structural bone microenvironment and their eﬀects on tumor cell gene
expression and behavior have yet to be explored. We hypothesized that
the trabecular architecture of bone can modulate the expression of os-
teolytic genes, including Gli2, PTHrP, and ITGB3, to promote the bone-
destructive phenotype of breast cancer cells. To test this, we created
novel 3D tissue-engineered bone constructs (TEBCs) that mimic the
trabecular structure of human bone at diﬀerent anatomical sites such as
the femur, tibia, and vertebrae. There were signiﬁcant diﬀerences in the
expression of Gli2, PTHrP, and ITGB3 by bone-metastatic breast cancer
cells (MDA-MB-231) cultured on TEBCs, even when compared to that of
cells seeded on a scaﬀold with uniform pore size. Interestingly, breast
cancer cells with relatively low metastatic potential (MCF-7 and
SUM159) also diﬀerentially express Gli2, PTHrP, and ITGB3 on these
bone constructs. These data indicate that bone microarchitecture reg-
ulates osteolytic gene expression in breast cancer cells and underscores
the potential of the 3D bone microenvironment to promote breast
cancer-induced osteolysis. A better understanding of tumor cell re-
sponse to the bone microenvironment can help investigators develop
new therapies to treat tumor-induced bone disease.
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Epigenetic targeting of the myeloma-bone microenvironment in
3D
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EZH2, the methyltransferase subunit of Polycomb Repressive Complex
2 (PRC2), catalyzes H3K27me3 histone modiﬁcation and epigenetically
regulates genes involved in cellular pluripotency and diﬀerentiation.
EZH2 regulates MM cell survival, and its elevated expression correlates
with poor prognosis in MM patients. EZH2 inhibitors including GSK126
in combination with conventional therapies showed promising anti-
myeloma eﬀects.With a focus on reversal of MM osteolytic bone dis-
ease, we showed that GSK126 rescued MM-induced suppression of BM-
MSC osteogenic diﬀerentiation. We provide new evidence that GSK126
blocks MM-induced hyperactivation of osteoclast precursors (OCLp).
RNA-seq proﬁling revealed that inhibition of EZH2 re-activated 115
genes associated with bivalent and/or H3K27me3 promoter signatures
including OCL inhibitory factors MafB, Irf8, Bcl6b and Arg1. In contrast,
we found that OCLp expansion in MM1.S-conditioned media (MMCM)
induced signiﬁcant gene expression changes, which correlated with
TNF and IKK signaling, inﬂammatory responses and CXC-chemokine
receptor pathways. We evaluated the eﬀectiveness of GSK126 in the
context of the bone microenvironment in a novel 3-dimensional (3D)
model of MM co-cultures (3D-MM). We combined basement membrane
extract (BME) hydrogels with devitalized bone slices to mimic the 3D
setting of MM with OCL-resorbing endosteal surface. This enabled us to
test the eﬀetcs of GSK126 alone or in combination with bortezomib
simultaneously on MM survival and OCLp diﬀerentiation and bone re-
sorption. While GSK126 exhibited potent anti-MM eﬀects and blocked
OCL diﬀerentiation, mature OCL added to 3D-MM co-cultures increased
the IC50 MM inhibition dose of both bortezomib and GSK126 by 40%
and 50% respectively. The synergistic eﬀect of these two drugs on MM
inhibition was further reduced by 70%. 3D-MM co-cultures with total
bone marrows of diﬀerentially (1-12 months old) aged mice showed
selective protection from GSK126, but not bortezomib, on MM viability.
Furthermore, the resistance to GSK126 was age-dependent, with the 12-
month-old bone marrows causing the greatest protection of the MM
cells. Using confocal ﬂuorescence microscopy, we found that the re-
sistant MM cells were in close proximity to osteoprogenitor cells, sug-
gesting that this interaction reduces the eﬀectiveness of epigenetic drug
targeting against MM. This novel 3D-MM system enables us to rapidly
screen drug combinations, and simultaneously evaluate the inﬂuence of
bone-microenvironmental interactions on MM drug resistance and bone
marrow cell responses to the drugs.
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Blocking Cysteinyl leukotriene receptor type 1 (CysLT1) inhibits
blood platelets’ prometastatic activity.
Audrey Houssin, Johnny Ribeiro, Irma Machuca-Gayet, Olivier
Peyruchaud
INSERM U1033, Lyon, France
Metastases are the main causes of death in cancer patients because
current primary tumor-targeted therapies are missing of speciﬁcity
against the metastasis process. Therefore, development of targeted anti-
metastasis therapeutics is urgently required. Blood platelets contribute
to the poor survival of patients with advance cancers. Unfortunately
platelets are mandatory for human life due to their paramount function
in hemostasis. The main objective of our project was to deﬁne new anti-
metastasis therapies exhibiting a high speciﬁcity for the pathological
tumor cell–blood platelet interaction without abrogating normal pla-
telet function. The project was based on an in vitro high-throughput
screening of a bank of molecules comprising 1280 compounds showing
that pharmacological blockade of cysteinyl leukotriene receptor 1
(CysLT1) with two already FDA-approved drugs in a asthma
(Zaﬁrlukast, Montelukast), inhibited speciﬁcally the pro-tumoral ac-
tivity of human blood platelets on MDA-B02 human breast cancer cells
with an IC50 around 0.5µM. CysLT2 inhibitor HAMI3379 had no eﬀect
on this assay conﬁrming the speciﬁc involvement of CysLT1. CysLT1/2
receptors are restricted to the myeloid cell lineage. We conﬁrmed that
MDA-B02 cells did not express these receptors and were insensitive to
stimulation with CysLT1 ligand, LTD4. MDA-B02 cell conditioned
media (MC) added alone did not induce platelet aggregation.
Remarkably, MDA-B02 cell MC potentiated the mild platelet agonist
activity of a low dose of ADP (1µM) from a reversible to a full platelet
aggregation that was totally blunted with Zaﬁrlukast. This result sug-
gested that cancer cells produced CystLT1 ligands (LTC4, LTD4 or
LTE4) that were active on platelet aggregation in presence of ADP. We
then addressed in the impact of Zaﬁrlukast on platelet function in vivo.
Based on a bleeding test we conﬁrmed that blocking CysLT1 in mouse
had no impact on hemostasis. However, we found that the treatment
with Zaﬁrlukast (0.4mg/kg/day per os) for 7 days decreased by 60%
the incidence of metastasis in mice after intra-arterial injection of MDA-
B02 cells and inhibited by 90% the number of tumor cells that colo-
nized the bone. Our study revealed for the ﬁrst time that CysLT1 re-
ceptor is a potential new target for blocking early events of the bone
metastasis cascade by targeting a new partner involved in blood platelet
and tumor cell connections.
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Inhibition of multiple myeloma exosomes prevents bone loss and
reduces tumor growth
Sylvia Faict1, Joséphine Muller2, Kim De Veirman1, Ken Maes1,
Elke De Bruyne1, Rik Schots1, Karin Vanderkerken1, Roy
Heusschen2, Jo Caers2, Eline Menu1
1Vrije Universiteit Brussel, Brussels, Belgium. 2Université de Liège, Liège,
Belgium
Multiple myeloma, one of the most common hematological malig-
nancies, will often manifest osteolytic lesions during disease develop-
ment, throughout the whole body.
MM is still considered an incurable malignancy, with a supportive
micro-environment in the bone marrow. Extracellular vesicles such as
exosomes are known to play an important tumor-promoting role in this
micro-environment, by inducing angiogenesis and immune suppression.
The aim of our study was to examine the eﬀects of MM exosomes on
osteolysis in vitro and in vivo, and to determine whether inhibition of
exosome secretion can lead to a delay in tumor growth and prevent
bone loss.
We used the 5TGM1 model which is a syngeneic murine MM model,
presenting typical MM characteristics such as osteolysis, angiogenesis
and a serum M-spike. We examined the eﬀects of conditioned medium
from these MM cells and MM-derived exosomes on cell viability and
proliferation of the MC3T3 pre-osteoblast cell line and on their ability
to produce alkaline phosphatase (ALP). We saw a decrease in viability
and ALP activity when adding exosomes or conditioned medium of the
5TGM1 myeloma cells to the osteoblasts. Moreover, RT-PCR analysis
showed a decrease of various osteogenic diﬀerentiation genes when
osteoblasts were exposed to 5TGM1 exosomes, demonstrating a
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diminished capacity of osteoblastic diﬀerentiation.
We next added the exosome secretion inhibitor GW4869 to the 5TGM1
cells, thereby reducing the number of exosomes in the conditioned
medium. This was conﬁrmed through western blot of the typical exo-
some markers. The negative eﬀects of the 5TGM1 conditioned medium
on osteoblasts could be overturned by reducing the exosome content
therein.
In vivo, we injected 5TGM1 exosomes intravenously in healthy mice for
three weeks and examined the eﬀects on osteolysis by microCT and
TRAP staining. We saw an increase in osteolysis, comparable to the
typical osteolytic lesions in tumor-bearing mice. Furthermore, when
inhibiting the exosome secretion in vivo in 5TGM1 mice, we observed a
signiﬁcantly reduction in tumor load.
Through this study we can conclude that exosomes from multiple
myeloma cells can induce osteolytic lesions by inhibiting osteoblast
proliferation and diﬀerentiation. These eﬀects can be reversed by in-
hibiting the secretion of exosomes.
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REFILLING OF BONY MYELOMA LYTIC LESIONS MEDIATED BY
TOTAL THERAPY 4 TREATMENT
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Veterinary Medicine & Biomedical Sciences, Houston, USA
Multiple myeloma (MM) is a disease characterized by proliferation of
clonal plasma cells. At diagnosis, 70% of MM patients with extensive
osteolytic bone lesions. Aim of this study was to investigate the eﬀect of
chemotherapy and autologous stem-cell transplantation on bone for-
mation at lytic bone sites with more than one centimeter in largest
diameter.
We included 233 patients (144 males and 89 females, age range: 38-84
years) enrolled in the Total Therapy (TT4) trial. TT4 encompassed in-
duction chemotherapy, tandem autologous stem-cell transplantation
and maintenance with proteasome inhibitors and immunomodulatory
drugs. All patients shared low risk according to the gene expression
proﬁling (GEP70 risk-classiﬁer). Lytic lesion were distributed in ﬂat and
long bones in 96% and 4% of cases, respectively. Remineralization/
reﬁlling was deﬁned as a sclerotic CT changes within lytic lesion.
Healing at the lytic site was calculated as a percentage, using the initial
lesion size reference.
With a median follow-up of 3 years we observed a decreased lesion size
in 147 patients (63%), with 13 individuals (5%) demonstrating com-
plete remineralization. An improvement between 25-50% was docu-
mented in 26 subjects (11%), 50-75% in 19 patients (8%), and 75-100%
in 18 patients (8%). The healing status had no signiﬁcant impact on
overall or event free survival. We compared the parameters as gender,
age, race, LDH, B2M, albumin, and international staging system (ISS)
between patients with vs. without healing. The proportion of patients
with ISS stage III was signiﬁcantly lower in the group of healing pa-
tients (24 vs 38%). Comparison of gene expression proﬁles indicated
higher expression in the gene for Vitamin D receptor in non-healing
subjects.
This retrospective analysis of 233 myeloma patients demonstrated a
signiﬁcant healing of lytic lesions in two third of patients treated with
intensive chemotherapy. The underlying mechanism remains elusive,
however our results suggest that the grade of disease and the expression
level of the Vitamin D receptor impact this phenomenon.
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Bone seeking MMP-2 inhibitors can prevent bone metastatic breast
cancer
Marilena Tauro, Conor Lynch
H Lee Moﬃtt Cancer Center, Tampa, USA
Bone metastasis is a common event during breast cancer progression.
The resultant lesions are painful and currently incurable. The ad-
vancement of bone metastatic breast cancer is critically dependent on
interactions with the surrounding microenvironment. Therefore, iden-
tifying the underpinning molecular mechanisms is vital for the devel-
opment of new therapies.
Gene expression analysis and validation in human and murine speci-
mens of bone metastases revealed that MMP-2 is highly expressed in the
bone metastatic microenvironment. These data support the rationale for
the development of a highly speciﬁc MMP-2 inhibitor for the eradica-
tion of active bone metastatic breast cancer.
Given that previous broad-spectrum MMP inhibitor trials were un-
successful due to dose limiting systemic side eﬀects, we utilized a novel
chemical approach to synthesize bone seeking MMP inhibitors
(BMMPIs) on a bisphosphonic backbone, with speciﬁcity for MMP-2
(IC50=140 nM).
Based on our previous data about BMMPI’s ability to signiﬁcantly re-
duce breast cancer growth in the bone microenvironment, we decided
to investigate the role of BMMPI such as ML115 in preventing dis-
semination of cancer cells into the skeleton.
Balb-c female mice (n=10/group), pretreated for 7 days with vehicle,
standard of care bisphosphonate (Zoledronate= 1 mg/kg) and BMMPIs
(ML115= 1 mg/kg), were randomized and intra-cardiac injected with
luciferase expressing 4T1 (2x105) breast cancer cell line. Tumor growth
was assessed via luminescence quantitation overtime. At day 14, mice
were sacriﬁced and tibias were collected for ex vivo analysis. Our
preliminary total body bioluminescent data suggest that pretreatment
with ML115 can signiﬁcantly reduce the amount of breast cancer cells
homing into the bone, compared to vehicle and standard bispho-
sphonate. Cancer induced bone disease was measured ex vivo by μCT,
Xray and histomorphometry. Ex vivo analysis conﬁrmed the signiﬁcant
beneﬁcial eﬀects of the BMMPIs in reducing the size of osteolytic le-
sions. We are currently measuring MMP activity in vivo and ex vivo via
speciﬁc activatable MMP probes, in order to conﬁrm BMMPI me-
chanism of action.
Given the well tolerated nature of bisphosphonates in the clinical set-
ting, we predict that BMMPIs could be used as preventive treatment to
impair breast cancer metastasis to bone.
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PRECLINICAL TESTING OF TRAIL THERAPEUTICS FOR SARCOMA
Zakareya Gamie, Anja Krippner-Heidenreich, Craig Gerrand,
Kenneth Rankin
Northern Institute for Cancer Research, Newcastle University, Newcastle
upon Tyne, United Kingdom
Despite intensive, multimodal therapy, patients with bone sarcomas
have poor 5-year survival, close to 50%. TNF-related apoptosis-indu-
cing ligand (TRAIL) can induce apoptosis in cancer cells, via the ex-
trinsic pathway, after binding to its death receptors: DR4 and DR5,
while sparing nontransformed cells. TRAIL provides an approach that
can overcome current therapeutic limitations, such as drug resistance
and toxicity associated with high doses, when administered alone or
combined with conventional therapies.
To characterise sarcoma cells for Death Receptor (DR) expression and
factors that render them susceptible to TRAIL therapy, and to assess the
eﬀectiveness of diﬀerent forms of TRAIL.
We characterized osteosarcoma cell lines (U2OS, SAOS-2 and SJSA-1),
Ewing's sarcoma cell line (TC-71), bone ﬁbrosarcoma cell line
(HT1080), chondrosarcoma cell line (SW1353), for Death Receptor 4
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(DR4) and Death Receptor 5 (DR5) expression at the RNA and protein
levels. Sarcoma and normal human cell lines were exposed to diﬀerent
forms of TRAIL.
DR5 was found to be upregulated in sarcoma cell lines. Crosslinked
forms of TRAIL were more cytotoxic when compared to non-crosslinked
forms of TRAIL. Fibroblasts and stem cells were resistant to TRAIL
therapy; however, human hepatocytes cells were sensitive.
SuperKillerTRAIL (SKT) and a newly designed scFv:TRAIL variant tar-
getting NG2, also upregulated in U2OS and SW1353 cell lines, de-
monstrated signiﬁcantly enhanced cell killing when combined with
doxorubicin.
Our pilot in vitro data indicate that osteosarcoma cell lines such as
U2OS can be killed by pre-oligomerised versions of TRAIL and more
resistant cell lines such as SJSA-1 and SW1353 can be sensitised to
TRAIL by current chemotherapeutics. Furthermore, resistant cell lines
such as SW1353 can also be sensitised by Birinapant, which is an im-
provement on previous smac mimetics. We plan to test the therapeutics
in vivo in an orthotopic mouse model of bone sarcoma.
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Breast Cancer Bone Metastasis for Preclinical Validation of Novel
Immuno-Oncology Therapies
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Immunotherapy provides promising results in the treatment of breast
cancer, but there is a high variability in response between diﬀerent
subtypes. Triple-negative breast tumors have a high number of tumor
inﬁltrating lymphocytes (TILs) and respond well to immunotherapy.
Conversely, hormone receptor positive breast tumors attract fewer
immune cells and are less sensitive to immunotherapy. Based on the
phenotype these tumors are referred as “hot” and “cold”. In both breast
cancer subtypes, the patients typically develop bone metastases that are
currently incurable. Novel immunotherapies hold the potential for
more eﬀective treatment of patients with bone metastatic disease. The
aim of this study was to establish two diﬀerent preclinical breast cancer
models in humanized mice to be used in preclinical evaluation of the
eﬃcacy of new immunotherapies in bone metastatic setting.
Female CIEA NOG mice engrafted with human CD34+ hematopoietic
stem cells (huNOG, Taconic Biosciences) were inoculated with human
BT-474 (ER+, PR+, HER2+) or MDA-MB-231(SA) (ER-, PR-, HER2-)
cells into the bone marrow of tibia. Tumor-induced changes in bone
were monitored by X-ray imaging. Tumor-induced bone alterations
were analyzed by micro-computed tomography (µCT) imaging.
Histological analyses were performed for quantitation of tumor area in
bone and immunohistochemical analyses for quantitation and locali-
zation of TILs.
BT-474 cells induced osteoblastic bone growth in the mice. Tumor-in-
duced changes in bone were visible in X-ray imaging at 4 weeks after
inoculation. At 8 weeks, the µCT analysis showed an increased bone
volume compared to intact tibia. MDA-MB-231(SA) cells induced os-
teolytic bone loss. In a 3 weeks study, the osteolytic lesions were
moderate in size and the mice exhibited cachectic features including
decreased body weight, curved spine, and muscle loss. µCT quantitation
of bone volume showed a moderate decrease compared to intact tibia.
The BT-474 model resembled a “cold” tumor, and a low number of TILs,
CD4+ and CD8+ cells were observed in this model. In contrast, the
MDA-MB-231(SA) model resembled a “hot” tumor, and a large quantity
of CD4+ TILs were seen in the tumor with CD8+ cells.
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Multiple myeloma is a plasma cell malignancy, which develops in the
bone marrow and frequently leads to severe bone destruction. Current
anti-resorptive therapies to treat the bone disease do little to repair
damaged bone; therefore, new treatment strategies incorporating bone
anabolic therapies are urgently required. We hypothesised that com-
bination therapy using the standard of care anti-resorptive zoledronic
acid (Zol) with a bone anabolic (anti-TGFβ/1D11) would be more ef-
fective at treating myeloma-induced bone disease than Zol therapy
alone. JJN3-bearing mice (n=8/group) were treated with vehicle, Zol
or 1D11 alone or Zol and 1D11 combined. Bone loss was analysed at the
end stage of disease by ex vivo micro-CT and histomorphometry. U266-
bearing mice (n=8/group) with established lytic bone lesions were
treated with vehicle, Zol or Zol and 1D11 combined. Bone changes were
monitored overtime by in vivo micro-CT, serum bone markers and dy-
namic histomorphometry. JJN3 myeloma-bearing mice treated with
combined Zol and 1D11 resulted in a 48% increase (P≤0.001) in tra-
becular bone volume compared to Zol alone and a 65% (P≤0.0001)
increase compared to 1D11 alone. The most signiﬁcant ﬁnding was the
substantial repair of U266-induced lytic bone lesions with combination
therapy, which resulted in a signiﬁcant reduction in lesion area com-
pared to vehicle (P≤0.01) or Zol alone (P≤0.01). These results reveal a
novel ﬁnding and demonstrate that combined anti-resorptive and bone
anabolic therapy are signiﬁcantly more eﬀective at treating established
myeloma-induced bone disease than Zol alone. This is a highly trans-
lational strategy which could signiﬁcantly improve bone outcomes and
quality of life in myeloma patients.
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Inhibiting IL-1B signalling increases therapeutic eﬃcacy of dox-
orubicin and zoledronic acid in immunocompetent models of
mammary cancer bone metastases.
Diane Leﬂey, Claudia Tulotta, Amy Spicer-Hadlington, Penelope
Ottewell
University of Sheﬃeld, Sheﬃeld, United Kingdom
We have identiﬁed IL1B as a biomarker for breast cancer patients who
develop metastasis to bone. Our previous studies have shown that in-
hibiting IL-1 signalling using the IL-1R antagonist, Anakinra, inhibits
bone metastases. In the clinic patients with this condition are com-
monly treated with a combination of chemotherapy (such as doxor-
ubicin) and zoledronic acid (ZA). We are therefore investigating whe-
ther addition of Anakinra to this combination can further increase
eﬃcacy.
Investigate the eﬀects of Anakinra, doxorubicin and ZA alone and in
combination on breast cancer bone metastases.
Mouse syngeneic E0771 GFP-Luc or 4T1 Luc2 mammary cancer cells
were administered to 6-8 week old C57BL/6 (n=14/group) or BALB/c
(n-16/group) mice via intra-cardiac injection. Treatment with Anakinra
(1mg/kg/day), doxorubicin (2mg/kg/ week), ZA (100ug/kg/ week –
24h post dox) or placebo, alone or in combination, commenced 3 days
after tumour cell injection. Tumour size and location were monitored
using IVIS bioluminescent detection. Eﬀects on bone were measured by
uCT, P1NP, TRAPc.
Journal of Bone Oncology 13 (2018) 11–54
35
Treatment with a combination of all three drugs reduced the number
mice with bone metastases from 50% to 0% in mice injected with
E0771 cells and from 25% to 14.2% in mice injected with 4T1 cells.
Adding Anakinra to doxorubicin and ZA also reduced non-bone me-
tastases from 50% to 16.67% in mice injected with E0771 cells and
from 87.5% to 57.1% in mice injected with 4T1 cells. Anakinra alone
reduced bone metastases to 16.67% (P=0.0294) and 12.5% (P=
0.0.0201) in mice injected with E0771 and 4T1 cells respectively.
Neither Anakinra alone or doxorubicin followed by ZA reduced non-
bone metastases. Administration of Anakinra or ZA alone or in com-
bination had signiﬁcant anabolic eﬀects on bone inhibiting tumour
associated bone loss.
Administration of Anakinra inhibits breast cancer growth and bone
metastases in vivo. When added to a combination of doxorubicin and
ZA this further increased the eﬃcacy reducing bone and non-bone
metastases. Our data indicate that inhibiting IL-1B signalling in patients
with breast cancer metastasis may increase the therapeutic potential of
their current standard of care.
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Tumour derived IL-1B Induces diﬀerential tumour promoting
mechanisms in breast cancer bone metastasis
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Breast cancer bone metastases are incurable and associate with poor
prognosis. After homing and colonising bone, breast cancer cells may
remain dormant, until signals from the microenvironment stimulate
their proliferation to form overt metastases. We have recently identiﬁed
interleukin-1B (IL-1B) as a potential marker for predicting breast cancer
patients at increased risk for developing metastasis and established a
role for IL-1 signalling in tumour cell dormancy in bone. Our novel data
support that tumour-derived, microenvironment-dependent IL-1B play
major roles in breast cancer metastasis and growth in bone.
In tissue samples from >1300 patients with stage II/III breast cancer,
active IL-1B in tumour cells correlated with relapse in bone (hazard
ratio 1.73; 95% CI 0.99-3.05; P=0.0387) and other sites (hazard ratio
1.72; 95% CI 1.04-2.84; P=0.0016). In a model of spontaneous human
breast cancer metastasis to human bone, administration of the clinically
available anti-IL-1B monoclonal antibody, Ilaris, or the receptor an-
tagonist, Anakinra, signiﬁcantly reduced metastasis to bone (8/10
control, 1/10 Ilaris and 2/10 Anakinra). Both agents reduced the
number of tumour cells shed from the primary site into the circulation.
Genetic manipulation of breast cancer cells to overexpress IL-1B de-
monstrated that exogenous production of IL-1B by breast cancer cells
promoted EMT (decreased E-Cadherin, N-Cadherin and G-Catenin),
invasion, migration and organ-speciﬁc homing in ER-ve (MDA-MB-231)
and ER+ve (T47D and MCF7) cells in vitro and in vivo.
In the bone microenvironment, contact between tumour cells and os-
teoblasts or bone marrow cells increased IL-1B secretion from all three
cell types. Exposure of tumour cells to IL-1B in the absence of bone cells
did not stimulate tumour cell proliferation. Instead, high concentrations
of IL-1B caused expansion of the bone metastatic niche (increased os-
teoblasts and blood vessels) that in turn stimulated tumour prolifera-
tion.
Our novel data demonstrate that IL-1B/IL-1R1 signalling plays an im-
portant role in breast cancer metastasis to bone. Pharmacological in-
hibition of IL-1B has potential as a novel treatment.
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Interleukin-34 is a recent discovered cytokine sharing functional simi-
larities with the macrophage-colony stimulating factor (M-CSF) in
regulating the proliferation/diﬀerentiation/survival of myeloid cells.
IL-34 expression is associated with an increase of osteosarcoma growth
in bone site as well as the formation of lung metastases. It has already
been established that recruitment of M2 macrophages, new vessel for-
mation and extravasation of immune cells are the main mechanisms by
which IL-34 plays a key role in the pathogenesis of osteosarcoma.
Owing to this, IL-34 is a potential therapeutic target in osteosarcoma.
The present study aimed to determine the therapeutic eﬀect of IL-34
targeting in osteosarcoma by using murine pre-clinical models and anti-
IL34 blocking antibodies.
Human GFP-MNNG/HOS and mouse MOS-J osteosarcoma cells where
used to establish human and mouse xenograft models in im-
munodeﬁcient and immunocompetent environment respectively. Cells
were inoculated in close proximity to the tibia, and anti-IL-34 mono-
clonal blocking antibodies were administered (i.p.) three times weekly
at 100 microg/injection. Tumour volumes were measured twice a week
with calipers, and tumour samples were processed for im-
munohistochemistry.
As expected the inoculation of osteosarcoma cells led to the develop-
ment of palpable tumour mass after 10 days. The administration of
mouse anti-human IL-34 antibodies did not modulate the tumour
growth in contrast to rat anti-mouse IL-34 which markedly blocked the
tumour progression.
In osteosarcoma development, IL-34 appears mainly produced by the
murine tumour microenvironment. The inhibition of IL-34 speciﬁc
blocking antibodies demonstrates that the therapeutic beneﬁt to abro-
gate IL-34 in osteosarcoma. IL-34 may be a novel therapeutic target in
bone associated-diseases.
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Combination of capecitabine and radium-223 for patients with
breast cancer and bone metastases: Results of the CARBON trial
phase IB initial safety stage
Janet Brown1, Jessica Kendall2, Sarah Brown2, Sacha Howell3,
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INTRODUCTION: Median survival time in breast cancer after the de-
velopment of bone metastases remains around 2-3 years. Many patients
with bone involvement also have metastasis in other sites. Thus, com-
bining a bone-targeted treatment such as radium-223 with systemic
chemotherapy, may provide a more eﬀective treatment with minimal
additional side eﬀects. In the CARBON study, we are assessing the
safety and preliminary eﬃcacy of the combination of radium-223 and
capecitabine. We present data from the safety phase of the CARBON
trial.
METHODS: CARBON is a randomised, multi-centre, open-label phase
IB/IIA study, for female breast cancer patients with bone metastases,
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with or without metastasis elsewhere. The initial safety phase employed
a modiﬁed 3+3 design aiming to determine the feasibility and safety of
administering radium-223 (55kBq/kg 6-weekly starting cycle two) with
capecitabine (standard of care, 1000mg/m2 on days 4-17 of each cycle,
for up to 12 cycles). The primary endpoint was the number of patients
experiencing dose limiting toxicities (DLTs) within the ﬁrst two cycles.
Phase IIA then aims to establish preliminary information on eﬃcacy
(bone turnover markers and progression in bone and non-skeletal sites)
and further characterise the safety proﬁle.
RESULTS: Six patients (mean age 54.2 years) were recruited to the
initial safety phase. There were no DLTs and three non-trial treatment
related serious adverse events in two patients. Five CTCAE grade 3
adverse events (malignant neoplasm breast, neutropenia, headache,
leptomeningeal disease and hand-foot syndrome) were observed in four
patients with one related to capecitabine and one related to both
treatments. Four patients required capecitabine dose reductions.
Patients received an average of 8.7 treatment cycles with two patients
completing all 12 cycles and the remaining stopping early due to ex-
traskeletal disease progression (n=3) and disease progression plus
toxicities (n=1).
Discussion: As no DLTs were observed and the treatment was generally
well tolerated, the Safety Review Committee approved the opening of
the randomised extension IIA phase of the study. To date, of the 36
patients required for the extension phase, 12 patients have been re-
cruited and randomised on a 2:1 basis (combination vs capecitabine
alone).
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Enrichment and detection of tumor cells in novel models of breast
cancer bone colonization
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Breast cancer cells frequently home to the bone, but the mechanisms
controlling tumor colonization of the bone marrow remain unclear.
This deﬁcit is partially due to the lack of in vivomodels that recapitulate
prolonged tumor latency and our limited ability to detect low levels of
tumor burden in the bone. We therefore investigated the ability of three
breast carcinoma cell lines (ER+ human MCF7, ER+ murine D2.0R,
and ER- human SUM159) to disseminate to the bone following in-
tracardiac inoculation with or without estrogen (E2) supplementation.
Using ﬂow cytometric and quantitative PCR approaches, tumor cells
were detected in >80% of MCF7 tumor-inoculated mice, regardless of
E2 (n=8/10 mice -E2, n=7/8 mice +E2), and were signiﬁcantly en-
riched in +E2 mice (up to 46-fold, p=0.0042-0.03). Tumor cells were
detected at the histological level in +E2, but not -E2, mice. These data
indicate that exogenous E2 is not required for tumor cell dissemination
to the bone marrow, but is necessary for tumor cells to grow in and
colonize the bone. While MCF7 cells (with E2 supplementation) have
been used by multiple groups in bone colonization studies, this study is
the ﬁrst to describe the ability of D2.0R and SUM159 cells to home to
bone following intracardiac inoculation. Tumor cells were detected in
the bone marrow of up to 100% of D2.0R (n=9 mice -E2, n=6 mice
+E2) and SUM159 (n=8 mice)-inoculated mice, depending on the
detection method. We propose these cell lines as additional models in
which to study prolonged latency periods by bone-disseminated tumor
cells, given that D2.0R cells exhibit a time-course similar to the MCF7
model (~7 weeks) and SUM159 cells exhibit a prolonged latency period
(13 weeks). Importantly, a distinct advantage of the D2.0R model is
that tumor cells are inoculated into immunocompetent mice allowing
for the impact of the immune system on tumor dormancy to be in-
vestigated. These ﬁndings establish novel models of bone colonization
in which to study mechanisms underlying tumor cell seeding to the
marrow and prolonged latency, and provide highly sensitive methods to
detect these rare events.
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Patients that succumb to osteosarcoma (OS), the most common primary
skeletal malignancy, typically do so from lung metastatic disease.
Disappointingly, overall survival rates for patients with advanced OS
have remained static over the past two decades despite the develop-
ment of several novel therapies for other solid malignancies. We
therefore examined a battery of FDA therapies for their ability to impact
the growth of OS cell lines and identiﬁed Panobinostat, a histone dea-
cetalyase (HDAC) inhibitor, has having a broad eﬃcacy across the
panel. Using the immunocompetent K7M2 OS model we addressed
three questions. 1. Can panobinostat treat primary OS growth and
prevent spontaneous metastases? Mice were intratibially inoculated
with K7M2-Luc cells, randomized into treatment (n=12) and control
(n=11) groups. Panobinostat (10mg/kg) or vehicle were administered
intraperitoneally for 5 consecutive days followed by 2 days of rest (all in
vivo studies). Tumor growth was measured by bioluminescence (RLU).
Primary OS growth was signiﬁcantly reduced by panobinostat treat-
ment (p<0.05) with the median time to our clinical endpoint (RLU
=106) being 21 days (control) and 53 days (panobinostat) (p<0.05).
The time to detection of spontaneous lung metastasis was signiﬁcantly
delayed from 10 days in the control group to 21 days in the panobi-
nostat group (p<0.05). 2. Can panobinostat pretreatment prevent OS
lung seeding? Mice were pretreated with vehicle (n=9) or panobino-
stat (n=5) for 5 days prior to tail vein inoculation of 1x106 K7M2-Luc
cells. Panobinostat signiﬁcantly (p<0.05) delayed tumor growth
compared to control animals. This translated to a 58% increase in
median survival rate, 54 days (control) vs. 93 days (panobinostat)
(p<0.05). 3. Can panobinostat treat established lung metastases?
Mice were tail-vein inoculated with 1x106 K7M2-Luc cells and rando-
mized after successful engraftment (n=12/group). We observed pa-
nobinostat signiﬁcantly reduced growth of and number of established
OS lung metastases and improved overall survival times (p<0.05).
These data suggest FDA approved panobinostat would be useful for the
treatment of OS patients. Our current eﬀorts are focused on identifying
the speciﬁc HDACs responsible for panobinostat to test more speciﬁc
inhibitors, and understand the genetic program being regulated by
HDACs that drive osteosarcoma progression.
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BMP4 gene therapy inhibits myeloma tumor growth, but has a
negative impact on bone
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Multiple myeloma (MM) is a hematological cancer caused by accumu-
lation of malignant plasma cells in the bone marrow. One of the hall-
marks of MM is the loss of bone, caused by increased bone degradation
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and reduced bone formation. The latter is due to reduced number of
functional, mature osteoblasts. BMP-signaling is important for both pre-
and postnatal bone formation. Additionally, several BMPs induce
growth arrest and apoptosis in MM cells. Thus, increasing BMP-sig-
naling in MM patients has the potential to both reduce tumor growth
and to restore bone formation. We therefore investigated if BMP4 gene
therapy inﬂuenced tumor growth and bone formation in a human-
mouse model of MM.
RAG2-/- GC-/-mice were implanted with calcium phosphate scaﬀolds
seeded with human mesenchymal stromal cells and allowed to diﬀer-
entiate in vivo for 8 weeks. Then, adeno-associated virus serotype 8
expressing BMP4 under control of a liver speciﬁc promotor (AAV8-
BMP4) or control vector (AAV8-CTRL) were administered by tail-vein
injection. After 2 weeks, when BMP4 can be detected in the circulation,
ﬂuorescently labelled MM cells were injected into the scaﬀolds. Tumor
growth was examined by imaging every week. Strikingly, tumor growth
was signiﬁcantly reduced in AAV8-BMP4 mice compared with the
AAV8-CTRL mice (p<0.01), suggesting that increased circulating levels
of BMP4 reduced tumor growth. However, bone formation was not
increased in scaﬀolds of the AAV8-BMP4 mice. At end of the experi-
ment, circulating serum levels of BMP4 in the AAV8-BMP4 mice were
50-200ng/ml.
To delineate the eﬀects of BMP4 overexpression on bone per se, without
direct inﬂuence from the cancer cells, we examined the femurs by µCT.
Surprisingly, the AAV8-BMP4 mice had signiﬁcantly reduced trabecular
bone volume (p=0.017), trabecular numbers (p=0.016) as well as
signiﬁcantly increased trabecular separation (p<0.001) compared with
the AAV8-CTRL mice. Thus, high levels of circulating BMP4 seem to
inhibit trabecular bone formation. There was no diﬀerence in cortical
bone parameters.
Taken together, BMP4 gene therapy inhibited MM tumor growth, but
also reduced trabecular bone formation in mice. Care should therefore
be taken when considering using BMP4 as a therapeutic agent.
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Myeloid Derived Suppressor Cells promote Multiple Myeloma cell
survival by AMPK activation
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Ginderachter, Els Van Valckenborgh, Karin Vanderkerken
Vrije Universiteit Brussel, Brussels, Belgium
Multiple Myeloma (MM) is an incurable malignancy of terminally dif-
ferentiated plasma cells, which are predominantly localized in the bone
marrow. Myeloid derived suppressor cells (MDSC), a heterogeneous
population of immature myeloid cells, are thought to promote MM
progression by secretion of cytokines and growth factors, suppression of
the immune system and induction of angiogenesis. The presence and
activation of MDSC in MM patients has been well-documented, how-
ever their direct role in drug resistance and cell survival is still unclear.
In this study, we performed coculture experiments of 5TMM derived
MDSC with 5TMM cells in vitro, resulting in increased survival and
proliferation of MM cells. These cocultures also resulted in a protection
against drug-induced apoptosis of MM cells by bortezomib (2.5-5nM) or
melphalan (15-30µM). To investigate underlying pathways, we per-
formed a Pathscan® Intracellular Signaling Array demonstrating an
upregulation of AMPK (Adenosine Monophosphate-activated Protein
Kinase) phosphorylation in 5TMM cells after coculture with MDSC. As a
cellular energy sensor, AMPK regulates lipid and glucose metabolism
and could be essential in cancer cell survival during stress conditions.
AMPK activation was conﬁrmed by western blot and we could observe
an increase in anti-apoptotic factors Mcl-1 and Bcl-2, and autophagy-
marker LC3II. In addition, 5TMM cells were inoculated and showed a
clear upregulation of AMPK phosphorylation in vivo, while 5TMM cells
cultured in vitro had a reduced AMPK expression. AMPK targeting by
BML-275 (Compound C) resulted in apoptosis and reduced viability of
human myeloma cell lines (LP-1, RPMI-8226, U266), primary MM cells
and 5TMM cells. Importantly, we observed that the tumor-promoting
eﬀect of MDSC was partially mediated by AMPK activation. More ma-
ture cell types like macrophages and ﬁbroblasts were not able to induce
AMPK phosphorylation. In conclusion, our data clearly demonstrate
that MDSC directly increase the survival of MM cells and that this eﬀect
was partially mediated by AMPK phosphorylation, identifying this
pathway as a new target in the treatment of MM patients.
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The role of serum vitamin-D and bone turnover markers in prog-
nosis of bone metastasis and prediction of beneﬁt from adjuvant
zoledronic acid in patients with early breast cancer.
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40,000 women die from breast cancer (BC) annually in the US alone,
mainly from distant relapse, which often occurs years after initial BC
diagnosis. Because bone metastases ultimately aﬀect more than two-
thirds of patients with advanced disease, biomarkers related to bone
metabolism such as vitamin-D and bone turnover markers may have
value in identifying patients with early BC who are at high risk of re-
lapse in bone.
The AZURE clinical trial recruited 3360 patients with early BC at
moderate/high risk of recurrence, randomised 1:1 to receive standard
adjuvant therapy +/- zoledronic acid (ZOL). Serum samples at study
entry were collected from UK patients (441 control arm, 431 ZOL arm)
for measurement of vitamin-D and bone turnover markers. Associations
between biomarker levels and distant relapse events (median follow-up
84.2 months) were explored using Cox proportional hazards regression,
adjusted for lymph node involvement, ER status, tumour stage and
type/timing of systemic therapy.
The overwhelming majority of women in this study (91.2%, control;
87.7%, ZOL) had deﬁcient levels of vitamin D (<30ng/ml, a level
considered necessary for good bone health). There was no diﬀerence in
the proportion of patients with baseline values <30ng/ml by meno-
pausal status. In categorical analyses of normal (≥30ng/ml) vs low
(<30ng/ml), vitamin-D was prognostic for distant metastasis at any
site (p=0.038) and approached signiﬁcance for bone metastasis at any
time (p=0.067).
In log transformed continuous analyses, the bone formation marker N-
terminal propeptide of type-1 collagen (P1NP) and the bone resorption
markers C-telopeptide of type-1 collagen (CTX) and pyridinoline cross-
linked carboxy-terminal telopeptide of type-1 collagen (1-CTP) were
each signiﬁcantly associated with relapse in bone at any time
(p=0.006; p=0.009; p=0.008 respectively), but not with ﬁrst relapse
in bone only (p=0.411; p=0.320; p=0.190 respectively). None of the
bone turnover markers was prognostic for overall distant recurrence i.e.
they were bone metastasis-speciﬁc and none were predictive of treat-
ment beneﬁt from ZOL.
Bone turnover markers in early BC are prognostic for future relapse in
bone. Adequate vitamin-D at breast cancer diagnosis may signal pro-
tection against future distant relapse.
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Lysyl oxidase promotes survival and outgrowth of cancer cells in
the bone marrow, enabling bone metastasis formation.
Caroline Reynaud, Paola Di Mauro, Croset Martine, Edith
Bonnelye, Philippe Clezardin
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Lysyl oxidases LOX and LOXL2 are secreted copper-dependent amine
oxidases whose primary function is to drive collagen crosslinking and
extracellular matrix stiﬀness. LOX in colorectal cancer (CRC) synergizes
with hypoxia-inducible factor-1 (HIF-1α)) to promote tumour pro-
gression. Here we investigated whether LOX/HIF1-α endows CRC cells
with full competence for aggressive colonisation in bone. We show that
a high LOX expression in primary tumours from CRC patients was as-
sociated with poor clinical outcome, irrespective of HIF-1α.
Additionally, LOX was expressed by tumour cells in the bone marrow
from CRC patients with bone metastases. In vivo experimental stu-
dies show that LOX overexpression in CRC cells or systemic delivery of
the conditioned medium from LOX-overexpressing CRC cells promoted
tumour cell dissemination in the bone marrow and enhanced osteolytic
lesion formation, irrespective of HIF-1α. Conversely, silencing or
pharmacological inhibition of LOX activity blocked dissemination of
CRC cells in the bone marrow and tumour-driven osteolytic lesion for-
mation. In vitro, tumour-secreted LOX supported the attachment and
survival of CRC cells to and in the bone matrix, and inhibited osteoblast
diﬀerentiation. LOX overexpression in CRC cells also induced a robust
production of IL-6. In turn, both LOX and IL-6 were acting in concert to
stimulate osteoclast diﬀerentiation, thereby creating an imbalance be-
tween bone resorption and bone formation. Collectively, our ﬁnd-
ings show that LOX supports CRC cell dissemination in the bone
marrow and they reveal a novel mechanism through which LOX-driven
IL-6 production by CRC cells impairs bone homeostasis. We are now
conduing experiments in the breast cancer model, showing that both
LOX and LOXL2 endow the tumor cells with the ability to thrive in the
bone marrow microenvironment.
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One in 8 men will receive a prostate cancer (PC) diagnosis during their
lifetime. As a result of androgen deprivation therapy (ADT) and newer
therapies, survival rates have improved considerably over the past four
decades (current 5- year survival is 85% in all patients), so many pa-
tients now live with their disease for many years. However, cancer
treatment induced bone loss (CTIBL) and the potential for osteoporosis
has become a substantial issue and updated guidance on management
of CTIBL is required.
This guidance was developed by a group of experts in the UK, identiﬁed
from key opinion leaders in the management of PC and bone disorders
and patient representatives. Input and endorsement was also sought
from a range of specialist societies. A systematic literature search was
undertaken using PubMed and Ovid MEDLINE databases. Randomised
controlled trials, observational studies and meta- analyses were in-
cluded for assessment.
Although national and international guidelines make recommendations
that fracture risk is considered for all men with PC receiving ADT, they
lack speciﬁc guidance for the management of bone health. Specialist
societies have proposed useful guidelines suggesting that BMD assess-
ment is undertaken prior to the initiation of long-term ADT, and that
the FRAX tool should be used to estimate individual fracture risk.
However, there is currently no guidance as to the intervention thresh-
olds that should be used to initiate treatment, or the most appropriate
bone targeted therapy or who should have overall responsibility for
managing bone health in this group of patients.
Recommendations: All men starting long-term ADT for PC should:
1. Be provided with individualised and patient-centred information,
including appropriate lifestyle advice regarding optimisation of
bone health
2. Be referred to a supervised resistance and aerobic exercise pro-
gramme of at least 12-weeks duration (in accordance with NICE
guidelines)
3. Achieve or maintain adequate daily calcium (at least 1200mg) and
vitamin D (800-1000 IU) intake through dietary intake, sunlight
exposure, and supplementation
4. Have the 10-year probability of major osteoporotic and/or hip
fracture assessed using FRAX® (without BMD initially) https://
www.sheﬃeld.ac.uk/FRAX/tool.jsp; including the presence of
secondary osteoporosis as a risk factor.
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Tumor-associated macrophages are involved with the progression of
various primary malignancies. Myeloid-derived monocytes and mac-
rophages, that can polarize into pro- and anti-inﬂammatory pheno-
types, are abundant in bone. Roles for these cell types in regulating
bone injury repair have been described. Surprisingly, little is known
about how polarization states and temporal dynamics impact osteoblast
and osteoclast activity in skeletal malignancy; a gap in our knowledge
that is diﬃcult to address with traditional biological approaches.
Previously, we have shown that data-driven computational modeling,
combined with in vivo experimentation/validation, can be used to un-
derstand the dynamics of cancer cell-bone stroma (osteoblast/osteo-
clast) interaction. Here, we integrate empirical and published data on
macrophage polarization states during bone remodeling into an or-
dinary diﬀerential equation (ODE)-based models. To this end, in-
tratibial injuries were performed on C57BL/6 mice and bone marrow
ﬂushes were proﬁled by FACS analysis at days 0, 1, 2, 3, 7 and 14
(n=5/timepoint) for pro- and anti-inﬂammatory myeloid content
(CD11b, Ly6G, Ly6C, NOS2 and ARG1). Contralateral tibias collected at
the same timepoints were histologically assessed for bone volume
(μCT), osteoblast (Runx2), and osteoclast (TRAcP) numbers. The col-
lated data was used to power ODE population-based models. The ODE
model captures dynamic shifts in macrophage phenotypes during bone
repair and their interaction with osteoclasts and osteoblasts that were in
agreement with biological data. Model simulations and data ﬁtting also
revealed insights into inﬂammatory monocyte-macrophage sources and
their viability/diﬀerentiation dynamics. Further, altering pro- or anti-
inﬂammatory macrophages had profound eﬀects on bone repair times.
Having generated an ODE that takes into account macrophage
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dynamics during normal bone repair, we are now assessing macrophage
polarization phenotype and quantity over time in immunocompetent
models of common skeletal malignancies such as multiple myeloma
(5TGM1) and bone-metastatic prostate cancer (RM1). We are in-
tegrating these parameters to examine the eﬀects of macrophage be-
havior on cancer-associated bone disease and response to applied
therapeutics.
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Host-derived matrix metalloproteinase-13 contributes to the pro-
gression of multiple myeloma
Chen Hao Lo1,2, Gemma Shay1, Daniel Sullivan1, Lori Hazlehurst3,
Conor Lynch1
1Moﬃtt Cancer Center, Tampa, USA. 2University of South Florida, Tampa,
USA. 3West Virginia University, Morgantown, USA
Multiple myeloma promotes systemic skeletal bone disease that greatly
impact the patient’s quality of life. Processing of the type I collagen-rich
bone matrix results in the release of sequestered growth factors that can
drive progression of the disease. Matrix metalloproteinase 13 (MMP-13)
is a type-I collagenase that is expressed predominantly in the skeleton
by mesenchymal stromal cells (MSCs). Analysis of public datasets de-
monstrate that myeloma signiﬁcantly induces the expression of MMP-
13 in MSCs (1.81 LogFC, p<0.05.) Consistent, with this observation,
immunoﬂuorescent analyses of human myeloma biopsies also demon-
strated MMP-13 expression in bone-lining osteoblasts but interestingly,
not in bone-resorbing osteoclasts. We therefore determined whether
host-derived MMP-13 could contribute to myeloma progression and
overall survival. Immunocompromised mice, wild type or null for MMP-
13, were inoculated with luciferase-expressing 5TGM1 myeloma cells
(n=8/group). Using bioluminescence, IgG2b and im-
munohistochemistry as a readout for tumor burden, we detected no
diﬀerence in myeloma growth rate. Surprisingly, we did observe a
signiﬁcant increase in overall survival in the MMP-13 null group (mean
39 vs. 43 days; p<0.05.) Ex vivo analysis by high resolution μCT,
normalized to age-matched control mice, demonstrated that myeloma-
induced bone resorption was signiﬁcantly reduced in the MMP-13 null
mice (0.5 vs. 0.23 ratio; p<0.05). Analysis of stromal co-cultures
identiﬁed that MMP-13 null osteoclast formed more slowly than their
wildtype counterparts with reduced functionality (24% reduction in
resorption of a bone mimetic, P<0.05.) Exploration of wildtype and
MMP-13 null MSC-derived condition media indicate a number of po-
tential substrates through which MMP-13 may be contributing to os-
teoclast formation and function. We further conﬁrmed eﬀects of MMP-
13 ablation in multiple myeloma progression using a novel selective
MMP-13 exosite inhibitor, RF-36. Mice (n=10/group) were injected
with 5TGM1 luciferase-expressing cells and received either vehicle or
RF-36 (daily treatment at 2mg/kg). Our data demonstrate MMP-13
inhibition signiﬁcantly delayed myeloma growth. Although recent re-
ports have highlighted non-catatlytic roles for MMP-13 in myeloma
mediated osteoclastogenesis, our data suggest that inhibition of MMP-
13 activity remains a viable approach for the treatment of the disease.
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Imaging upregulated cell surface proteins, altered tumor metabo-
lism and structural bone changes in multiple myeloma
Monica Shokeen
Washington University School of Medicine, Saint Louis, USA
Multiple myeloma (MM) is a cancer of terminally diﬀerentiated plasma
B-cells in the bone marrow (BM). The BM niche is a complex interplay
of vasculature, bone remodeling cells, stroma, and other cells, including
adipocytes and plasma cells. In the presence of myeloma cells, however,
the highly regulated BM niche is disrupted. This leads to the increase in
osteoclast activity, destruction of the cortical bone, reduction of con-
stitutive marrow adipose tissue relative to the red marrow, increase of
vascularization and altered metabolism within the BM. The changes in
BM architecture and composition facilitate tumor survival, progression
and drug resistance. Myeloma cells also diﬀerentially express cell sur-
face proteins such as very late antigen-4 and CD38 to actively interact
with the BM microenvironment for progression and survival. In this
presentation, I will highlight the use of nuclear, optical and magnetic
resonance imaging techniques with molecularly targeted agents for
understanding myeloma progression in pre-clinical mouse models of
MM. Speciﬁcally, imaging of very late antigen-4 and CD38 with posi-
tron emission tomography (PET) and near-infrared optical imaging will
be presented. To demonstrate the unique metabolic signatures of MM,
we will present our work on L-type amino acid transporter-1 (LAT1)
targeted imaging with 18F-FDOPA-PET and its complimentary role with
the clinical standard 18F-FDG-PET imaging. Lastly, the utility of tar-
geted iron-oxide nanoparticles for magnetic resonance imaging of MM
will be demonstrated.
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The eﬀects of cathepsin K inhibition on osteocytes: its role in bone
restoration in MM bone disease
Masahiro Hiasa1,2, Jumpei Teramachi3, Hirofumi Tenshin2, Kotaro
Tanimoto2, Takeshi Harada1, Ariunzaya Bat-Erdene1, Masami
Iwasa1, Fujii Shiro1, Shingen Nakamura1, Hirokazu Miki1, Kumiko
Kagawa1, Eiji Tanaka2, Itsuro Endo1, Toshio Matsumoto4,
Masahiro Abe1
1Department of Hematology, Endocrinology and Metabolism, Tokushima
University Graduate School, Tokushima, Japan. 2Department of
Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate
School, Tokushima, Japan. 3Department of Histology and Oral Histology,
Tokushima University Graduate School, Tokushima, Japan. 4Fujii Memorial
Institute of Medical Sciences, Tokushima University, Tokushima, Japan
Multiple myeloma (MM) develops devastating bone destruction by
enhanced osteoclastic bone resorption and impaired bone formation.
The bone disease not only deteriorates QOL in MM patients but also
aggravates MM tumor expansion. In order to improve the therapeutic
eﬃcacy for MM, we need to develop novel therapeutic anti-MM mod-
alities to ameliorate the comorbidity associated with the skewed bone
marrow microenvironment. In this regard, proteasome inhibitors have
drawn considerable attention to their anabolic actions on bone forma-
tion in good responders. Cathepsin K (CatK) inhibitors potently sup-
press bone resorption while sparing cytotoxic damage in osteoclasts
(OCs) to retain their coupling to osteoblastogenesis. We previously
demonstrated that CatK inhibitor increased bone formation in mouse
MM models partly through enhance coupling of OCs to osteo-
blastogenesis. Osteocytes, the most abundant cells in bone, are regarded
as a major source of sclerostin, a potent Wnt inhibitor to suppress os-
teoblastogenesis. In the present study, we explored the therapeutic ef-
ﬁcacy of CatK inhibition for MM bone diseases, focusing on its eﬀect on
osteocytes. We prepared mouse models with MM bone destruction by
intra-tibial inoculation of 5TGM1 MM cells. OCs strongly expressed
CatK in the tibiae with MM bone disease. Interestingly, osteocytes also
expressed CatK along with screlostin. MLO-A5 and MLO-Y4, osteocytic
cell lines, were found to express CatK and sclerostin, and further en-
hanced their expression in co-culture with MM cells. Intriguingly, the
treatment with CatK shRNA or the CatK inhibitor ONO-5334 suppressed
sclerostin expression and production by MLO-Y4 cells. Furthermore,
sclerostin levels in sera were increased in the MM models. However,
oral administration of ONO-5334 alone reduced serum sclerostin levels,
and prevented bone destruction with an increase in BMD in the MM-
bearing mice. Importantly, ONO-5334 was able to further reduce the
sclerostin levels and increase bone formation while almost completely
eradicating MM in combination with bortezomib. These results suggest
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that downregulation of sclerostin production by osteocytes may con-
tribute to the bone anabolic eﬀects of CatK inhibition. CatK inhibitors
and proteasome inhibitors appear to be a beneﬁcial therapeutic com-
bination for MM with bone destruction.
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Human osteoclasts generated from diﬀerent individuals show a
highly variable sensitivity to zoledronic acid in vitro – this sensi-
tivity relates to in vivo characteristics of each individual
Anaïs MJ Møller1, Jean-Marie Delaisse1, Troels Bechmann2, Jonna
S Madsen3, Lone M Volmer2, Kent Søe1
1Dept. Clinical Cell Biology, Lillebaelt Hospital, University of Southern
Denmark, Vejle, Denmark. 2Dept. of Oncology, Lillebaelt Hospital, Vejle,
Denmark. 3Dept. of Clinical Immunology and Biochemistry, Lillebaelt
Hospital, Vejle, Denmark
Zoledronic acid (Zol) is used to treat cancer-induced bone disease. In
general, Zol signiﬁcantly reduces the risk of skeletal related events, but
not for all patients. In our ongoing clinical trials, we observe that CTX
levels after three months of Zol-treatment varies by 26- (from 0.034 to
0.899 ng/ml) and 25-fold (from 0.04 to 1.0 ng/ml) in two cohorts of
breast and prostate cancer patients with bone metastases (n=22, n=9),
respectively. In our present study we wish to investigate if part of this
variable sensitivity may be due to intrinsic diﬀerences in Zol sensitivity
of osteoclasts between individuals. In an ongoing protocol, we have
isolated peripheral blood CD14+ monocytes from female blood donors
(n=36; ages 40 to 66) and have diﬀerentiated these cells into osteo-
clasts in vitro. Demographic data, CTX and PINP-levels in vivo were
obtained. The resorptive activity of osteoclasts was quantiﬁed and their
sensitivity to Zol determined. Multiple linear regression analyses show
that the total resorptive activity of osteoclasts in vitro is positively
correlated to donor characteristics (age p=0.015; years since meno-
pause p=0.028; PINP p=0.045). This suggests that characteristics of
the donors can be traced in in vitro experiments. We also ﬁnd that the
sensitivity of osteoclasts to Zol in vitro varies by up to 140-fold (IC50:
0.09 to 12.6 µM). Multiple linear regression analyses show that some of
this variation signiﬁcantly correlates with in vivo characteristics of do-
nors (PINP p=0.025; smoking status p=0.015) explaining up to 34% of
the variation. The IC50 increases by 2.6% per unit increase of PINP
(range: 23.01 to 100.3 µg/L) and by 284% from non-smoker to smoker.
Furthermore, osteoclasts resorb bone in two modes - osteoclasts in
trench-mode are more sensitive to Zol than those in pit-mode
(p=0.001) and it is only those in trench-mode that respond to Zol ac-
cording to in vivo characteristics. We conclude that the sensitivity of
osteoclasts to Zol in vitro is inﬂuenced by in vivo characteristics of the
donors.
We raise the hypothesis that the variable sensitivity of cancer patients
to Zol could partly be due to intrinsic (epigenetic?) diﬀerences between
patients.
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Investigating the osteoblast-breast cancer cell interaction at early
stages of bone metastasis
Marie-Therese Haider, Hiroaki Saito, Eric Hesse, Hanna
Taipaleenmäki
Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and
Reconstructive Surgery, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
Osteoclast activation is the cellular hallmark of breast cancer-induced
osteolytic bone disease. However, based on the ﬁnding that osteoblast
conditioned medium stimulates breast cancer cell (BCC) migration in
vitro (p<0.01), we hypothesize that osteoblasts are also playing a role
during early stages of bone metastasis.
We identiﬁed the homeodomain protein TG-interacting factor-1 (Tgif1)
as a strongly up-regulated molecule in osteoblasts upon stimulation by
BCCs, suggesting a potential role of Tgif1 in the osteoblast-BCC inter-
action. Indeed, conditioned medium from osteoblasts of mice that have
a germline deletion of Tgif1 (Tgif1-/-) failed to induce BCC migration
compared to control medium obtained from wild-type osteoblasts
(p<0.05), indicating that Tgif1 in osteoblasts might support the acti-
vation of BCC movement. To better understand this observation, we
performed SILAC and RNA-seq analyses using Tgif1-/- osteoblasts.
Interestingly, Semaphorin 3E (Sema3E), a negative regulator of cell
migration, was abundantly secreted by Tgif1-/- osteoblasts. These ﬁnd-
ings suggest that in osteoblasts Tgif1 may suppress Sema3E expression,
thereby supporting BCC migration.
To test the hypothesis that Tgif1 contributes to the initiation of meta-
static bone disease in vivo, we employed a syngeneic metastasis model
in Tgif1-deﬁcient mice. In support of our hypothesis, ongoing studies
revealed a decreased number of bone metastases in Tgif1-/- mice com-
pared to littermate controls (33% vs. 64%, respectively) determined by
bioluminescence imaging 7 days after intracardiac injection of 4T1-
GFP-Luc BCCs. Consistently, the presence of single BCCs or micro-me-
tastases in the tibiae was reduced by 25% in Tgif1-/- mice determined by
confocal microscopy. Further histological analyses demonstrated that
BCCs localize in close proximity to Endomucin-positive vascular cells as
well as to osteoblasts. Although Tgif1-deﬁciency did not aﬀect the bone
marrow vasculature, the number and activity of osteoblasts were re-
duced compared to littermate controls (p<0.05). This suggests that the
protective eﬀect on bone metastases might be mediated by the osteo-
blasts and not by the bone marrow vasculature.
In summary, we propose that lack of Tgif1 in osteoblasts is protective
against cancer cell migration and metastasis formation, possibly
through the suppression of Sema3E. Thus, our ﬁndings establish os-
teoblasts as important regulators during early stages of bone metastasis.
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Deﬁning the role of P2X7 receptor in the dormant population of
prostate cancer cells
Hector Arredondo, Colby Eaton, Ning Wang
The Mellanby Centre for Bone Research, Department of Oncology &
Metabolism, Sheﬃeld, United Kingdom
Prostate cancer (PCa) most commonly metastasizes to the bone, causing
considerable morbidity and mortality. Bone metastases could occur
several years after the removal of primary tumours, indicating a longer
tumour dormancy during PCa metastasis. Our recent studies have
suggested that the expression of P2X7 receptor (P2X7R) is tran-
scriptionally up-regulated in the dormant metastasis initiating cells,
while others suggested that P2X7R mediates the status of invasiveness/
EMT of PCa cells. Therefore, we hypothesize that P2X7R plays a pivotal
role in the induction of PCa dormancy.
To test whether the P2X7R is functionally up-regulated in dormant PCa
cells and whether genetically knocking out P2X7R will aﬀect tumour
dormancy.
Dormant PCa cells (PC3 and C4 2B4 cells) were isolated using a method
developed previously based on their ability to retain ﬂuorescent lipo-
philic dyes when not dividing in vitro. The functional expression of
P2X7R was assessed using an ethidium uptake assay (membrane pore
formation) under stimuli of exogenous P2X7R agonist BzATP and/or
antagonist A740003. After genetically depleting P2X7R in PCa cells
with CRISPR/Cas9 technique (targeting exon 13, a C-terminal domain
critical for function), alterations in frequency of dormant population,
function of P2X7R and proliferation/viability of PCa cells were then
examined in vitro, using FACS, ethidium uptake assay, MTS and Glo MT
assay, respectively.
Dormant populations of both PCa cell lines showed increased pore
formation in response to exogenous BzATP (Linear regression compar-
ison of 30 minutes, n=3, p<0.001), suggesting enhanced functional
expression of P2X7R in dormant PCa cells. Successfully disrupting the
P2X7R by CRISPR/Cas9 led to complete abolishment of pore formation
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in both cell lines and altered frequency of dormant tumour cells (t-test,
n=3, p<0.05), without aﬀecting the proliferation and viability (t-test,
n=3, p>0.05).
Our data supports the hypothesis that the P2X7R plays an important
role in PCa cell dormancy and warrants further studies to exploit its
pharmaceutical potentials for ﬁghting PCa bone metastasis.
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Characteristics of the stromal cells in the premetastatic and he-
matopoietic niches
Stephanie Rossnagl1, Alexander Lubosch1, Inaam Nakchbandi2,1
1University of Heidelberg, Heidelberg, Germany. 2Max-Planck Institute for
Medical Research, Heidelberg, Germany
Dormant cancer cells in the bone marrow apparently use the same niche
as the hematopoietic stem cells. Furthermore, stimulating stromal cells
of osteoblastic origin increases the number of hematopoietic stem cells,
and possibly their niches. We aimed to characterize the stromal con-
stituents of the niche and determine whether they are similar in the
hematopoietic and the premetastatic niche.
We used a murine model of homing, where cancer cells are injected
intracardially and their number in the bone marrow is quantiﬁed
(Cancer Research 2017). Decreasing the number of stromal cells in the
bone marrow pharmacologically enhanced cancer cell homing to the
bone marrow. In contrast, an increase in the number of stromal cells in
transgenic mice (in which b1 integrin is deleted in the marrow) or by
administering G-CSF diminished cancer cell homing. To establish
causality between changes in stromal cells and homing we injected
stromal cells expressing Sca1 intravenously and found a decrease in
cancer cell homing. Taken together these data suggest an inverse re-
lationship between stromal cells and cancer cell homing. Using multiple
regression analysis we characterized a subpopulation expressing
Sca1+CD31+CD146+CD44- that diminishes whenever cancer cell
homing is increased. In prostate and breast cancer patients, related
subpopulations were lower in the presence of cancer cells in the bone
marrow.
In order to determine whether the subpopulation identiﬁed is present in
the hematopoietic stem niche, we diminished the subpopulation in mice
pharmacologically and depleted hematopoietic stem cells using either
radiation or chemotherapy. After bone marrow transplantation, sur-
vival improved and recovery from leukopenia was faster in mice in
which stromal cells were diminished compared to untreated controls.
Recovery of thrombocytes was even more pronounced than controls
treated with parathyroid hormone after chemotherapy. This suggests
that the stromal cell subpopulation also represents part of the hema-
topoietic stem cell niche.
Taken together, a subpopulation of stromal cells with stem cell char-
acteristics and vascular potential in the bone marrow unequivocally
constitutes part of the premetastatic niche, and is possibly shared with
the hematopoietic niche. Furthermore, manipulating this niche might
oﬀer a new possibility for decreasing metastasis formation.
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Learning from osteoblasts how to ﬁght cancer
Hiba Ghura1, Carla Sens1, Inaam Nakchbandi2,1
1University of Heidelberg, Heidelberg, Germany. 2Max-Planck Institute for
Medical Research, Heidelberg, Germany
Osteoblasts lining the inner surface of bone are in proximity to the bone
marrow and aﬀect diﬀerentiation of several hematopoietic cell types.
Osteoblasts also modify their own diﬀerentiation by producing various
ﬁbronectin isoforms. We therefore asked whether ﬁbronectin from os-
teoblasts modiﬁes the immune response against cancer, and whether
the lessons learned could be applied to suppress cancer growth.
Deletion of osteoblast ﬁbronectin in mice (conditional-Knockout: cKO)
suppressed both myelopoiesis and growth of breast cancer bone lesions
in two models (PLoS Biology 2016). Lower myeloid cell numbers were
detected in cKO tumors. To establish a causal relationship between
myeloid cells and cancer growth, adoptive transfer experiments were
performed. Myeloid cells from cKO mice diminished cancer growth
compared to myeloid cells from controls, suggesting a diﬀerence in
their behavior towards cancer. Osteoblasts produce several ﬁbronectin
isoforms. Nevertheless, only exposure to EDA-containing ﬁbronectin
changes myeloid cell behavior in adoptive transfer experiments. In vitro
experiments showed that only EDA-ﬁbronectin increased arginase I (an
inhibitor of the immune response to cancer) by acting on a5b1-integrin,
while the classical ligand failed to aﬀect a similar change. In vivo ex-
periments conﬁrmed that interfering with binding of EDA-ﬁbronectin to
its receptor diminishes cancer growth.
Tissue sections of breast cancer lesions showed high EDA-ﬁbronectin
expression. We therefore hypothesized that EDA-ﬁbronectin production
by breast cancer cells suppresses the immune response and increases
cancer growth. Bone lesions induced in mice using a knockdown of
EDA-ﬁbronectin in MDA-MB-231 were smaller and contained less
myeloid cells than controls. In these cells arginase I was decreased si-
milarly to cKO mice. To test whether these myeloid cells not exposed to
EDA locally were responsible for diminished cancer growth, they were
depleted using liposomes containing clodronate. Cancer growth in-
creased compared to mice receiving empty liposomes.
Thus, EDA-ﬁbronectin both originating from the osteoblasts and locally
produced in cancer inhibits the immune response against cancer. In its
absence, cancer growth is diminished. Since this is mediated by a un-
ique action of EDA-ﬁbronectin on a5b1-integrin, developing a speciﬁc
a5b1-integrin modulator oﬀers a new possibility to enhance the im-
mune response against cancer and diminish cancer growth.
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Myeloma-speciﬁc oncolytic adenovirus induces signiﬁcant tumour
oncolysis in vitro and in vivo and prevents cell line regrowth.
Simon Tazzyman, Jack Harrison, Daniel Holligan, Georgia
Stewart, James Yeomans, Beverly King, Darren Lath, Michelle
Lawson, Munitta Muthana, Andrew Chantry
University of Sheﬃeld, Sheﬃeld, United Kingdom
Multiple myeloma is a largely incurable disease and despite current
therapies achieving good initial responses, patients frequently relapse.
Therefore, new approaches are required that not only reduce the tu-
mour load, but also prevent the growth of residual disease. One such
approach is the use of oncolytic viruses. We developed an oncolytic
adenovirus that utilizes transcriptional control of E1A under the mye-
loma-speciﬁc promoter CS1 (ADCE1A). We hypothesised that ADCE1A
would be myeloma-speciﬁc, inducing cell death and preventing tumour
regrowth.
Myeloma cell lines (JJN3, U266 and 5TGM1) and a melanoma cell line
(MDA-MD-435) were assessed for CS1 expression by ﬂow cytometry
(FC). Myeloma cell lines (JJN3, U266, OPM2 and 5TGM1), primary
plasma cell leukaemic cells, MDA-MD-435 cells, and normal healthy
cells were infected with ADCE1A (MOI 20) and cell death was mon-
itored after 4 days using FC and propidium iodide staining. Apoptosis
and autophagy were assessed following viral infection using qPCR and
annexin V staining. Myeloma cell regrowth in vitro was assessed after
bortezomib (0.56-2.81nM) or bortezomib and ADCE1A treatment. Viral
eﬃcacy was tested in a xenograft model of myeloma, where 5 weeks
after tumour cell injection (106 U266 cells intravenously), mice were
treated with ADCE1A (1x107 pfu, 2x/wk) or control (PBS) for 3 weeks.
Tumour burden was measured ex vivo in the long bones by FC.
CS1 was expressed in all myeloma cell lines, but not in MDA-MD-435
cells. ADCE1A infection induced signiﬁcant increases in cell death in all
myeloma cell lines and primary cells, reaching greater than 90%
(p<0.001), whilst not aﬀecting MDA-MD-435 or normal healthy cells.
There was no increase in expression of FASL (apoptotic marker), ATG5,
LC3B (autophagy markers) or annexin V positivity at 8h and 24h post
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infection compared to control cells. Interestingly in preliminary ex-
periments, ADCE1A prevented regrowth of myeloma cell lines fol-
lowing treatment with bortezomib in vitro. In the U266 xenograft
model, tumour load was signiﬁcantly reduced (p<0.05) compared to
control treated mice.
In conclusion, ADCE1A has signiﬁcant anti-myeloma eﬀects that are not
mediated via apoptosis. We are currently investigating.
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FACS-based isolation of primary and metastatic osteosarcoma cells
in mice: a new tool to allow downstream molecular analysis and
target identiﬁcation
Charlotte Palmer
University of Cambridge, Cambridge, United Kingdom
The survival of patients with osteosarcoma (OSA) has not improved
substantially over the last 20 years, despite the evolutions in surgical
intervention and chemotherapeutics. Current knowledge of the genetic
drivers of osteosarcoma progression is very limited. Lung metastasis is
the main cause of morbidity and mortality, and over 80% of human and
canine cases have clinically undetectable microscopic metastasis at
diagnosis. Progression to metastatic disease limits the 5-year survival
rates to only 60-75%. Murine models are invaluable tools to study
disease progression and pathogenesis. A number of canine and human
OSA cell lines have been characterized in vitro and in vivo, but a widely
accepted orthotropic mouse model of OSA with reliable metastasis has
not been established. We have re-evaluated and optimised a clinically
relevant orthopic bioluminescent mouse model system that allows rapid
isolation of key biological processes and eﬀective evaluation of ther-
apeutic agents in In Vivo. We have utilised the model to gain better
understanding of the dynamics of metastatic spread by modelling the
growth of the primary tumour, detecting circulating tumour cells and
quantifying tumour burden in the lung by FACS sorting. Ultimately, this
clinically relevant in-vivo model of osteosarcoma growth and metas-
tasis will allow research into novel molecular drivers of disease which
can potentially be used as both prognostic markers and as targets for
biological and/or drug therapies.
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Inhibition of p62-ZZ Domain-Mediated Signaling in Myeloma Bone
Disease Induces Osteoblast Diﬀerentiation and Overcomes
Bortezomib Resistance.
Silvia Marino1, Daniela Nicoleta Petrusca1, Juraj Adamik2,
Rebecca Silbermann1, Judith L. Anderson1, Xiang-Qun Xie3,4,
Deborah L. Galson2, G. David Roodman1,5
1Indiana University School of Medicine IUSM, Department of Medicine,
Division of Hematology-Oncology, Indianapolis, USA. 2University of
Pittsburgh School of Medicine, Department of Medicine, Division of
Hematology-Oncology, UPMC Hillman Cancer Center, McGowan Institute
of Regenerative Medicine., Pittsburgh, USA. 3University of Pittsburgh,
Department of Pharmaceutical Sciences., Pittsburgh, USA. 4University of
Pittsburgh, Computational Chemical Genomics Screening Center, Pittsburgh,
USA. 5Richard L. Roudebush VA Medical Center, Indianapolis, USA
Multiple myeloma bone disease (MMBD) is characterized by bone le-
sions that do not heal even when the patients are in complete remission
due to the persistent suppression of osteoblast diﬀerentiation. We pre-
viously reported that MM cells induce persistent changes in MM patient
bone marrow stromal cells (BMSC) via epigenetic repression of Runx2-
P1 promoter induced by the transcriptional repressor Gﬁ1, thereby
preventing osteoblast diﬀerentiation. We found that the p62-ZZ domain
in BMSC was critical for the formation of MM-induced signaling com-
plexes that mediate osteoblast suppression and identiﬁed XRK3F2 as an
inhibitor of the p62-ZZ domain. ChIP-qPCR analyses showed that
XRK3F2 both prevented and reversed MM-induced Gﬁ1 occupancy at
the Runx2-P1 promoter, thus preventing or reversing MM-induced de-
creases in the chromatin activation mark H3K9Ac at the Runx2-P1
promoter. XRK3F2 partially relieved the block in diﬀerentiation of
BMSC induced by MM cells allowing them to increase OB marker gene
expression and to mineralize. Finally, the eﬀects of XRK3F2 were po-
tentiated when combined with the proteasome inhibitor (PI),
Bortezomib (BTZ), a standard anti-MM drug with potential bone ana-
bolic eﬀects. XRK3F2 treatment of stromal cells also blocked TNFα-
induced upregulation of Gﬁ1 and suppression of OB diﬀerentiation,
eﬀects that were further increased by BTZ.
We previously showed that XRK3F2 induced dramatic new cortical
bone formation in mice with established MM but had no eﬀect on tumor
burden in vivo. We wonder if XRK3F2 could enhance BTZ-induced MM
cell cytotoxicity and overcome BTZ resistance. We found that the
XRK3F2-BTZ combination signiﬁcantly reduced MM cell viability
compared with either drug alone at the same doses, and increased MM
cells sensitivity to BTZ, without aﬀecting OB viability. Mechanistic
studies revealed that XRK3F2-BTZ combination signiﬁcantly increased
annexin V in MM cells, reduced expression of the anti-apoptotic Bcl-2
protein, extensively activated caspase 3 and cleaved PARP1.
These data suggest that p62-ZZ antagonists in combination with PIs,
have both anti-tumor and bone anabolic eﬀects, and may overcome PI
resistance in MM cells, making p62 an attractive target for the treat-
ment of MMBD.
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The Role of Receptor Activity Modifying Protein 1 in Prostate
Cancer.
Jessica Warrington, Gareth Richards, Ning Wang, Ameera Al
Jailani, Paris Avgoustou, Tim Skerry
University of Sheﬃeld, Sheﬃeld, United Kingdom
Prostate cancer (PCa) aﬀects 1 in 8 men in the UK and metastasis to
bone can lower prognosis by ~70%. Receptor activity modifying pro-
tein 1 (RAMP1) is a single transmembrane protein that interacts with G
protein-coupled receptors (GPCRs) including the calcitonin receptor
(CTR) and calcitonin-like receptor (CLR). Calcitonin gene related pep-
tide (CGRP) binds to the RAMP1-CLR complex and has been shown to
be increased in the serum of PCa patients. RAMP1 has also been iden-
tiﬁed as a potential biomarker of PCa as it is upregulated in prostate
tumour tissue compared with healthy tissue. To determine the role of
RAMP1 in PCa we have used CRISPR/Cas9 to generate RAMP1
knockouts in PC3 cells.
PC3 cells were co-transfected with a CRISPR/Cas9 and homology-di-
rected repair (HDR) plasmid. Cas9 induced a double stranded break in
the RAMP1 DNA, incorporating the HDR insert (containing an RFP
marker and stop codon) stably into the gene. RFP labelled cells were
sorted using FACS and successful RAMP1 knockouts were validated
using PCR. RAMP1 knockouts were tested in vitro using assays for
viability, migration, invasion, colony formation and apoptosis and then
used in vivo in a xenograft mouse model.
Successful RAMP1 knockout was detected with endpoint and qPCR and
conﬁrmed with sanger sequencing and DD CT analysis. RAMP1 KO cells
had 58% reduced viability compared with PC3 wildtype (P =
<0.0001) and caspase 3/7 activity was increased two-fold (P =
<0.0001). The ability of RAMP1 KO cells to adhere to ECM proteins
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was reduced 33% (P = 0.01) and invasion through Matrigel mem-
branes was decreased by 92% compared with PC3 WT (P = 0.005).
Subcutaneous injection of RAMP1 knockout cells into nude mice re-
sulted in a 90% reduction in tumour volume and mass compared with
PC3 WT cells (P = <0.0001). IHC analysis showed structural diﬀer-
ences between RAMP1 KO and WT tumours. However, no signiﬁcant
diﬀerences were seen in staining for the proliferative marker Ki67.
Deletion of RAMP1 reduced the tumorigenic ability of PC3 cells in vitro
and in vivo, indicating an important role for RAMP1 in PCa and its in-
hibition may potentially prevent PCa metastasis to bone.
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Investigating the inﬂuence of bone marrow adipocytes on breast
cancer metastasis
Nadia Halidi, Emma Morris, Claire Edwards, Gillian Farnie
University of Oxford, NDORMS, Botnar Research Centre, Oxford, United
Kingdom
Breast cancer (BC) is the most common cancer aﬀecting women, with
metastasis to the bone presenting the majority of secondary cancer
development. Clinical consequences of BC metastasis to bone sig-
niﬁcantly impacts patient survival and quality of life. The micro-
environment that the bone provides is an important factor in inﬂuen-
cing metastasis, colonization, proliferation and dormancy/activity of
breast cancer cells (BCCs) and response to treatment. However the
molecular mechanisms underlying these processes, speciﬁcally the role
of bone marrow adipose tissue (BMAT) are not fully understood. Here,
we examined the eﬀects of co-culturing BMAT with BCCs to study the
inﬂuence of bone marrow adipocytes on BCCs activity and dormancy.
We used an indirect co-culture system either using conditioned media
from adipocytes on BCCs or co-culturing adipocytes and BCCs in a
transwell system. Adipocytes were derived from diﬀerentiated murine
Bone Marrow Stromal (ST2) Cells and the BC cell lines cover the fol-
lowing subtypes: MCF7 (Estrogen receptor positive), BT-474 (Estrogen
receptor and HER2 positive), MDA-MB-231 and SUM-159 (both triple
negative).
Conditioned media from ST2 or adipocytes collected at increasing time
points (24, 48 and 72h) applied to 2D cultured BCCs showed decreased
proliferation in MCF7 and BT-474 cells, whereas MDA-MB-231 and
SUM-159 showed increased proliferation with both ST2 and adipocyte
media. We applied the mammosphere assay to investigate the eﬀect of
adipocytes media on cancer stem cell activity. Mammosphere formation
also depended on BCC type, where only MCF7 and SUM-159 cells
showed an increase in mammosphere formation eﬃciency, with SUM-
159 cells showing a signiﬁcant increase in mammosphere formation in
adipocyte compared to ST2 media (72h). Initial experiments in-
vestigating cell migration show co-culture with adipocytes increased
cell migration in MDA-MB-231 and SUM-159, but migration was de-
creased in MCF7 and BT-474 cells when compared to ST2 media.
Our preliminary investigations show that BMAT has distinct inﬂuences
on BCCs, dependent on the type of BCCs. We need further studies to
understand the diﬀerent biological eﬀects on the BC subtypes, including
downstream signalling, such as EMT and WNT signaling. We are also
developing a direct co-culture system to better understand the breast
cancer metastatic niche.
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Leukaemia inhibitory factor: a novel mediator of prostate cancer
bone metastasis?
Christina Turner, X Cheng, Srinivasa Rao, Jessica Whitburn,
Freddie Hamdy, Claire Edwards
University of Oxford, Oxford, United Kingdom
Bone metastasis is a frequent complication of advanced prostate cancer
(PCa). Following metastasis, ﬁve-year survival rates plummet to just
30% and treatment options become limited. There is therefore an
urgent need to elucidate the mechanisms that drive metastasis to
identify novel therapeutics and biomarkers. Leukaemia inhibitory
factor (LIF) is an IL-6 family cytokine known to be involved in a wide
range of biological functions including haematopoiesis and bone for-
mation. Moreover it has shown to be overexpressed in a number of
tumour types including breast which also commonly metastases to
bone. The aim of this study was to elucidate the role of LIF in PCa bone
metatases.
We employed a powerful combination of in vitro, in vivo and ex vivo
techniques including; cytokine array analysis of patient serum, murine
models of PCa-bone metastasis, co-culture systems, qPCR and ELISAs.
Soluble LIF was elevated in patient serum before development of bone
metastases vs non-metastatic patients (57.15% ± 17.06% increase,
p<0.01). LIF mRNA and protein expression was increased in bone
metastatic PCa cell lines (p<0.001). In a murine model of PCa bone
metastasis, LIF mRNA expression strongly correlated with tumour
burden (Pearson r = 0.9941). LIF serum levels correlated with late
stage weight loss in tumour-bearing mice (p<0.01) as well as leptin
levels (p<0.05). In vitro, chronic LIF treatment was found to prevent
diﬀerentiation into adipocytes, but promote cells towards the osteo-
blastic lineage. Recombinant LIF treatment of PCa cells resulted in an
increase in pSTAT3, P70 S6K and pMAPK. Furthermore PCa/stromal
cell co-cultures demonstrated that PCa cells upregulate LIF expression
in stromal cells (p<0.001), accompanied by an upregulation in RANKL
(p<0.001) and a downregulation of osteoprotegerin (OPG) gene ex-
pression (p<0.0001) indicating a mechanism by which LIF may be
involved in PCa-induced bone disease.
Our results indicate LIF is associated with bone metastases in human
PCa patients, is a potential biomarker of disease progression and in-
duces functional eﬀects in cells of the tumour-bone niche.
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Myeloma cell down-regulation of adiponectin in bone marrow
adipose tissue promotes growth and survival via TNF-alpha
Emma Morris1, Karla Suchacki2, Joseph Hocking1, Rachel
Cartwright1, Ryan Lea1, Beatriz Gámez1, William Cawthorn2,
Claire Edwards1
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United Kingdom. 2University/BHF Centre for Cardiovascular Science, The
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Multiple myeloma (MM) is a destructive cancer of plasma cells which
predominantly reside in the bone marrow. One of the most abundant
cell types in the marrow is the bone marrow adipocyte (BMAT) which
are implicated in MM progression. BMAT secretes numerous adipo-
kines, including adiponectin, known to have anti-tumour properties.
However, in MGUS and MM, adiponectin is down-regulated, creating a
permissive environment for MM. Our goal was to understand how
myeloma cells regulate BMAT and adiponectin to promote disease pa-
thogenesis.
We have combined in vivo studies using the 5TGM1 MM model and
BMAT imaging using osmium staining and microCT and IHC. Studies
have used a panel of MM cell lines and primary MM cells, BMAT dif-
ferentiated from ST2 bone marrow stromal cells (BMSCs) or patients
with MM and white adipocytes diﬀerentiated from 3T3-L1 ﬁbroblasts.
In vivo studies revealed that BMAT is elevated in early MM (p=0.042)
with low tumour burden (p=0.015). Coculture of MM cells with BMAT
increased MM cell viability by up to 95%, induced a 4-fold increase in
migration and decreased apoptosis. MM cells were found to migrate
towards and subsequently uptake lipids isolated from the bone marrow
of patients with MM. Coculture of MM cells with BMAT signiﬁcantly
decreased adiponectin mRNA expression, protein expression and se-
cretion (p<0.05). Expression of adiponectin was lower in white adi-
pocytes and in contrast to BMAT, coculture of MM cells with white
adipocytes had no eﬀect on adiponectin expression. TNF-α and IL-6 are
cytokines secreted by MM cells and elevated during obesity. BMAT
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treated with recombinant TNF-α or IL-6 exhibited a down-regulation of
adiponectin. Addition of a TNF-α neutralizing antibody to MM-BMAT
cocultures reversed the reduction in adiponectin.
Our studies show that BMAT is elevated during MM development in
vivo. BMAT can support MM growth and survival, and we provide a
novel mechanism by which MM-derived TNF-alpha down-regulates
adiponectin, so avoiding the myeloma-suppressive eﬀects of this key
adipokine.
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3D Perfusion Bioreactor Model of Tumor-Induced Bone Disease
Joseph Vanderburgh, Gregory Lowen, Alyssa Merkel, Julie
Sterling, Scott Guelcher
Vanderbilt University, Nashville, USA
Interactions between tumor and the bone microenvironment are known
to play a critical role in the progression of tumor-induced bone disease
(TIBD). However, there remains a limited understanding of those in-
teractions and thus it is not possible to predict which tumors will induce
bone disease or how tumors will respond to therapeutics. This is largely
due to the inability to adequately model these cell-matrix interactions.
The objective of this study is to develop an in vitro model of TIBD to
predict the course of disease progression and response to drug treat-
ments in individual patients. 3D-printed Tissue Engineered Bone
Constructs (TEBCs) developed in our lab that recapitulate the me-
chanical and topological properties of trabecular bone have been em-
ployed in a perfusion bioreactor to simulate the in vivo bone micro-
environment. Human mesenchymal stem cells (hMSCs), human
monocytes (hMc), and MDA-MB-231 breast cancer cells were sequen-
tially seeded onto the TEBCs in static culture and subsequently cultured
under perfusion conditions for 30 days. The TEBC remodeling caused
by the osteoblasts (OBs) and osteoclasts (OCs) was measured grav-
imetrically and by micro-computed tomography (µCT). The cohort of
TEBCs containing only a co-culture of OBs and OCs exhibited no net
change in mass or volume, suggesting a remodeling balance had been
struck between the two cell types. In the tri-culture cohort of TEBCs
containing OBs, OCs and tumor, a net loss in mass was observed, sug-
gesting that the tumor disrupted the balance toward an osteolytic
phenotype. Tartrate-resistant acid phosphatase (TRAP) staining and
toluidine blue staining for resorption pitting indicated signiﬁcant OC
activity in 2D culture experiments conducted in parallel using the same
cell types and TEBC material, reinforcing the hypothesis that the mass
losses found in the 3D experiments are a direct result of increased OC
activity. In summary, perfusion bioreactor culture of bone cells indicate
TEBCs can be remodeled by OBs and OCs, these changes can be mea-
sured gravimetrically and by µCT, and tumor cells stimulate resorption
of the TEBCs. Incorporation of patient tumor cells and therapeutics will
make this in vitro model a powerful predictive tool for studying patient
tumor progression and response to therapeutics.
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Unravelling the metabolic relationship in the prostate cancer-bone
microenvironment; a novel role for the pentose phosphate
pathway
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It is now widely accepted that metabolic changes are a hallmark of
malignant transformation. To aid this cancer cells are thought to de-
velop a metabolic relationship with surrounding stroma. Prostate
cancer (PCa) has an unusually high propensity for metastasizing to
bone, and interactions between PCa cells and the bone microenviron-
ment promote tumour growth and survival, drug resistance and de-
velopment of a destructive bone disease. These processes require
energy, reducing power and a source of biosynthetic precursors. We
hypothesized that identifying the metabolic changes that occur when
PCa cells interact with bone would reveal new therapeutic approaches.
In silico analysis of PCa cells isolated from patients with bone metas-
tases as compared with primary tumours revealed that metabolic
pathways were the most signiﬁcantly altered gene sets. Comparing
metastatic sites, speciﬁc changes were detected that were unique to
bone metastases, including 7/19 genes involved in the pentose phos-
phate pathway (PPP) were signiﬁcantly altered in bone metastases vs
primary PCa, whereas 0/19 genes were altered in liver/lung metastases.
The PPP is a metabolic pathway, parallel to glycolysis that generates
NADPH, nucleotides and nucleic acids. As such, this pathway may play
an important role in PCa bone metastases, however its contribution is
unknown. In support of this, metabolic proﬁling of PCa cells following
coculture with bone marrow stromal cells or presoteoblasts revealed
changes in glycolysis, the TCA cycle and the PPP, with a signiﬁcant
increase in PPP metabolites including R5P and NADPH (p<0.001).
Expression of PPP proteins was higher in bone metastatic PCa cell lines
(PC3, MDA-1a, MDA-1B) compared to non-bone metastatic cell lines
(22RV1, LNCaP). Expression of the rate-limiting PPP enzyme G6PD was
induced in a non-bone metastatic cell line by BMSC co-culture. This
eﬀect can be suppressed by inhibition of the PPP with 6-aminonicoti-
namide (6-AN). PPP inhibition reduced PCa cell viability, with a greater
inhibition in bone –metastatic PCa cells. Our data suggests that the
bone microenvironment promotes up-regulation of the PPP in PCa cells.
Targeting this pathway alone, or in combination with current therapies,
could have the potential to provide beneﬁt to patients with incurable
bone metastatic prostate cancer.
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Eﬀect of tumour-derived extracellular vesicles on the molecular
proﬁle of osteoblasts and on endothelial functions
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Extracellular vesicles (EVs) are membrane-bound cargoes of biologi-
cally active molecules shed by cells, which are emerging as mediators of
several pathological processes, including cancer. We investigated EV-
mediated communication among MNNG osteosarcoma (MNNG-HOS) or
osteotropic breast cancer cells (MDA-MB-231), osteoblasts and en-
dothelial cells. In mouse osteoblasts, HOS- and MDA-EVs inhibited the
expression of Cyclin D1 (-75%, p=0.02), Alp (-35%, p=0.002) and Osx
(-40%, p=0.06), and enhanced the expression of Nos2 (15-fold,
p=0.015). An increase of mRNA and protein expression of IL-1β (12-
fold, p<0.001), IL-6 (10-fold, p=0.05), RANKL (1.5-fold, p=0.02) and
LCN2 (4-fold, p=0.01) was also observed in tumour cell-EVs-treated
osteoblasts. A cytokine protein array on conditioned media (CM) col-
lected from osteoblasts treated with HOS EVs showed a decrease of
IGFBP2 compared to CM from untreated osteoblasts, and an increase of
Pentraxin 3, a positive modulator of tumour-associated inﬂammation.
Moreover, the chemokines CXCL2, CCL2, CCL5, CCL20, Lix and MMP3,
which were undetectable in untreated osteoblasts, were expressed by
HOS EV-treated osteoblasts. Similarly, MDA-treated osteoblasts pre-
sented with an increase of CXCL1, CXCL2, CXCL10, CCL2, CCL3, CCL5
and of MMP2 and MMP3, thus suggesting shared pathways in the
regulation of osteoblasts by the two tumour cells. HOS EV transcrip-
tional proﬁle showed the expression of genes involved in bone meta-
bolism, such as CLCN7, TGFβ1, Cathepsin K and VEGFA. Consistent with
this latter result, HOS EVs signiﬁcantly increased endothelial cell che-
motaxis (p=0.02, AUC) and in vitro tube formation (3-fold, p=0.007),
evaluated by scratch assay and number of branching formed in HUVEC
cell cultures. Moreover in vivo angiogenesis, evaluated by the matrigel
plug assay, was signiﬁcantly enhanced by HOS-EVs (3.5fold, p=0.001;
Journal of Bone Oncology 13 (2018) 11–54
45
n.mice=5/group). In conclusion, these data allowed to elucidate i) the
transcriptional proﬁle of osteosarcoma and breast cancer derived EVs
and ii) their impact on osteoblast and endothelial physiology.
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LKB1 deﬁciency exhibits vulnerable mitochondrial defects by ra-
pamycin on urothelial carcinoma cells
Myeong Joo Kim, Min Ji Cho, In Ho Chang, Young Mi Whang
Chung-Ang Unciversity, Seoul, Korea, Republic of
Rapamycin, a Mammalian target of rapamycin (mTOR) inhibitor, has
signiﬁcant potential for the application of mTOR inhibitors in treatment
of urothelial carcinoma (URCa) of the bladder. Previous studies have
exhibited that regulation of the AMPK/mTOR signaling pathway en-
hances the apoptosis via induction of autophagy or mitophagy in
bladder cancer. Alteration of LKB1-AMPK signaling leads to mi-
tochondrial dysfunction and accumulation of autophagy-related pro-
teins as a result of altered mitophagy, resulting in enhanced sensitivity
to drug treatments. Therefore, we hypothesized that LKB1 deﬁciency on
URCa cells could confer to sensitivity to rapamycin by mitochondrial
defect-mediated mitophagy induction. Rapamycin enhanced growth
inhibition and apoptosis in stable LKB1 knockdown URCa cells and
xenograft mouse model. In spite of stably downregulated LKB1 ex-
pression, rapamycin induced activation of AMPK in URCa cells, which
caused loss of mitochondrial membrane potential ATP depletion, and
ROS accumulation, indicating alteration of mitochondrial biogenesis.
Our ﬁndings suggest that that presence or absence of LKB1can be tar-
geted to induce dysregulated mitochondrial biogenesis by rapamycin
treatment as the design of novel therapeutic strategies on bladder
cancer.
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Pretreatment with metformin alters the host microenvironment to
increase myeloma tumour burden and bone disease in vivo
Beatriz Gamez, Emma Morris, Sam Olechnowicz, Claire Edwards
University of Oxford, Oxford, United Kingdom
Multiple myeloma (MM) is a B cell malignancy that develops almost
exclusively in the bone marrow (BM) and causes osteolytic bone lesions
due to a dysregulated bone turnover. It is widely believed that MM
arises from an asymptomatic state referred to as monoclonal gammo-
pathy of undetermined signiﬁcance (MGUS), however the mechanisms
that drive MGUS progression to MM are unknown. Metformin is uni-
versally used in the treatment of type 2 diabetes and recently it has
been reported to have anti-cancer activities, including reducing the risk
of progression from MGUS to myeloma. The goal of the current study
was to determine whether pretreatment with metformin could alter the
bone microenvironment and reduce subsequent development of MM in
vivo.
C57Bl/KaLwRij mice were treated with metformin for 4 weeks prior to
inoculation of MM cells, when metformin treatment was halted. In
contrast to our hypothesis, we found that pretreatment with metformin
induced a two-fold increase in tumour burden, evidenced by the pro-
portion of MM cells in BM (p<0.001). This was associated with an
increase in osteolytic bone lesions (p<0.05). During in vitro studies,
2T3 preosteoblasts were treated with metformin, prior to addition of
MM cells. This resulted in an increase in MM cell adhesion to pre-
osteoblasts (p<0.05), an increase in non-dividing MM cells and in-
crease in p21 expression. Metformin treatment increased the osteogenic
capacity of osteoblasts and increased osteopontin (OPN) expression in
osteoblasts in vitro. Silencing OPN expression in osteoblasts resulted in
a reduction in MM cell attachment in response to metformin, suggesting
that metformin-mediated OPN expression is at least partially
responsible for the increase in adhesion. Furthermore, im-
munohistochemistry demonstrated an increase in OPN expression in
osteoblasts following metformin treatment in vivo.
Altogether our results show that metformin pre-treatment induces
changes in the bone microenvironment, increasing the capacity to
harbour myeloma cells. This can be partially explained by the increase
in osteoblastic OPN expression in vitro and in vivo which may act as
chemoattractant for MM cells. In addition, metformin increases the
osteogenic capacity of osteoblasts, potentially expanding the endosteal
niche where MM dormant cells reside. Overall these results highlight
the need for caution when considering the use of metformin in non-
diabetic patients with MGUS as an approach to reduce progression to-
wards MM.
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Marrow Adipose Tissue is Associated with Regions of Hypoxia
During Metastatic Colonization of the Bone
Kassandra Spiller1, Edward LaGory2, Colleen Wu1
1Duke University, Durham, USA. 2Stanford University, Stanford, USA
Marrow adipocytes can be found within close proximity to malignant
cells in the bone microenvironment (BME) and increased marrow
adiposity promotes metastatic colonization. These ﬁndings suggest
marrow adipose tissue (MAT) may contribute to metastatic dissemina-
tion to the bone; however, the cellular and molecular mechanisms
regulating MAT formation during metastatic bone colonization have
not been fully elucidated. We show that upon intra-cardiac delivery,
breast carcinoma and melanoma cell lines colonize to hypoxic regions
in the bone microenvironment. Intriguingly, these hypoxic regions are
also associated with marrow adipocytes and whole bone homogenates
isolated from tumor bearing bones showed increased expression of Pgc-
1 alpha, a gene which is coupled to both adipogenesis and the hypoxia
inducible factor (HIF) signaling pathway. Given these observations, we
hypothesized that cancer cells within the bone marrow secrete factors
to induce MAT formation in a hypoxia dependent manner. To test this
hypothesis, multipotent bone marrow stromal cells (BMSC) were iso-
lated from 8 week old B6 mice and were cultured with either, adipo-
genic induction or conditioned media (CM) isolated from cancer cell
(CC) lines. In the presence of induction media and under 20% O2, BMSC
underwent adipogenic diﬀerentiation as measured by the presence of
lipid formation and Oil Red O staining. Interestingly, CM alone was also
able to induce lipid formation in BMSC. Next, to examine the inﬂuence
of hypoxia on BMSC lipid formation we cultured cells in 1% O2. In
hypoxia, adipogenic diﬀerentiation of BMSC with induction media was
impaired; however, CM isolated from CC lines induced lipid formation
even in the presence of low oxygen. Our data suggests that CC residing
in the hypoxic BME may modulate MAT through the secretion of pro-
adipogenic factors. Our studies have begun to elucidate the potential
contribution of hypoxia in regulating MAT during bone colonization by
metastatic tumor cells.
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Transcriptional regulators of oncogenesis and of osteoblastic dif-
ferentiation revealed by microRNA proﬁling of osteosarcoma cell
lines and primary human osteoblasts
Brendan Norman1, Peter Wilson1, Mohd Osman1, Nick Rhodes1,
Lakshminarayan Ranganath2,1, James Gallagher1
1Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool,
United Kingdom. 2Liverpool Clinical Laboratories, Royal Liverpool &
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MicroRNAs (miRNAs) are 20-24 nucleotide non-coding RNAs which are
increasingly recognised as regulators of aberrant gene expression in
oncogenesis. In this study we performed miRNA proﬁling on three os-
teosarcoma cell lines, MG-63, TE85 and Saos2 and compared them with
primary human osteoblasts (HOBS).
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Human osteosarcoma cell lines were from extensively characterised lab
stocks. HOBS were cultured from explants of bone from six donors.
MiRNA was isolated and puriﬁed from cell culture homogenates using
the miRNeasy Mini Kit (Qiagen). MiRNA proﬁling was performed with
an Aﬀymetrix GeneChip scanner 3000 7G on an Aﬀymetrix miRNA 4.0
array.
In total 2587 miRNA were proﬁled across all samples. Principal com-
ponents analysis (PCA) showed that the clearest diﬀerence in miRNA
expression proﬁles was between osteosarcoma cell lines collectively
and HOBS: 157 miRNAs were diﬀerentially expressed between these
two cell types (p<0.05 (FDR-adjusted), fold change >2). Clustering
analysis on these miRNAs identiﬁed three primary miRNA clusters,
with similar expression proﬁles, that showed clear diﬀerences between
osteosarcoma and HOBs: two clusters comprised miRNAs up-regulated
in osteosarcoma cells compared to HOBS, whereas one cluster showed
down-regulated miRNAs in osteosarcoma cells. miRNA annotation
based on validated gene targets (odds:expected ratio >1.5) found
miRNA clusters up-regulated in osteosarcoma cells were involved in
diverse pathways such as oncogenesis, immune response, VEGF sig-
nalling and glutathione metabolism. MiRNAs down-regulated in os-
teosarcoma cells were also associated with cancer pathways, but also
arginine, proline and glutathione metabolism amongst other pathways.
Interestingly, PCA analysis also identiﬁed proﬁle diﬀerences between
the three osteosarcoma cell lines: 85 miRNA were signiﬁcantly diﬀerent
(p<0.05 (FDR-adjusted), fold change >2) between at least two cell
lines. PCA component 3, which accounted for 9.8% of the variation,
captured the sequential order of osteoblast diﬀerentiation between the
cell lines. The miRNAs contributing most to this sequence of diﬀer-
entiation were hsa-miR-155-5p, hsa-miR-212-3p, hsa-miR-708-5p and
hsa-miR-143-3p.
In conclusion, this study revealed major diﬀerences in miRNA proﬁles
between HOBS and cell lines derived from human osteosarcoma.
Several groups of miRNAs linked by expression proﬁles were identiﬁed
as potential epigenetic regulators of the ‘transformed’ oncogenic state of
osteosarcoma cells. Functional annotation of these miRNAs suggests
diverse and complex regulatory roles particularly in cancer-related
pathways but also in numerous other signalling and metabolic path-
ways.
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Vascular cell adhesion molecule (VCAM) 1 and α4β1 integrin in-
teractions regulate myeloid-derived suppressor cells (MDSC) mo-
bilization from the bone marrow of tumor hosts
Kyung Jin Lee, Eun Jeong Lee, Bo Yeon Seo, Serk In Park
Korea University College of Medicine, Seoul, Korea, Republic of
MDSCs are a subset of immature bone marrow-derived cells that play
diverse pro-tumorigenic roles such as suppressing T cell-mediated anti-
tumoral immunity. We have previously reported that tumor-derived
parathyroid hormone-related peptide (PTHrP) increased MDSC re-
cruitment in the tumor tissue. In contrast, little is known about how
MDSCs are mobilized from the bone marrow of tumor hosts. In this
study, we investigated whether interactions between α4β1 integrin
expression in MDSCs and VCAM 1 expression in the bone marrow
stromal cells (BMSC) regulate retention and release of MDSCs in the
bone marrow. CD11b+Gr1+ cells (commonly deﬁned as murine
MDSCs) were isolated from the murine femurs by ﬂow cytometry, and
in vitro cell binding assays were performed. Brieﬂy, MDCS were car-
boxyﬂuorescein succinimidyl ester (CFSE)-stained and co-cultured with
MC3T3E1 pre-osteoblastic cells in the presence of anti-VCAM 1 and/or
anti-β1 integrin neutralizing antibodies (0.5 to 2 µg/mL). After washing
unbound cells, ﬂuorescence intensity was measured to quantify MDSC-
BMSC binding. VCAM-1 and/or β1 integrin neutralizing antibodies
dose-dependently decreased MDSC-BMSC binding, suggesting that
MDSCs bind to BMSC via VCAM-1 and β1 integrin. We further
examined whether tumor-derived PTHrP disrupts the VCAM-1 and β1
integrin axis of MDSC-BMSC. PTHrP (1-34) administration rapidly in-
creased MDSCs in the peripheral blood in vivo. In addition, PTHrP
conditioned-media from calvarial osteoblasts reduced MDSC-BMSC
binding in vitro compared with control conditioned media, and the ef-
fects were reversed by anti-interleukin (IL)-6 or anti-vascular en-
dothelial growth factor (VEGF)-A antibodies, suggesting that PTHrP-
induced IL-6 and VEGF-A expression in osteoblasts mobilize MDSCs. In
addition, recombinant IL-6 and VEGF-A reduced MDSC-BMSC binding
in vitro. Lastly, immunohistological analyses of the femurs of tumor-
bearing mice showed that CD11b+Gr1+ cells localized adjacent to
trabecular osteoblasts. In summary, our data demonstrate that bone
marrow stromal cells regulate MDSC traﬃcking from the bone marrow
to the peripheral blood, and also that VCAM-1 (expressed in BMSC) and
α4β1 integrin (expressed in MDSC) interactions regulate MDSC reten-
tion and mobilization. Further studies on the PTHrP-induced expression
of proteinases such as matrix metalloproteinases and A Disintegrin and
Metalloproteinase (ADAM) in the bone microenvironment will further
elucidate the mechanism of MDSC mobilization in the bone marrow of
tumor hosts.
P47
Modelling the human bone-tumour niche ex vivo
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Bone is the most common site for tumour metastasis, particularly in
breast and prostate cancers where ~70% of patients show evidence of
metastatic bone disease. Consequently, a large ﬁeld of research has
evolved to speciﬁcally study cancer-bone disease, along with a large
number of diﬀerent animal models. These include inoculation of human
or mouse tumour cells at extra-osseous sites e.g. heart, or implanted
directly into skeletal sites. The limitations of in vivo bone-tumour
models include a common mixed approach using human cells in mice,
using immuno-compromised mice which do not clearly represent the
contribution of the immune system within the bone-tumour niche, and
the wide-ranging inherent diﬀerences between mice and humans.
To more accurately re-create the human bone-human tumour micro-
environment, and importantly, replace the use of animals in un-
necessary or poorly validated model systems, we aimed to develop an
ex vivo assay mimicking the tumour-bone cell interactions which occur
following cancer metastases to skeletal sites.
Fresh trabecular bone samples were collected following hip replace-
ment surgery under approved Ethical and HTA procedures. Uniform
areas of trabecular bone were created approx. 5mm2, and cultured with
PC3-EGFP prostate cancer cells +/- HS-5-mCherry human bone
marrow stromal cells. Cells were inoculated to the living bone by either
direct plating upon the bone surface, insertion into small cores within
the bone or by introducing the cells in a matrigel suspension. Following
culture for 7-10 days the tumour-bone co-culture was processed for
histomorphometric analysis.
Viable bone cells were clearly visible (osteoblasts, osteoclasts) and
abundant fat deposits, common in ageing human bone. Importantly,
tumour cells were observed adhered to the bone surface and occupying
marrow spaces within the bone network when introduced within ma-
trigel, suggesting the capacity to grow and colonise the bone niche.
However, few GFP+ tumour cells were seen when inoculated by other
means. Our assay has used human intact bone and human tumour cell
lines to model the bone-tumour niche seen in patients with metastatic
bone disease and suggests a potential alternative to the use of animal
models in cancer-bone research.
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Approximately 35% of patients with kidney cancer, most commonly
renal cell carcinoma (RCC), develop bone metastases. Resulting ske-
letal involvement is not only painful and devastating, but also very
costly to the patient. Despite the numerous advancements in systemic
RCC therapies stemming from the elucidation of hypoxia-inducible
factor (HIF) signaling and its regulation by von Hippel-Lindau (VHL)
gene, the molecular mechanisms behind this highly lytic behavior of
metastatic RCC tumors remain not understood. An important feature of
metastatic RCC is that in contrast to other bone-trophic malignancies,
which largely localize to the axial skeleton, RCC often involves per-
ipheral sites, such as long bones. Notably, the peripheral skeleton is
abundantly ﬁlled with marrow adipocytes, whose numbers increase
exponentially with age and metabolic pathologies. Marrow fat cells play
metabolically important functions, and have emerged as strong con-
tributors to metastatic progression from several types of cancers. They
are also known to express signiﬁcant levels of receptor activator for NF-
κB ligand (RANKL), one of the key regulators of osteoclastogenesis.
Here we hypothesize that tumor-induced lipolysis and metabolic
changes in marrow adipocytes promote osteoclastic activity and bone
loss, and consequently support tumor growth and survival.
We demonstrate that adipocyte-supplied factors promote osteoclast
diﬀerentiation and maturation in vitro. Transwell co-culture of RCC cell
lines with adipocytes highly induces the levels of RANKL in fat cells, a
process that is further potentiated by the stimulation of lipolysis. Both
the interaction with RCC cells and the pharmacological induction of
lipolysis promote thermogenesis in marrow adipocytes as indicated by
the signiﬁcantly elevated expression of uncoupled protein 1 (UCP1).
Furthermore, two molecules with key roles in inﬂammatory bone re-
sorption: cyclooxygenase (COX-2), a rate-limiting enzyme in pros-
taglandin synthesis, and a downstream eﬀector of beta-adrenergic sig-
naling in adipose tissue; and macrophage chemoattractant protein
(MCP1), are highly induced in adipocytes interacting with tumor cells
in vitro and in tumor-bearing tibia in vivo. Studies are currently un-
derway to elucidate the precise molecular mechanisms behind the
highly destructive RCC behavior in bone and its regulation by bone
marrow adipocytes.
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TRAF6 and Docetaxel reduces breast cancer skeletal metastasis
and osteolysis
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Tumour necrosis factor receptor-associated factor 6 (TRAF6) has been
implicated in breast cancer and bone remodelling, but its role in the
initiation and progression of breast cancer osteolytic metastasis remains
unknown. Here we describe the eﬀects of the veriﬁed small-molecule
inhibitor of TRAF6, 6877002 on skeletal tumour growth, metastasis and
osteolysis in a syngeneic mouse model of breast cancer. We observed
that TRAF6 is highly expressed in a panel of human and mouse breast
cancer cell lines including the parental human MDA-MB-231 and mouse
4T1 and their bone-tropic clones. Exposure of these cells to the TRAF6
inhibitor 6877002 suppressed breast cancer cell proliferation in a
concentration-dependent manner (IC50, 24-31μM). 6877002 (3µM)
also suppressed RANKL-stimulated migration (38.4%, p<0.05) and
invasion (57.3%, p<0.05) of MDA-MB-231 cells in vitro and reduced
skeletal tumour growth following the intra-cardiac injection of 4T1 in
immuno-competent mice by 67.5% (p<0.05). Furthermore, 6877002
exhibited synergism with a panel of chemotherapeutic agents including
standard-of-care Docetaxel in vitro, and combined administration of
6877002 (20mg/kg/day) and Docetaxel (15mg/kg/week) reduced
skeletal tumour growth (86.1% reduction, p<0.05) and inhibited os-
teolytic bone damage (bone volume, 57.2% increase, p<0.05 compared
to vehicle treated) following the injection of syngeneic 4T1 in immuno-
competent mice. Functional and mechanistic studies in bone and breast
cancer cells revealed that 6877002 reduced RANKL-induced RANK/
TRAF6 binding, IkB phosphorylation and osteoclast formation by up to
80%, whilst having no eﬀect on osteoblast viability or diﬀerentiation.
Collectively, our ﬁndings suggest that targeting of TRAF6, alone or in
combination with conventional chemotherapies, shows promise for the
treatment of advanced breast cancer.
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Multiple myeloma (MM) is an incurable cancer of plasma cells (PC),
with a median survival of 5-7 years. Osteolytic bone disease and ske-
letal complications occur in more than 80% of MM patients and sig-
niﬁcantly contribute to the morbidity and mortality of these patients.
Glycosphingolipid (GSL) composition, constituents of the outer leaﬂet
of the cellular membrane, is altered in multiple myeloma and other
cancers with increased expression of GM3 and GM2. We previously
reported that GM3 promotes osteoclastogenesis and that the GSL in-
hibitor N-butyl-deoxynojirimycin (NB-DNJ) reduced myeloma bone
disease in the 5TGM1 mouse model of MM. NB-DNJ prevented OC
development and activation by disrupting RANKL-induced localization
of TRAF6 and c-SRC into lipid rafts and preventing nuclear accumula-
tion of transcriptional activator NFATc1.
Using a new GSL inhibitor with less gastrointestinal side eﬀect and
weight loss, we now show in vitro dose dependent inhibition of both
osteoclast formation (p < 0.01) and MM cell growth (p < 0.0001, thus
GSL inhibition can potentially relieve two main features of MM - tu-
mour burden and bone destruction. In vivo we found the GSL inhibitor
can suppress germinal centre formation in mouse spleen induced by the
injection of sheep red blood cells. Moreover, we determined that the
GSL inhibitor decreased MM tumour burden, as evidenced by a re-
duction in the proportion of myeloma cells within bone marrow and
spleen and bone loss in the 5TGM1 model of myeloma.
These studies elucidate mechanistic links between osteoclasts and in-
creased susceptibility to MM. Moreover, as GM3 has been strongly
implicated in adipocyte function in diabetes, we postulate that the GM3
rich environment created by the myeloma cells may create a supportive
adipocyte niche in the bone marrow as well as providing the preclinical
platform for GSL inhibition as a new tool against MM bone lesions and
abnormalities in bone marrow adipocytes.
Journal of Bone Oncology 13 (2018) 11–54
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Multiple myeloma disrupts bone homeostasis causing lytic lesions,
skeletal damage and pain. Mechanisms underlying myeloma-induced
bone destruction are incompletely understood and current therapies do
not restore lost bone mass. We have previously reported RNASeq
transcriptomic proﬁling of isolated endosteal cell types from a murine
myeloma model, not previously described in the cancer-bone niche. We
found bone morphogenetic protein (BMP) signalling to be upregulated
in mesenchymal progenitor cells of the bone lining niche in myeloma-
bearing mice.
BMP signalling is not previously reported to be dysregulated in mye-
loma bone disease. In the current study, inhibition of BMP signalling in
vivo using either a small molecule Type 1 BMP receptor antagonist
(LDN193189) or a solubilized Alk3-Fc (Bmpr1a-Fc) receptor ligand trap
prevented trabecular and cortical bone volume loss caused by myeloma,
without altering tumour burden. These inhibitors directly reduced os-
teoclast formation and activity, increased osteoblast number and new
bone formation, and suppressed bone marrow levels of sclerostin, a Wnt
inhibitor implicated in mediating the failure of bone repair in myeloma
suﬀerers. RNASeq of mesenchymal progenitor cells from myeloma-
bearing mice showed upregulation of collagen matrix formation and
vitamin D signalling gene sets with LDN193189 treatment, indicating
enhancement of osteoblast maturation.
This work describes a novel technique in the investigation of myeloma-
niche interactions, shows its use in revealing a novel pathway involved
in the pathogenesis of myeloma bone disease, and demonstrates that
the therapeutic targeting of the BMP pathway has both anti-resorptive
and anabolic beneﬁts to bone metabolism, which could have a role
alongside anti-tumour treatments.
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The majority of women with advanced breast cancer develop osteolytic
bone metastases, which are incurable. Secretion of osteolytic factors
from bone metastatic tumor cells drives this process, which is fueled by
tumoral eﬀects of growth factors, such as TGFß, released from resorbed
bone matrix. Smad signaling is an important mediator of TGFß-sti-
mulated gene expression. In earlier studies using a human xenograft
breast cancer bone metastases model dependent on TGFß-stimulated
secretion of PTHrP (”MDA-SA” cells), treatment with turmeric-derived
dietary polyphenols (curcuminoids) reduced breast cancer bone me-
tastasis progression and inhibited Smad-dependent TGFß-stimulated
secretion of PTHrP. However, the active metabolite in vivo was unclear
since curcumin, analogous to many other dietary polyphenols, is
rapidly glucuronidated (G-CURC), allowing for minimal systemic ex-
posure to aglycone curcumin (CURC) in mice or humans. Studies were
therefore undertaken: 1) to compare the ability of CURC vs G-CURC to
inhibit Smad-dependent TGFß signaling in a panel of TGFß-dependent
bone metastatic breast cancer cells, and 2) to examine bone-speciﬁc
metabolism of orally ingested CURC in mice. In vitro, phosphorylated
receptor Smad2 levels were signiﬁcantly decreased in TGFß-stimulated
human (MDA-MB-231-derived MDA-SA, 1833, and 2287 cells) and
murine (4T1) bone tropic breast cancer cells in response to treatment
with CURC (30 µM), while G-CURC was without eﬀect. To query
whether site-speciﬁc deconjugation of G-CURC could explain the in vivo
protective eﬀects of CURC in bone, systemic vs. site speciﬁc CURC
metabolites were assessed following oral CURC administration. In
serum, aglycone CURC accounted for 1.1% of total circulating curcumin
[CURC + G-CURC]), while 39.6% was in the aglycone form (CURC) in
bone (p < 0.01), where CURC levels were 10-fold higher as compared
to serum (p < 0.05). Hemopoietic (but not tumor) cells in bone ex-
pressed glucuronidase (by Western analysis and enzyme activity assay),
an enzyme with a Km of 72 µM that readily deconjugated G-CURC ex
vivo, suggesting that site speciﬁc activation (deconjugation) of orally
administered CURC within the bone microenvironment could con-
tribute to its bone protective eﬀects. Because many bone protective
dietary polyphenols are similarly glucuronidated, these ﬁndings suggest
that site-speciﬁc deconjugation of these “pro-drugs” may contribute to
their bone-targeted bioactivity.
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Prostate cancer (PC) is the 2nd leading cause of cancer related deaths in
U.S. men. The reason of prostate cancer mortality is not from the pri-
mary cancer but spread of the primary cancer cells to distant organs,
especially bone. The current bone metastases therapy modalities are not
eﬃcient to cure bone metastasis because of the inability to deliver
therapeutic concentrations of anticancer-agents (Cabazitaxel; CTX) to
PC lesions in bone. To address the limitations, we synthesized a bone
targeted amphiphilic triblock copolymer, pVTK-poly(ethylene)-b-poly
(acrylic acid)-b-poly(methyl methacrylate), which self-assembles in
aqueous medium forming nano-sized micelles that can encapsulate CTX
in the hydrophobic core. Cross-linkage of the PAA blocks using a ketal-
linker forms an acid-labile shell, which stabilizes the formed micelles at
physiologic pH but allows selective release of the loaded cargo in acidic
environments. The average size of the particles was around 100 nm.
Further, we investigated the optimum bone binding mole percent of
pVTK (0, 5, 10%) in the particles using HA-disc, bone powder, and
bone-chip relying on FITC ﬂuorescence of the peptide. The percent of
bound of 5% and 10% pVTK micelles on HA-discs were 58 and 61,
respectively, while the same formulations binding percentage on rat
bone powder were 42 and 38, respectively. Furthermore, the CTX
loading eﬃciency of 5 and 10% pVTK-micelles were around 26.0 and
18.8%, respectively. Based on the cytotoxicity results of the particles,
pVTK-micelles (0, 5, 10%) did not have any cytotoxic eﬀect on PC cells.
The IC50 values of CTX-loaded non-targeted, 5%, and 10% pVTK-mi-
celles were 0.76, 2.46, 0.37 nM, respectively with the control of 0.60
nM free CTX. These results indicate pH-sensitive, CTX-loaded, bone-
targeted pVTK-micelles can preferentially bind to bone and achieve
tunable CTX release in tumor lesion, which can selectively kill tumor
cells while limiting systemic side eﬀects.
Journal of Bone Oncology 13 (2018) 11–54
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Mechanical signals retain musculoskeletal endpoints while sup-
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Post-menopausal, estrogen-receptor-positive breast cancer patients
treated with aromatase inhibitors to inhibit disease progression ex-
perience adverse musculoskeletal eﬀects such as bone loss and muscle
weakness. Mechanical signals, generated during physical activity and
exercise, help maintain musculoskeletal homeostasis; however, many
patients are unable to participate in regimented exercise. Low intensity
vibrations(LIV), high-frequency low magnitude mechanical signals
analogous to skeletal muscle contractions, were previously demon-
strated as safe, deterring bone loss in two cancer models. We hy-
pothesized similar eﬀects in C57BL6 mice undergoing complete es-
trogen deprivation to model breast cancer therapy. Models were
generated via ovariectomy at 8wo age and daily administration of ar-
omatase inhibitor letrozole 24w. To test our hypothesis, mice were
administered either LIV(n=10) or control-LIV(CTL; n=10) for 4w prior
to and 24w post-surgery. Whole-body DXA scanning was performed to
measure lean and fatty tissue. LIV signiﬁcantly increased lean mass over
the 28w-treatment period relative to CTL. Total fat increased by 97% in
CTL relative to baseline, while increasing by only 56%(p<0.001) in
LIV-treated mice. Forelimb strength, from triplicate grip measurements,
were signiﬁcantly greater(p<0.05) in LIV-treated mice than in CTL, a
32% diﬀerence between groups at 28w. High-resolution ex vivo micro-
computed tomography scanning was performed on lumbar vertebrae
(resolution=12microns). Bone volume fraction and connectivity den-
sity were both signiﬁcantly(p<0.05 and p<0.01, respectively) greater
following LIV. Dynamic histomorphometry was performed on calcein-
double-labeled PMMA-embedded femora and vertebrae. Bone forma-
tion rate and mineralizing surface normalized to bone surface were
each signiﬁcantly greater in distal femora(p<0.01) and L5 trabeculae
(p<0.05) in response to LIV. Additionally, as compared to non-LIV-CTL
bones, mineral apposition rate was signiﬁcantly greater(p<0.05) in
LIV-treated L5 vertebrae, a site harboring greater metabolic response to
mechanical signals. Von Kossa-stained LIV-treated lumbar vertebrae
sections had signiﬁcantly greater(p<0.05) osteoblast number per bone
surface area than CTL. Conversely, TRAP-stained sections indicated
signiﬁcantly lower osteoclast surface area(p<0.01) and osteoclast
number(p<0.05) normalized to bone surface in LIV-treated mice. A
glucose tolerance test was performed indicating that the area-under-
the-curve was signiﬁcantly(p<0.03) lower in LIV-treated mice relative
to CTL-treated mice. Together, these data highlight the eﬀect of es-
trogen on musculoskeletal tissue and support the role of physical ac-
tivity and mechanical signals in reducing fat while increasing lean
tissue and bone.
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Biomarkers predicting the risk of breast cancer metastatic spread to
bone (BCBM) are urgently required. Our previous in vitro studies have
identiﬁed Wnt-family inhibitor Dickopf-1 (DKK1) as a potential such
biomarker. Also, bone sialoprotein (BSP) has shown elevated expression
within breast primary tumours that metastasize to bone and BSP levels
are also increased within serum samples from BCBM patients. The re-
ceptor protein CXCR4 is another potential biomarker of bone metastasis
shown to bind stromal-derived-factor-1 (SDF1 / CXCL12) released by
bone. In the current study, we tested these proteins as predictors of
bone-metastasis within tissue-microarrays from the AZURE trial in
which 3360 patients with early breast cancer at moderate/high risk of
recurrence, were randomised 1:1 to receive standard adjuvant therapy
+/-zoledronic acid (ZOL).
In this pilot study, primary tumour cores from AZURE trial patients
were stained with antibodies towards DKK1, BSP or CXCR4.
Cytoplasmic staining was assessed independently by two trained op-
erators, blinded to outcome data, under supervision of an experienced
breast histopathologist. DKK1, BSP and CXCR4 levels were correlated
with local and distant recurrences by multivariate analysis, adjusted for
systemic therapy plan, ER status and lymph node involvement. Distant
events examined included: ﬁrst distant recurrence (metastasis to any
site), ﬁrst recurrence in bone (even if concurrent with relapse in other
sites) and ﬁrst recurrence in non-skeletal sites.
Pilot-scale analysis of 462 patients revealed statistically signiﬁcant as-
sociation of BSP levels with ﬁrst distant recurrence (whole population,
p = 0.005; ZOL arm, p = 0.013) and with ﬁrst event in non-skeletal
sites (whole population, p = 0.008; ZOL arm, p = 0.046).
• CXCR4 levels displayed statistically signiﬁcant association with ﬁrst
distant recurrence (whole population p = 0.031) and ﬁrst recur-
rence in bone (ZOL arm, p = 0.030).
• DKK1 was not signiﬁcantly associated with distant events in this
analysis.
• No signiﬁcant associations were found for other distant events
Our pilot studies suggest that BSP and CXCR4, but not DKK1 may have
potential as biomarkers predictive of metastasis to bone and/or non-
bone sites. However these are initial data and we are currently ex-
tending these analyses within a larger patient group.
P57
Functionalized Rare earth-doped Nanoparticles for Breast Cancer
Detection and Potential Bone-targeting Contrast Agents
Akhil Jain1,2, Pierrick Fournier1, Gustavo Hirata2, Patricia Juárez1
1Centro de Investigación Cientíﬁca y de Educación Superior de Ensenada,
Ensenada, Mexico. 22Universidad Nacional Autónoma de México - Centro
de Nanociencias y Nanotecnología, Ensenada, Mexico
Breast cancer is the second leading cause of cancer death among women
and represents 14% of death in women around the world. Breast cancer
metastasizes to bone in more than 80% of patients with advanced dis-
ease, causing severe skeletal related events and bone metastases are
incurable. The standard diagnosis method for breast tumor is mam-
mography, which is often related with false-negative results leading to
therapeutic delays and contributing indirectly to the development of
metastasis to bone. Here, we have established a nanoparticle platform
using ﬂuorescence and CT imaging for the detection of breast cancer
and bone metastasis by conjugating folic acid (FA) to rare-earth-doped
luminescent nanoparticles (RE)
RE were synthesized using sucrose-assisted combustion synthesis and
functionalized with FA using EDC-NHS coupling. Transmission electron
microscopy analysis indicated an average nanoparticle diameter of 55
nm. FA-conjugated RE nanoparticles exhibited strong red emission at
613 nm with a 35% quantum yield. MTT analysis demonstrated that the
nanoparticles had negligible cytotoxic eﬀect on normal 293T cells and
T47D breast cancer cells in vitro. Cellular uptake analysis showed
signiﬁcantly higher internalization of FA-conjugated RE nanoparticles
into T47D cells (Folrhi) compared to MDA-MB-231 breast cancer cells
(Folrlo).
In vivo studies in CD1 mice indicated that FA-conjugated RE nano-
particles are rapidly cleared from blood circulation after 2h post-injec-
tion thus minimizing the risk of toxic response. Additionally, these na-
noparticles were well tolerated in mice even at doses as high as 300 mg/
kg, after i.v. injection. We next evaluated the targeting ability of FA-
conjugated RE nanoparticles in xenograft models of MDA-MB-231 and
T47D breast cancer cells. Confocal and CT imaging studies indicated that
FA-conjugated RE nanoparticles accumulated more eﬃciently in T-47D
tumor xenograft compared to the MDA-MB-231 tumor. Overall, our re-
sults showed that our FA-conjugated RE nanoparticles have high tumor
speciﬁcity and biocompatibility representing an advanced tool that can
be applied for preclinical and clinical applications Further studies are
going on to evaluate bone targeting ability of surface functionalized RE
nanoparticles in a murine model of bone metastasis.
P58
An agent based model of the bone remodelling process and its
disruption by multiple myeloma.
Curtis Palasiuk1, Andrew Chantry2, Dawn Walker1
1Insigneo Institute for in silico Medicine, Sheﬃeld, United Kingdom.
2Sheﬃeld Myeloma Research Team, Sheﬃeld, United Kingdom
Living bone tissue is constantly in a dynamic state of damage and re-
pair. The bone remodelling process requires a delicate equilibrium
between bone resorption and formation, removing damaged bone and
replacing it with new tissue respectively. The mechanisms that regulate
this cycle are disrupted by the presence of multiple myeloma, a cancer
of plasma cells. Myeloma causes upregulation of osteoclastic activity,
increasing resorption, while inhibiting osteoblastic bone reformation,
resulting in bone lesions and associated risk of fracture in patients. By
better understanding the nature of the bone remodelling process and
how it is aﬀected by multiple myeloma, we can better target future
research into novel treatments for this debilitating disease.
A computational model has been developed in order to provide a
deeper insight into the complex interplay of regulatory factors present
within the bone marrow microenvironment. This agent-based model
(ABM) allows each individual cell within the environment to be re-
presented as a distinct entity, allowing for a level of granularity not
possible in traditional mathematical models. Our approach currently
simulates osteoclasts, osteoblasts, osteocytes, precursor osteoclast cells,
myeloma cells and bone cells, along with a variety of associated che-
mokines and other factors facilitating intercellular interactions. This
prototype model has produced emergent behaviour consisting of a cycle
of bone remodelling, including trauma applied to bone, detection of
and reaction to this trauma by osteocytes, and ﬁnally resorption and
formation by osteoclasts and osteoblasts respectively.
Future iterations of this generic, cellular-based model will be further
reﬁned based on available clinical data and introduce new actors to the
system to better understand individual mechanisms. Our primary in-
terests for extensions include TGF-β and counteracting anti-TGF-β
treatment, RANKL/OPG interactions aﬀecting the diﬀerentiation of
osteoclasts and osteoblasts, and contemporary treatments for myeloma
such as Lenalidomide, Zoledronic Acid and Bortezomib. By performing
this type of in silico experimentation it is hoped that clinically relevant
novel avenues of treatment can be identiﬁed for future mouse model
studies.
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Teriparatide use among post-menopausal women: A meta-analysis
Cristina C. Morales1, Henry G. Cañizares1,2
1Philippine Heart Center, Quezon City, Philippines. 2Vicente Sotto Memorial
Medical Center, Cebu City, Philippines
BACKGROUND: In the most recent guideline on the management of
osteopenia and osteoporosis published by the American College of
Physicians, teriparatide was excluded as a treatment option. This ex-
clusion has sparked a controversy among specialty groups involved in
the management of the disease.
METHODS: Published reports of randomized controlled trials (RCTs) in
English from August 2007 to August 2017 were sought via PubMed and
Google Scholar. Twenty-one studies were identiﬁed, of which 7 were
included in the meta-analysis. Data from these studies were pooled to
determine the eﬃcacy of teriparatide in decreasing incident fractures
and increasing bone mineral density.
RESULTS: Teriparatide reduced the risk of fractures and improved the
bone mineral density at the lumbar spine, femoral neck and total hip.
Pooled data from 1535 post-menopausal women showed that ter-
iparatide reduces the risk of fractures [risk ratio= 0.35 (95% con-
ﬁdence interval [CI], 0.41, 0.80)] with an overall eﬀect, Z, of 3.31 (P =
0.0009). Greatest improvement was seen at the lumbar spine with a
mean diﬀerence of 6.03% (Z = 6.82; P < 0.00001). More modest
improvements at the femoral neck of 2.79% (Z=2.29; P = 0.02) and
total hip 0.64% (Z = 16.77; P < 0.0001) were also noted.
CONCLUSION: Teriparatide may be considered as a pharmacologic
option among patient with decreased bone mineral density, especially
at the lumbar spine, and/or at high risk for fractures.
MP4
Denosumab-like anti-RANKL treatment reverts osteolytic and os-
teomalacic changes in a murine model of Fibrous Dysplasia.
Biagio Palmisano1, Rossella Labella1, Emanuela Spica1, Cristina
Remoli1, Annamaria Di Filippo1, Alan Boyde2, Alessandro Corsi1,
Mara Riminucci1
1Department of Molecular Medicine, Sapienza University of Rome, Rome,
Italy. 2Dental Physical Sciences, Barts and The London School of Medicine
and Dentistry, Queen Mary University of London, London, United Kingdom
Fibrous Dysplasia (FD) is a rare genetic disease of the skeleton caused
by activating mutations (R201C, R201H) of the stimulatory G protein
α subunit (Gsα). We previously generated transgenic mice that express
GsαR201C under the control of ubiquitous and constitutive promoters
(EF1α-GsαR201C mice, PGK-GsαR201C mice ) and reproduce a FD-like
skeletal phenotype. Studies performed on these mouse models demon-
strated that disregulated bone resorption plays a major role in the de-
velopment and progression of FD lesions and allowed us to identify
RANKL as one important molecular mediator of the abnormal osteo-
clastogenesis associated with the disease.
The aim of this work was to investigate the eﬀects of RANKL-inhibition
on the development and progression of skeletal lesions in EF1α-
GsαR201C mice.
Based on radiographic analysis, we selected 2 month old EF1α-GsαR201C
mice with early lytic intracortical lesions in the tail vertebrae and fe-
murs. We generated multiple experimental groups, each of which was
treated with an anti-mouse RANKL antibody according to a diﬀerent
regimen. Control groups were generated by treating transgenic mice
with Rat IgG2a Isotype antibody.
The anti-RANKL treatment caused an overall increase in radiographic
bone density, with disappearance of lytic areas. The radiographic
changes were due to the replacement of the pathological ﬁbrotic tissue
with newly-formed bone, Of note, the new bone deposited in anti-
RANKL treated mice was mineralized and, at least in part, lamellar, in
contrast with the osteomalacic and woven FD bone observed in control
mice. Furthermore, the anti- RANKL treatment also prevented the
development of bone deformities as well as the appearance of new lytic
areas.
The comparison of diﬀerent treatment regimens demonstrated that a
loading dose in the ﬁrst week and a dose interval no longer than 3
weeks were required to eﬀectively revert FD tissue changes and to
prevent bone deformities.
This study demonstrates that RANKL inhibition may be an eﬀective
strategy to treat established FD lesions and to prevent the progression of
the disease. Furthermore, by comparing diﬀerent treatment regimens in
our mouse model we paved the way to the development of eﬀective
therapeutic protocols for human patients.
MP5
Visualization of immune response during initiation and progres-
sion of heterotopic ossiﬁcation in mouse model of ﬁ-
brodysplasiaossiﬁcansprogressiva (FOP)
Kalyan Nannuru, Johanna Jimenez, LiQin Xie, Xialing Wen, Lily
Huang, Lili Wang, Vincent Idone, Aris Economides, Sarah Hatsell
Regeneron Pharmaceuticals, Tarrytown, USA
Fibrodysplasia ossiﬁcans progressiva (FOP) is a rare debilitating genetic
disorder characterized by progressive heterotopic endochondral ossiﬁ-
cation of skeletal muscle and tendons. FOP results from missense mu-
tations in the type I BMP receptor ACVR1, the most common being
R206H. FOP mutations alter the sensitivity of ACVR1 to Activin A from
an antagonist to an agonist. We have previously shown that Activin A is
necessary for driving heterotopic ossiﬁcation (HO) in murine FOP
(MGI:5763014, Acvr1[R206H]FlEx/+; Rosa-CreERT2 mice) in part by
showing that prophylactic inhibition of Activin A blocks HO. Natural
histories of FOP patients indicate that HO is often associated with ﬂare-
ups, which might be due to a soft tissue injury or other inﬂammatory
stimuli. In order to explore the role of inﬂammation in the initiation of
HO in FOP mice, we visualized the homing of phagocytes to the site of
injury. Phagocytes were tracked by intravenous administration of
Exitron nano - radio dense nanoparticles that are readily taken up by
phagocytes and can be imaged by in vivo µCT. Phagocytes are recruited
to the site of injury rapidly following the injury-inducing event, and
remain in place for at least 4 days post-injury. Phagocytes can also be
tracked in vivo using probes that target myeloperoxidase (a marker of
activated phagocytes) with chemiluminescence. Using this imaging
modality, we demonstrated a sustained increased inﬂammatory re-
sponse correlating with HO lesion progression. Our ﬁndings demon-
strate that HO formation is preceded by an inﬂammatory response at
the site of injury and that inﬂammation is sustained during the early
stages of mineralization of the lesions. This data is consistent with the
proposed model of how HO arises in FOP, i.e. that it is precipitated by
inﬂammation-inducing events that result in the recruitment of phago-
cytes, and which in turn express Activin A, the key HO-inducing factor
in FOP. The ability to mark the site of early HO-arising events using
imaging modalities that are compatible with life, enables investigation
of these early events in a longitudinal manner that can be coupled with
ex vivo interogations such as histology and gene expression proﬁling.
MP6
Paget’s disease of bone: are we missing something?
Geetha Lakshmi Janakiraman1, Stephen Tuck2,3
1ST6 Rheumatology, James Cook University Hospital, Middlesbrough,
United Kingdom. 2Consultant Rheumatology, James Cook University
Hospital, Middlesbrough, United Kingdom. 3Honorary Lecturer Newcastle
University, Newcastle upon Tyne, United Kingdom
Paget’s disease of bone (PDB) is the second commonest metabolic bone
disorder in the UK, but is underdiagnosed and undertreated. X –rays are
one of the commonest means by which the condition is identiﬁed. A
retrospective audit of 68873 X-rays was carried out in a tertiary hos-
pital for eighteen months (January 2015 to August 2016) to ascertain
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the number of Paget’s cases reported by radiologist and whether they
had been referred to secondary care for treatment. The search was for
the key word of Paget’s in the report and included: hands, abdomen,
hips, knee, pelvis and lumbo-sacral spine. There were 43 patients with
Paget’s identiﬁed, of whom 65% were males and 35% females. The
mean age of the cohort was 86.7 (age ranging from 65-99). Of these 43
patients 77% had established Paget’s changes on previous X-rays. Pelvic
imaging gave the maximum diagnostic yield of 65% of the cases with
0.2% of pelvic ﬁlms reporting PDB. Of the 43 patients 32 (74%) had not
been referred to secondary care for treatment. Despite lack of therapy
12% patients had joint replacement and only 2 of these had prior bi-
sphosphonate therapy with the risk of excessive blood loss. A further
21 % had fractures of involved bone and moderate to severe osteoar-
thritis of adjacent joints was found in 81%. This may partly explain the
lack of response found to treatment in the PRISM study. In the next 8
months from the end of the study period 30% (13 patients) died pos-
sibly reﬂecting the mean age of the subjects.
The alkaline phosphatase (ALP) was also reviewed. The value closest to
the time of imaging or the highest level pre-treatment was analysed.
The mean ALP level was 189 (range being 47-804 units/litre); 35% of
the patients had normal ALP. In conclusion only a quarter of the pa-
tients are being referred to rheumatology despite potential beneﬁts
from bisphosphonate therapy and specialist input.
MP7
Variation in RIN3 is associated with the onset and severity of
Paget’s disease and bone.
Raphaël De Ridder, Eveline Boudin, Geert Vandeweyer, Erik
Fransen, Geert Mortier, Wim Van Hul
University of Antwerp & Antwerp University Hospital, Antwerp, Belgium
Paget’s disease of bone (PDB) is the second most prevalent bone dis-
order and is characterized by late onset development of focal lesions
aﬀecting one or several bones. In ~40% of patients, mutations in the
SQSTM1 gene are found. Genomewide association studies involved 7
novel candidate loci. Ras and rab interactor 3 (RIN3), located at the
associated 14q32 locus, encodes for RIN3, a guanine-nucleotide ex-
change factor (GEF) which activates several small GTPases of the Rab5
subfamily.
Using molecular inversion probe technology, we screened 189 patients
and 165 controls of Western-European descent for variation occurring in
the coding regions and 5’UTR of the RIN3 gene. We identiﬁed 22 distinct
variants. Based on in silico functionality predictions, several interesting
and potentially deleterious variants can be distinguished. We identiﬁed 2
rare variants in the N-terminal region and the SH2 domain, respectively,
that occurred only in control individuals. Four more rare variants were
exclusively found in patients. These variants are located in the RIN-
homology and VPS9 domains of the protein that mediate Rab5 binding
and activation. Finally, a functional eﬀect was also predicted for a
common variant (p.R279C) described by Vallet et al..
In addition, we identiﬁed 6 common variants for which additive re-
gression models were ﬁtted looking for signiﬁcant associations between
genotype frequencies and disease state, disease extent, or age of onset.
Associations were only signiﬁcant for the abovementioned p.R279C
variant, which conﬁrms the association with PDB reported by Vallet et
al. The alternate allele occurs in a signiﬁcantly higher rate in control
individuals (p=0.01), decreasing the risk for PDB (OR
p.R279C+/-=0,562; p.R279C+/+=0.315). Our statistical analyses also
demonstrated a modifying eﬀect of this variant on the age of onset, with
an increased age of onset of 5,336 years per alternate allele.
In conclusion, in our patient cohort, we identiﬁed rare variants that
potentially alter RIN3 GEF activity. This could alter vesicular translo-
cation and intracellular transport and aﬀect osteoclast maturation and
activity. Furthermore, we conﬁrmed the previously reported associa-
tion of RIN3 with PDB and demonstrated that the rs117068593 variant
in RIN3 is a potential modiﬁer for PDB pathogenesis.
Paget’s guidelines
Paget’s Disease of Bone
Paget’s Disease of Bone: a clinical guideline prepared on behalf of the
Paget’s Association, The European Calciﬁed Tissues Society, and the
International Osteoporosis foundation.
Paget’s disease of bone (PDB) is a relatively common skeletal disease in
people of European descent but the evidence base for diagnosis and
treatment is limited. Here we provide an evidence based update on
previous guidelines for the diagnosis and management of PDB pub-
lished between 2002 and 2015 using GRADE methodology.
The remit of the guideline is to provide patient-centred, evidence-based
recommendations for the diagnosis and management of classical PDB in
adults. It addresses the tools for the diagnosis of PDB, the eﬀects of
bisphosphonates and other drug treatments on PDB, the predictors of
treatment response and the eﬀects of non-pharmacological treatments.
The guideline focused on classical PDB and did not consider the diag-
nosis or management of rare PDB-like syndromes. This guideline is not
intended to serve as a standard of care. Adherence to the re-
commendations will not ensure a successful outcome in every case, nor
should they be construed as including all proper methods of care or
excluding other acceptable methods of care aimed at achieving the
same result. The ultimate judgement must be made by the appropriate
healthcare professional(s) responsible for clinical decisions regarding a
particular clinical procedure or treatment plan. This judgement should
only be arrived at following discussion of the options with the patient,
covering the diagnostic and treatment choices available.
A Guideline Development Group (GDG) was established in January
2016 by the UK Paget’s Association, the European Calciﬁed Tissues
Society and the International Osteoporosis Foundation, which in-
corporated a multidisciplinary panel of medical practitioners, a non-
clinical scientist, a specialist nurse and one lay member (a patient with
PDB).
The GDG identiﬁed six relevant key questions and used GRADE meth-
odology for deﬁning diagnostic questions and management options. An
extensive literature search was undertaken, which initially searched for
systematic reviews that addressed the study question followed by ran-
domised controlled trials if no systematic reviews were available. If no
randomised controlled trials had been performed, we searched for ob-
servational studies and case series provided the number of individuals
studied was greater than 10. Individual case reports and case series of
less than 10 subjects were generally excluded, unless these provided
signiﬁcant insights into the question that were not addressed by larger
studies or clinical trials.The PDB guidelines process was validated in
accordance with the Appraisal of Guidelines for Research and
Evaluation, using the AGREE reporting check list 2016. The guidelines
are now open for external review.
Recommendations within this guideline are based on the best available
clinical evidence.
The following recommendations were highlighted by the guideline
development group as those that should be prioritised for im-
plementation.
1. Radionuclide bone scans, in addition to targeted radiographs, are
recommended as a means of fully and accurately deﬁning the extent
of metabolically active PDB. [based on very low-quality evidence from
observational studies and the opinion and clinical experience of the
GDG]
2. Serum total ALP is recommended as a ﬁrst line biochemical
screening test in combination with liver function tests in screening
for the presence of metabolically active PDB. If total ALP values are
normal and clinical suspicion of PDB is high, measurement of either
BALP or PINP may be considered. [based on very low-quality evidence
from observational studies and the opinion and clinical experience of the
GDG]
3. Bisphosphonates are recommended for the treatment of bone pain
associated with Paget’s disease. Zoledronic acid is recommended as
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the bisphosphonate most likely to give a favourable pain response.
[based on moderate quality evidence from randomised clinical trials and
the opinion and clinical experience of the GDG]
4. It is recommended that in patients with established PDB, the treat-
ment goal should be to control bone pain with bisphosphonates and
other drugs as opposed to giving bisphosphonates with the aim of
maintaining ALP concentrations in the reference range. [based on
low quality evidence from randomised clinical trials and the opinion and
clinical experience of the GDG]
5. Total hip or knee replacements are recommended for patients with
PDB who develop osteoarthritis in whom medical treatment is in-
adequate. There is insuﬃcient information to recommend one type
of surgical approach over another. [based on low quality evidence
from observational studies and the opinion and clinical experience of the
GDG]
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The role of small RNAs in Paget's associated osteosarcoma
Darrell Green, Tamas Dalmay, William Fraser
University of East Anglia, Norwich, United Kingdom
Small RNAs (sRNAs) are a class of non-coding RNA molecules that are
key regulators of gene expression. SRNAs are also speciﬁc biomarkers
due to their dysregulation in disease. Next generation sequencing is the
gold standard for sRNA discovery, proﬁling and expression analysis.
Bias has been found in diﬀerent platforms of sequencing due to RNA
ligase preference for sequence complementarity between sRNA and
adapters. We developed high deﬁnition (HD) adapters to overcome the
bias. We applied the use of HD adapters and sequencing to our studies
of bone cancer. One of these studies investigated sRNA expression in
Paget’s associated osteosarcoma, a rare complication of Paget’s disease
of bone that carries a poor prognosis. We found that expression of a
microRNA, miR-16, was highly expressed in Paget’s associated osteo-
sarcoma tissue when compared to controls and Paget’s disease of bone.
Bioinformatics analysis revealed miR-16 directly targets the sequesto-
some 1 (SQSTM1) messenger RNA. SQSTM1 protein has long been as-
sociated with Paget’s disease of bone development. SQSTM1 was hy-
pothesised to be involved with transformation to osteosarcoma as
SQSTM1 variants are positively associated with disease severity. We
speculated that negative regulation of SQSTM1 by miR-16 incapacitates
SQSTM1’s role in the Kelch-like ECH-associated protein 1 (KEAP1)-
nuclear factor erythroid 2-like 2 (NFE2L2) pathway, a major cellular
defence mechanism against oxidative stress and cancer development.
Molecular testing may help provide a robust diagnosis and is particu-
larly useful in rare cancers such as Paget’s associated osteosarcoma
where transformation is often missed until late stage. We are now in-
vestigating this biological data further, using single cell simultaneous
genome and transcriptome sequencing.
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